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Abstract 
 
  The majority of research on the placebo effect has focused on beneficial 
effects in patients or participants told to expect an active treatment, but who are 
actually given a placebo. Two important and relatively understudied aspects of the 
placebo effect are the extent to which expectancies influence outcomes in double-
blind randomised placebo-controlled trials (RCTs) and whether the placebo effect 
contributes to treatment side effects. The current project investigated these two issues 
in both clinical and experimental settings. The first study involved reanalysing a 
double-blind RCT of naltrexone and acamprosate for alcohol dependence based on 
whether participants believed they had been allocated to receive active treatment or 
placebo (perceived treatment). The second study extended on this by developing an 
experimental model for these effects using dummy (placebo only) double-blind RCTs 
for cognitive performance. This allowed for the manipulation of observable changes 
in the form of false feedback. The third study investigated whether warning 
participants about side effects increases their occurrence, frequency, and/or severity in 
three dummy trials for sleep difficulty in healthy volunteers. The final study 
complemented this by examining whether first time chemotherapy patients’ 
expectancies for nausea were associated with their post-chemotherapy nausea. The 
studies on perceived treatment in double-blind RCTs indicated that participants’ 
beliefs about their treatment allocation can influence their actual treatment outcomes 
via the placebo effect and that these beliefs are affected by the feedback they receive 
about their performance. The studies on placebo-induced side effects indicated that 
the placebo effect may contribute to treatment side effects but that this effect is 
generally likely to be small. These findings confirm that the placebo effect can 
influence treatment outcomes and emphasise the importance of considering patient 
 iii 
expectancies when delivering medical treatment. They also highlight some general 
limitations associated with research on the placebo effect, which include, whether 
conveying uncertainty undermines the placebo effect and whether measuring or 
manipulating expectancies is the best way to evaluate the placebo effect. 
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“One of the most successful physicians I have ever known has assured me that     
  he used more bread pills, drops of colored water, and powders of hickory  
  ashes than of all other medicines put together. It was certainly a pious fraud.”  
Thomas Jefferson, 1807  
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Chapter 1 – Nomenclature, Evidence, and Theories of the 
Placebo Effect 
 
 Medical treatment involves much more than the direct physiological action of 
the substance or procedure being administered. Treatment is typically administered or 
suggested by a health professional who communicates – intentionally or otherwise - 
the aim of the treatment, how likely it is to be effective, and whether or not it might 
produce side effects. The treatment occurs within a context, for example, a hospital 
ward, a general practice surgery, or at home. The way one treatment is delivered often 
differs from another, both in terms of invasiveness and complexity of the treatment 
regimen. In addition to this, patients often have preconceptions about the likely effects 
of a treatment based on previous experience, the experience of others, or what they 
have read or heard in the media. All of these factors are likely to affect what a patient 
expects from his/her treatment and these expectancies can influence the patient’s 
actual health outcomes, either positively or negatively, via the placebo effect. 
Understanding the placebo effect, then, may enable health professionals to maximise 
beneficial treatment outcomes whilst minimising adverse outcomes. This chapter 
reviews nomenclature, evidence and theories relating to the placebo effect before 
providing an overview of the current project.  
  
1.1 Nomenclature 
1.1.1 The placebo effect 
 The current literature contains varied definitions of the placebo effect. In most 
cases the differences do not reflect any serious disagreement about what constitutes a 
placebo effect, but are, instead, testament to the complexity of the placebo effect. The 
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only substantial difference concerns whether the placebo effect should be confined to 
positive responses or whether it should also include negative responses. 
 
 Researchers who define the placebo effect as exclusively positive often focus 
on clinical settings and refer to the therapeutic benefits experienced by the patient 
(e.g. Brody & Brody, 2000; Shapiro & Shapiro, 1997a, 1997b). This generally leads 
to separation of positive and negative responses, labelled respectively as the placebo 
effect and the nocebo effect (e.g. Evans & Rogers, 2003; Hahn, 1997a, 1997b; 
Harrington, 1999). According to these definitions, the placebo effect is when 
expectancies for positive outcomes cause positive responses and the nocebo effect is 
when expectancies for negative outcomes cause negative responses. While 
discriminating between positive and negative placebo effects can be quite useful for 
labelling such effects, separating them into placebo effects and nocebo effects leads to 
a number of logical inconsistencies.  
 
 Firstly, as with many medications and procedures, placebos can produce both 
beneficial and adverse effects simultaneously (e.g. Downing, Rickels, Rickels, & 
Downing, 1979). Therefore, defining these effects separately as placebo effects and 
nocebo effects would lead to the potentially confusing conclusion that a substance or 
procedure could be both a placebo and a nocebo at the same time (Siegel, 2002; 
Stewart-Williams & Podd, 2004). Secondly, it may not always be clear whether a 
response is positive or negative (Stewart-Williams & Podd, 2004). For example, 
placebo alcohol could cause a feeling of intoxication, which one person might 
experience as pleasant, while another person experiences it as unpleasant. This would 
mean that the placebo alcohol produced a placebo effect in the first person but a 
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nocebo effect in the second person. This is potentially confusing because the only 
difference between the placebo effect and nocebo effect here would be the 
individuals’ hedonic experiences, not the actual response, which was the same in both 
cases, i.e. intoxication. Thirdly, some responses may be neutral, especially if they are 
undetectable. For instance, minor increases or decreases in heart rate caused by 
placebo coffee are unlikely to be experienced as either positive or negative. If placebo 
effects are only positive and nocebo effects are only negative, then neutral responses 
must, rather illogically, be neither of these.  
 
 Stewart-Williams and Podd (2004) have provided a more general definition of 
a placebo effect which appears to overcome these problems. They state that “a 
placebo effect is a genuine psychological or physiological effect, in a human or 
another animal, which is attributable to receiving a substance or undergoing a 
procedure but is not due to the inherent powers of that substance or procedure” (p. 
326). In this way, the placebo effect is not confined to positive responses but includes 
positive, negative, and even neutral responses. Further, the genuineness of the placebo 
effect indicates that it is a real effect which cannot be accounted for by biases, such 
as, demand characteristics. The fact that it is attributable to receiving a treatment or 
procedure means that it is an effect beyond natural history, spontaneous remission, 
and regression to the mean. By extension, a placebo is simply a substance or 
procedure that has no inherent power to affect the psychological or physiological 
process of interest. 
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1.1.2 Placebo-induced side effects 
 Side effects are generally defined as responses to a treatment other than those 
for which the treatment is being administered (Barsky, Saintfort, Rogers, & Borus, 
2002). These can be beneficial, adverse, or neutral. An example of an adverse side 
effect is the gastrointestinal discomfort that sometimes follows the administration of 
aspirin for pain relief. If a placebo pill was administered instead of aspirin and the 
recipient also experienced pain relief and gastrointestinal discomfort, then, for the 
reasons stated above, both the pain relief and the gastrointestinal discomfort should be 
considered placebo effects. There is, however, some benefit in labelling these two 
responses differently. The pain relief caused by the placebo pill can simply be labelled 
a placebo effect, while the gastrointestinal discomfort it produced can be labelled a 
placebo-induced side effect. Although there may be no difference in the aetiology of 
these two effects, the placebo pill was administered for pain relief, whereas the 
gastrointestinal discomfort was a side effect of its administration. Importantly, this is 
identical to the distinction made between non-placebo treatment effects and their side 
effects. Pain relief caused by aspirin is aspirin’s treatment effect because it was 
administered for that purpose and the gastrointestinal discomfort is aspirin’s side 
effect. In this way, labelling responses as placebo effects and placebo-induced side 
effects appropriately parallels discussion of non-placebo effects.  
 
1.1.3 Expectancy 
 Expectancy is an intuitive although somewhat vague concept. It refers to a 
subjective sense of the probability of a future event. A number of different terms are 
used for expectancy in relation to placebo effects, which are often used 
interchangeably. These include: belief, conscious expectancy, and response 
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expectancy. The choice of the term used in this thesis will attempt to highlight some 
relevant characteristic of the expectancy being discussed. For example, when 
comparing expectancy and classical conditioning accounts of the placebo effect I will 
refer to conscious expectancies to emphasise that awareness reflects an important 
difference between these two theories. When discussing expectancies in double-blind 
RCTs I will refer to beliefs about treatment allocation so as to contrast this from 
expectancies regarding the efficacy of a treatment, even though they are both forms of 
expectancy that may contribute to the placebo effect.     
 
1.2 Evidence for the Placebo Effect 
1.2.1 Anecdotal evidence for the placebo effect 
 Some interesting anecdotal evidence for the placebo effect has emerged over 
the past few centuries. Shapiro and Shapiro (1997a; 1997b), for example, attribute 
most of the efficacy of pre-scientific medicine to the placebo effect. In the extreme, 
Benson (1997) cites voodoo death as an example of a negative placebo effect. Perhaps 
the most fascinating anecdotal account of the placebo effect is that of Mr Wright 
(Klopfer, 1957). Mr Wright was suffering from cancer of the lymph nodes and had 
not responded to any of the available anti-cancer treatments. As a result, both he and 
his physicians expected that he would not recover from the cancer. Mr Wright then 
heard about a new anti-cancer drug called krebiozen and became convinced that this 
would cure his cancer. After unrelenting requests, his physician injected him with 
krebiozen. Almost immediately, Mr Wright’s tumours rapidly reduced in size, so 
much so that he felt cured. That is, until he read preliminary findings that indicated 
that krebiozen was ineffective, whereupon he relapsed as quickly as he had recovered. 
His physician attempted to reverse this by telling him that the preliminary results 
 7 
regarding krebiozen were unconvincing and promised to inject him with a more 
potent dose of krebiozen. The injection actually contained water, but nonetheless Mr 
Wright again showed remarkable improvement. Sometime after this, Mr Wright read 
a final report declaring that krebiozen was completely ineffective. He relapsed and 
died two days later.  
 
1.2.2 The importance of controlling for natural history 
 Perhaps not surprisingly, these types of stories have led some investigators to 
claim that the placebo effect seems capable of curing any condition (e.g Buckman & 
Sabbagh, 1993). There is, however, one crucial aspect of heath and illness that these 
stories do not control for, that is, natural history. Natural history refers to the course of 
a condition when untreated and involves the duration of the condition, spontaneous 
remission or recovery, and random fluctuation in symptoms. Although medical 
treatments can effectively reduce the severity and duration of an illness, in many cases 
the illness will subside without treatment. For example, most people experiencing the 
common cold recover after six days simply as a result of normal immune-functioning 
(Diehl, 1953). In other cases, illnesses can spontaneously remit either temporarily or 
permanently without apparent explanation, as is common in cancer patients (see 
Huebscher, 1992 for a review). In addition to this, symptoms of both health and 
illness tend to fluctuate randomly, as evidenced by variations in pain intensity 
experienced by people with chronic pain (e.g. Foss, Apkarian, & Chialvo, 2006). 
These naturally occurring effects can be mistaken for placebo effects when placebo 
administration precedes a change in symptoms that they produce. For example, 
administering a placebo when pain is at its greatest is very likely to correspond with a 
reduction in pain due to the natural progression of pain, not the placebo effect 
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(Benedetti, 2009; Colloca & Benedetti, 2005). In order to detect a real placebo effect, 
then, it is necessary to compare placebo administration with a natural history group 
who receive no treatment, something which the anecdotal evidence above clearly 
lacks.  
 
1.2.3 Scepticism about the placebo effect 
 In stark contrast to anecdotal stories of extreme placebo effects and 
subsequent claims that the placebo effect is all powerful, some researchers have 
questioned whether the placebo effect exists at all. Most notably, Hróbjartsson and 
Gøtzsche  (2001; 2004) reviewed double-blind RCTs that included both a placebo 
group and a no treatment group and concluded that there was no evidence that the 
placebo effect was clinically significant. In their first review, they identified 114 
double-blind RCTs and categorised them according to the type of outcome measure 
used; either dichotomous or continuous, and objective or subjective. When analysing 
these pooled data they only found a significant placebo effect for studies with 
continuous, subjective outcome measures and for trials on pain and these effects were 
only small. In their second review, they conducted an identical analysis but added 52 
more recent double-blind RCTs that included a no treatment group. Again, they found 
a significant placebo effect only for studies with continuous, subjective outcome 
measures but this time they found these effects for pain and phobias. However, they 
considered the significant result for phobia unreliable due to small sample size (n=57) 
and argued that the effect size for pain, which corresponded to a 6mm decrease on a 
100mm visual analogue scale, was unlikely to be clinically significant. Based on these 
reviews, they concluded that the placebo effect is generally grossly overestimated and 
has little clinical importance. 
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 There are however, two important limitations to Hróbjartsson and Gøtzsche’s  
(2001; 2004) reviews which suggest that they underestimated the magnitude of the 
placebo effect. Firstly, they analysed the difference between placebo treatment and no 
treatment in double-blind RCTs. As discussed in detail in the next chapter, double-
blind RCTs often detract from the placebo effect because participants in these trials 
are aware that they may be receiving a placebo. That is, the placebo groups in their 
reviews consisted of patients given placebo treatment who may or may not have 
expected that they were receiving an active treatment, rather than patients given 
placebo treatment and who are told that they are receiving active treatment. As such, 
smaller placebo effects would be expected in the placebo groups they analysed. Vase, 
Riley, Price, and Vase (2002) demonstrated this by showing that the placebo effect 
was much larger in studies examining placebo analgesia compared with the double-
blind RCTs on pain included in Hróbjartsson and Gøtzsche’s (2001) first review.  
 
 Secondly, Hróbjartsson and Gøtzsche’s  (2001; 2004) reviews combined data 
from over forty different maladies. The pain studies, for instance, included trials on 
headaches, rheumatoid arthritis, low back pain, and fibromyalgia. This ignores the 
possibility that some conditions may be more amenable to the placebo effect than 
others (Evans, 2003) or even that some types of placebos might be more effective for 
one condition than another. Wampold, Minami, Tierney, Baskin, and Bhati  (2005) 
reanalysed the trials included in Hróbjartsson and Gøtzsche’s (2001) review, but also 
categorised each condition as amenable to the placebo effect or not. This was done by 
asking five doctoral psychology students who were unaware of Wampold et al.’s 
(2006) aims to rate the likelihood that each condition could be affected by the placebo 
effect. The results indicated a large placebo effect for conditions classified as 
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amenable and no placebo effect for conditions classified as non-amenable. In light of 
these limitations, Hróbjartsson and Gøtzsche’s  (2001; 2004) reviews appear 
inadequate to estimate the true magnitude of the placebo effect. In order to achieve 
this, well controlled studies that investigate the placebo effect on specific conditions 
are required.  
 
1.2.4 Convincing evidence for the placebo effect 
 There are a number of well controlled experimental studies that provide 
convincing evidence for the placebo effect in both clinical and non-clinical settings. 
The vast majority of these are on pain and typically show that a placebo, such as a 
benign topical cream or injection, believed to be an analgesic, produces pain relief 
that cannot be explained by natural history (e.g. Amanzio & Benedetti, 1999; 
Benedetti, Arduino, & Amanzio, 1999; Benedetti, Pollo et al., 2003; Montgomery & 
Kirsch, 1997; Voudouris, Peck, & Coleman, 1985; Voudouris, Peck, & Coleman, 
1989, 1990). Some of these studies are described in detail later in this chapter. An 
important aspect of placebo analgesia is that it can be reversed by a hidden injection 
of naloxone (Amanzio & Benedetti, 1999; Benedetti, Arduino et al., 1999; Levine & 
Gordon, 1984; Levine, Gordon, & Fields, 1978), suggesting that there is a 
physiological corollary to the pain relief and that the effect exists beyond demand 
characteristics. This point is strengthened by Zubeita et al.’s (2005) finding that 
participants exhibiting placebo analgesia showed greater activation of the endogenous 
opioid system, which inhibits pain and stress via μ-opioid receptors, than participants 
who did not show a placebo effect.  
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 There are also a handful of well controlled studies on the placebo effect in 
clinical settings other than pain. Placebo administration appears to reduce the sleep 
difficulty associated with sleeping in a laboratory for the first night compared with 
when no placebo is administered (Suetsugi, Mizuki, Yamamoto, Uchida, & 
Watanabe, 2007). People with Parkinson’s disease exhibit better motor performance 
when they are aware that they are receiving stimulation of the subthalmic nucleus 
compared with when they are unaware (Benedetti, Maggi et al., 2003; Mercado et al., 
2006; Pollo et al., 2002). Smokers attempting to quit have lower withdrawal 
symptoms when they are told they are receiving nicotine compared with when they 
are told they are receiving a placebo, regardless of whether or not they actually 
receive nicotine (Gottlieb, Killen, Marlatt, & Taylor, 1987). In addition, there is 
indirect evidence for the placebo effect in clinical settings, in that more invasive 
treatment regimens appear to elicit larger placebo effects. For example, placebo 
injections reduced pain due to migraine headaches more effectively than did placebo 
pills (de Craen, Tijssen, de Gans, & Kleijnen, 2000) and four placebo pills per day 
shortened recovery rates for stomach ulcers more than two placebo pills per day (de 
Craen et al., 1999).  
 
 In terms of non-clinical settings, decaffeinated coffee has been shown to 
improve reaction times in sleep deprived healthy volunteers when they are told that it 
contains caffeine compared with when they are aware that it is decaffeinated 
(Anderson & Horne, 2008). Healthy volunteers told that they are being given a 
relaxant or a stimulant, but are in fact given a placebo, show responses in the direction 
of the information they received, and this information can moderate the response to an 
active drug (Flaten et al., 1991). Healthy volunteers who expect that alcohol will 
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impair their cognitive performance demonstrate poorer information processing than 
those who expect that alcohol will not affect their cognitive performance, both when 
alcohol and placebo alcohol are administered (Fillmore, Carscadden, & Vogel-Sprott, 
1998). Taken together, these studies provide firm evidence for the placebo effect as 
measured by self report as well as when measured objectively.  
 
1.3 Theories of the Placebo Effect 
 Traditionally, two theories have been relied upon to account for the placebo 
effect: classical conditioning and expectancy theory. While these two accounts were 
often treated as mutually exclusive, most researchers now agree that both classical 
conditioning and conscious expectancy can contribute to the placebo effect (Brody & 
Brody, 2000; Evans, 2003; Pacheco-López, Engler, Niemi, & Schedlowski, 2006; 
Stewart-Williams, 2004; Stewart-Williams & Podd, 2004). This is a result of evidence 
that neither account, on its own, can explain the full range of placebo effects found in 
humans and other animals and the acknowledgement that classical conditioning can 
produce conscious expectancies.  
 
1.3.1 Classical conditioning  
 Pavlov (1927) showed that by pairing a tone with the delivery of morphine, 
dogs became restless and began to salivate when they heard the tone, even without the 
morphine itself. He described this processes as follows. The morphine was an 
unconditioned stimulus (US) in that it unconditionally caused the dogs to become 
restless and salivate. The dogs’ restlessness and salivation was an unconditioned 
response (UR), because it was caused unconditionally by the morphine. The tone, 
which was initially neutral with respect to the dogs’ activity and salivation, functioned 
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as a conditioned stimulus (CS). Through repeated pairings with the morphine, it 
acquired the power to produce restlessness and salivation in the dogs even in 
morphine’s absence. The restlessness and salivation in response to the tone was a 
conditioned response (CR) because it was conditional on the pairing of the tone and 
the morphine. Pavlov (1927) proposed that through repeated CS-US pairings the CS 
acquired the power to produce an effect, the CR, which was previously reserved for 
the US. This process of learning is known as the stimulus substitution model of 
classical conditioning.  
 
 Hernstein (1962) noticed how similar the stimulus substitution model of 
classical conditioning was to those that produce placebo effects. He demonstrated that 
after conditioning a rat with injections of scopolamine hydrobromide, which 
suppresses learned behaviour, an injection of saline also began to suppress the rat’s 
learned behaviour. He concluded that placebo effects must be instances of classical 
conditioning. Wickramasekera (1980) expanded on this. He proposed that when a 
person undergoes treatment, the context in which it is delivered, including the route of 
administration, the surroundings in which it is delivered, and even the person 
administering it, acts as a complex CS. This complex CS, through repeated pairings 
with the US, i.e. the drug itself, acquires the power to produce the drug effect on its 
own accord. In this way, proponents of the classical conditioning account argued that 
the placebo effect is simply a conditioned response that develops through CS-US 
pairings.     
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1.3.2 Expectancy theory  
 Kirsch (1985; 1997; 1999), on the other hand, has proposed an account of the 
placebo effect based on response expectancies. Response expectancies are 
anticipations of nonvolitional responses, such as, mood states, fear and anxiety, sexual 
arousal, perceptions of pain, and asthmatic responses (Kirsch, 1999). These response 
expectancies can be produced in a number of ways, including both direct and 
vicarious experience and verbal information (Kirsch, 1997). According to Kirsch, the 
anticipation of a response is sufficient to produce the response in and of itself. That is, 
activation of a response expectancy directly elicits that response. If a person expects 
pain relief after medical treatment, they will indeed experience pain relief. Similarly, 
a person who expects to feel alert after drinking a cup of coffee will feel alert after 
drinking it. Further, he viewed response expectancies as self-confirming. Once a 
response expectancy has been established it is sufficient to continue producing the 
response (Kirsch, 1997). In this way, he argued that placebo effects are the direct 
result of response expectancies. Kirsch (1985) was also adamant that this process is 
not confined to subjective states, but includes both the physiological processes that 
underlie them and physiological processes not related to subjective states. Of course, 
response expectancies are not the only determinants of behaviour. Rather, behaviour 
is the result of the interaction between conscious expectancies and other factors, such 
as the drug effect itself (Kirsch, 1997).  
 
1.3.3 Classical conditioning versus expectancy theory 
 A series of studies conducted from the mid-1980’s to the late-1990’s 
attempted to determine whether classical conditioning or expectancy theory could 
explain the placebo effect. Voudouris, Peck and Coleman (1985; 1989; 1990) showed 
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that the direction of the placebo effect followed the direction of the conditioning 
participants received, even when it contradicted the verbal information provided. 
They told two groups of participants that a placebo cream was an analgesic and gave 
one group surreptitious conditioning supporting this, i.e. lower pain intensity with the 
cream, while the other group received surreptitious conditioning contradicting this, 
i.e. higher pain intensity with the cream. Participants who received conditioning 
supporting the verbal suggestion that the cream was an analgesic showed placebo 
analgesia during the test phase, while those who received conditioning contradicting 
the verbal suggestion showed placebo hyperalgesia. As a result, Voudouris et al. 
(1985; 1989; 1990)  argued that classical conditioning causes placebo effects, not 
conscious expectancy.  
 
 Montgomery and Kirsch (1997) countered this by arguing that in the group 
that received contradictory conditioning, the conditioning trials simply created 
conscious expectancies that were stronger than the verbal information the participants 
received. Using a similar design to Voudouris et al. (1985; 1989; 1990), they 
administered placebo cream under the guise of an analgesic to two groups of 
participants. Both of these groups received conditioning trials consisting of reduced 
pain stimulation when the cream was applied. For one group the conditioning was 
surreptitious, as in the original study, however, the second group were informed that 
the painful stimulation was being decreased on the conditioning trials when the cream 
was applied. Despite the fact that both groups received identical conditioning, only 
those who were unaware of the conditioning manipulation exhibited placebo 
analgesia. That is, being informed that the conditioning was taking place eliminated 
the placebo effect. As a result, they concluded that the responses observed must have 
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been the result of the conscious expectancies created by interpretation of the 
conditioning trials, not the conditioning itself.  
 
 However, as Montgomery and Kirsch (1997) admit, their findings are only 
inconsistent with the stimulus substitution model of classical conditioning. Recent 
advances in classical conditioning theory have extended it from the low-order 
biological reflex first described by Pavlov to a more sophisticated learning process 
through which the organism comes to understand its environment (Rescorla, 1988). 
Rescorla (1988) argues that the importance of a conditioning trial lies in the 
information it provides about how one event relates to another. As such, simple CS-
US pairings may not be sufficient to produce learning. Instead, these pairings must 
convey some form of information about the structure of events. Thus, while the 
stimulus substitution model cannot account for the above findings, a contemporary 
learning theorist would argue that the awareness regarding the conditioning 
manipulation devalued the CS-US pairings and hence produced no learning (Evans, 
2003; Stewart-Williams & Podd, 2004). This means that both classical conditioning 
and expectancy theory can explain Voudouris et al. (1985; 1989; 1990) and 
Montgomery and Kirsch’s (1997) findings.  
 
 Nevertheless, there is evidence to suggest that neither account, on its own, can 
explain all types of placebo effect. Expectancy theory posits that any conditioning 
leading to placebo effects must be consciously mediated (Kirsch, 1997; Montgomery 
& Kirsch, 1997) and, as a result, that all placebo effects must be consciously 
mediated. There is, however, evidence from the conditioning literature that 
conditioned responding can be dissociated from conscious expectancies (c.f. the 
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Perruchet effect: Perruchet, 1985; Perruchet, Cleeremans, & Destrebecqz, 2006; 
Weidemann, Tangen, Lovibond, & Mitchell, 2009), which suggests that a placebo 
effect could occur either without the participant’s awareness or even in contrast to the 
participant’s expectancies. Benedetti, Amanzio, Baldi, Cassadio and Maggi (1999) 
have provided evidence that supports this. They found that a placebo led to respiratory 
depression after conditioning with buprenorphine, a mild respiratory depressant, in the 
absence of verbal suggestion and even though participants did not notice this response 
during conditioning or placebo administration. On the other hand, there is evidence 
that placebo effects can occur without prior drug experience (Pihl & Altman, 1971). 
For example, Wolf (1950) reported that information that ipecac had anti-emetic 
properties reversed the nausea a young woman was experiencing, even though this 
woman was unlikely to have had prior experience with the substance. Classical 
conditioning has difficulty accounting for these types of placebo effects because there 
has been no opportunity for conditioning to occur. Expectancy theory can, however, 
explain these types of placebo effects because verbal information is a source of 
response expectancies and, as such, is sufficient to produce a placebo effect. Thus, 
while both classical conditioning and conscious expectancies theory are sufficient to 
produce a placebo effect, neither appear necessary.  
  
1.3.4 Classical conditioning and expectancy theory: An integrated approach 
 Almost simultaneously, Benedetti, Pollo et al. (2003) and Stewart-Williams 
and Podd (2004) developed similar integrative models of the placebo effect. An 
interpretation of these two models is presented in Figure 1.1. It shows that 
information and classical conditioning produce conscious expectancies which lead to 
consciously mediated placebo effects. However, it also allows for nonconsciously 
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mediated placebo effects that are the direct result of classical conditioning. As such, 
consciously mediated placebo effects can be explained by what the person expects to 
happen, i.e. their conscious expectancy, which could result from information or prior 
experience. Nonconsciously mediated placebo effects, on the other hand, can occur in 
the absence of conscious expectancy or even contrary to it. These effects cannot be 
explained by what the person expects to happen, but rather by his/her previous 
experience. In this way, this model can account for evidence that verbal suggestion 
without prior experience leads to a placebo effect because verbal information is 
sufficient to produce a conscious expectancy and thereby a placebo effect. It can also 
account for placebo effects which participants appear unaware of, because it allows 
for classically conditioned placebo effects that are not consciously mediated.  
 
Figure 1.1. Model of the mechanism of the placebo effect based on those proposed by 
Benedetti, Pollo et al. (2003, p4321) and Stewart-Williams and Podd (2004, p336).  
 
 Support for this model comes from two studies conducted by Benedetti and his 
colleagues. In the first, Amanzio and Benedetti (1999) partitioned the contribution of 
information-based conscious expectancy and conditioning without conscious 
expectancy to placebo analgesia. To do this, they gave one group of participants a 
placebo injection (saline) but told them that it was a powerful analgesic, representing 
information-based conscious expectancy. A second group received prior conditioning 
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with morphine but were told that the placebo injection given in the test phase was an 
antibiotic that would have no effect on pain sensitivity. This group reflects 
conditioning without conscious expectancy, because they were told that the placebo 
injection was different from the one which they had been conditioned with. A third 
group received conditioning with morphine and were told that the placebo injection 
was the same powerful analgesic. This group represents a potential combination of 
conscious expectancy and nonconscious conditioning, because they were told the 
placebo injection was an analgesic and had received conditioning supporting this. In 
the test phase, all groups displayed significant placebo analgesia compared with a 
natural history group, suggesting that both information-based conscious expectancy 
and conditioning without conscious expectancy can produce placebo effects. 
Importantly, placebo analgesia was larger in the combined group than in the other two 
groups, indicating that neither information-based conscious expectancy nor 
conditioning without conscious expectancy could fully account for this effect. Instead, 
it would seem that these two mechanisms combined to produce a placebo effect 
greater in magnitude than either could on its own.  
 
 In the second study, Benedetti, Pollo et al. (2003) showed that information 
affects consciously mediated placebo effects but not nonconsciously mediated 
placebo effects. The consciously mediated placebo effects they examined were for 
pain in healthy participants and motor performance in Parkinson’s disease. In these 
conditions, the placebo effect followed the direction of the verbal suggestions 
participants received, even when it contradicted the conditioning they had received. 
For example, healthy participants who were told that a placebo injection was an 
analgesic showed placebo analgesia, while those who were told that a placebo 
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injection was a hyperalgesic showed placebo hyperalgesia, even though both groups 
had received prior conditioning with analgesic injections. The nonconsciously 
mediated placebo effects were for hormonal secretion. In these conditions information 
had no effect on hormone levels but conditioning did. For example, after conditioning 
with sumatriptan, growth hormone levels increased in response to placebo 
administration, mimicking the drug’s effect, regardless of whether participants were 
told that the placebo injection would increase or decrease their growth hormone 
levels. These two studies, therefore, support an integrative model of the placebo effect 
that incorporates the interaction between information and classical conditioning in 
producing conscious expectancies, as well as allowing for nonconscious placebo 
effects that result directly from classical conditioning. Thus, in exploring the placebo 
effect, it is important to consider both the information the participant has received and 
any prior experience he or she has had with the treatment itself and/or the treatment 
setting.  
 
1.4 Overview of the Current Project 
 Traditionally, the primary focus of research on the placebo effect has been on 
beneficial effects in patients/participants told to expect an active treatment but who 
are actually given a placebo. More recently, there has been interest in whether 
participant expectancies affect double-blind RCTs and whether the placebo effect 
contributes to treatment-related side effects. A detailed review of expectancies in 
double-blind RCTs is provided in Chapter 2. Briefly, there is preliminary evidence to 
suggest that participants’ beliefs about whether they have been allocated to receive 
active treatment or placebo affect their actual treatment responses (e.g. Bausell, Lao, 
Bergman, Lee, & Berman, 2005; Dar, Stronguin, & Etter, 2005). If so, this can greatly 
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reduce the validity of these types of trials, especially when participant blinding fails. 
A review of the possible contribution of the placebo effect to treatment side effects is 
provided in Chapter 5. In essence, evidence for negative placebo effects when 
participants or patients expect adverse outcomes, side effects being reported in 
placebo groups of double-blind RCTs, a relationship between expectancy and post-
chemotherapy nausea, and some experimental studies manipulating the information 
participants receive about side effects, has raised the possibility that the placebo effect 
could cause or exacerbate some side effects (e.g. Barsky et al., 2002). If so, warning 
participants about treatment side effects could lead them to expect and, thereby, 
experience more side effects.  
 
 To date the evidence supporting the claims that the placebo effect influences 
participants’ outcomes in double-blind RCTs and contributes to treatment side effects 
is quite limited. The current project, therefore, aimed to investigate these two aspects 
of the placebo effect more thoroughly. In each case this was done in an applied 
clinical setting with patients and experimentally with healthy volunteers. To examine 
the impact of expectancies in double-blind RCTs, I reanalysed a trial of acamprosate 
and naltrexone for alcohol dependence based on whether the participants believed 
they received active treatment or placebo (Chapter 3). In recognition of the limitations 
to these types of reanalyses, I developed an experimental model aimed at testing how 
observable changes affect participants’ beliefs about their treatment allocation and 
whether these beliefs affect their actual treatment responses in two dummy (placebo 
only) double-blind RCTs for cognitive performance (Chapter 4). To determine 
whether the placebo effect contributes to treatment side effects, I developed an 
experimental model to test whether warnings about side effects increase the actual 
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occurrence, frequency, or severity of side effects using placebo treatment for sleep 
difficulty in otherwise healthy volunteers (Chapter 6). This raised the possibility that 
placebo-induced side effects exist, but are only small. To address this possibility, I 
examined the extent to which patients’ expectancies for nausea were associated with 
their post-chemotherapy nausea in a large sample of first time chemotherapy patients 
(Chapter 7). Implications and limitations of these studies are discussed in Chapter 8.  
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Chapter 2: Review of Expectancies in Double-Blind RCTs 
 
 
2.1 Double-Blind Randomised Placebo-Controlled Trials 
 Double-blind randomised placebo-controlled trials (RCTs) are generally 
considered the benchmark for establishing the efficacy of a treatment. They are 
almost always required by the U.S. Food and Drug Administration for new drug 
approval (Shapiro & Shapiro, 1997b).This is because they aim to determine the true 
efficacy of a treatment, above and beyond the placebo effect and other forms of bias.  
 
 As their name suggests, there are three integral components to double-blind 
RCTs: a) placebo control, b) randomisation, and c) blinding. Placebo control involves 
comparing the treatment of interest (active treatment) with a placebo rather than with 
no treatment. This means that all participants in the trial engage in the treatment 
process, but only those in the active treatment group receive the specific component 
of the active treatment that is being tested. Randomisation involves randomly 
assigning participants to receive either the active treatment or placebo in an attempt to 
distribute any possibly confounding participant characteristics across these two 
groups evenly. This avoids biases that might arise if, say, those most likely to benefit 
are allocated to the active treatment (Altman & Bland, 1999). Blinding involves 
keeping which group the participants have been allocated to hidden from those 
involved in the trial.  
 
There are, in fact, three types of blinding possible in RCTs: single, double, and 
triple. Single blinding is when only the participants are unaware of their treatment 
allocation. In order to achieve this, participants are told that there is a chance that they 
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will receive active treatment or a placebo but that they will not know which one they 
have been given. Double blinding involves keeping the participants’ treatment 
allocation hidden from those administering the treatment as well as the participants. 
Triple blinding takes this one step further and ensures that researchers and/or 
assessors that have any contact with the participants are also unaware of the 
participants’ treatment allocation (Shapiro & Shapiro, 1997b). The three levels of 
blinding, then, can be thought of as; participant blinding, administrator blinding, and 
assessor blinding. Double-blind RCTs entail participant and administrator blinding, 
but not assessor blinding.  
 
In much the same way that randomisation is employed to distribute potentially 
confounding participant characteristics across groups, participant blinding is aimed at 
distributing expectancies evenly across groups. The rationale for this is that, if 
expectancies are balanced evenly across groups, then the placebo effect in each arm 
should be equivalent and any differences between the active treatment and placebo 
should be a direct result of the active treatment alone (Nash, 1962). As such, some 
participants in the treatment group may believe they are receiving active treatment, 
others may think they are on placebo, and others still might be unsure. Similarly, 
some participants in the placebo group might believe they are on active treatment, 
others may believe they are on placebo, and others still might be unsure. Importantly, 
it is not that participants will have no expectancy regarding their treatment allocation 
but that these expectancies are as evenly distributed across groups as possible. 
  
In addition to controlling for the placebo effect, blinding participants should 
also reduce sources of participant bias, such as demand characteristics and motivation 
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to change, that may influence the trial outcome as these should also be evenly 
distributed across groups. In a similar fashion, administrator blinding is intended to 
eliminate experimenter bias and control the context in which the treatment is 
delivered. Although often unintentional, experimenter bias may lead to biased 
interpretation of symptoms/outcomes that favour a preconceived hypothesis about the 
treatment or to differences in communication towards participants receiving active 
treatment and those receiving placebo (see Rosenthal, 2002 for a review). By ensuring 
that administrators are unaware of the participants’ treatment allocation any such bias 
should be equivalent in both the active treatment and placebo groups. Taken together, 
placebo control, randomisation, and blinding should mean that differences between 
the active treatment and placebo are real and occur as a direct result of the treatment’s 
efficacy and not the placebo effect, participant bias, or experimenter bias. This is why 
double-blind RCTs are considered such a powerful method for assessing the true 
efficacy of a treatment.  
 
 2.2 How Expectancies Can Limit the Validity of Double-Blind RCTs 
 Despite employing placebo control and blinding there are at least three ways 
in which participant expectancies can limit the validity of double-blind RCTs. The 
first of these is when participant blinding is unsuccessful, meaning that expectancies 
have not been adequately controlled. This can reduce the internal validity of these 
types of trials because the effect of the active treatment cannot be dissociated from the 
placebo effect. The second involves the possibility that the placebo effect could mask 
some or all of the active treatment’s effect, making it difficult to determine the 
magnitude of the true treatment effect, which can also reduce the internal validity of 
the trial. The third is that informing participants that they might receive a placebo 
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could reduce the external validity of double-blind RCTs because in standard clinical 
practice there is, presumably, no doubt that an active treatment is being administered. 
 
 Before discussing each of these potential limitations it is important to 
distinguish between the two types of expectancies with which participants are faced in 
double-blind RCTs: they are 1) expectancies regarding treatment allocation and 2) 
expectancies regarding treatment efficacy. Expectancies regarding treatment 
allocation (perceived treatment) involve beliefs about whether the participant has been 
allocated to receive active treatment or placebo and can be characterised by 
statements such as; “I believe I am taking active treatment” or “I believe I have been 
given the placebo”. Expectancies regarding treatment efficacy, on the other hand, 
involve beliefs about whether the treatment is likely to be effective. They can be 
characterised by statements such as “I believe this treatment is effective and will 
improve my symptoms” or “I do not believe this treatment is effective, it will not 
affect my symptoms”. Although expectancies regarding treatment allocation and 
efficacy are distinct, they are very likely to interact to produce an overall expectancy 
regarding the outcome of the treatment delivered in the double-blind RCT. For 
example, a participant may have a strong belief that the active treatment is effective, 
but may believe that he/she has been allocated to receive a placebo, in which case, 
he/she would likely expect no improvement. Alternatively, another participant may 
believe that the active treatment is highly effective and believe he/she has been 
allocated to receive active treatment in which case, he/she would likely expect 
improvement. In this way, perceived treatment might be thought of as the initial level 
of expectancy in double-blind RCTs that can activate or deactivate expectancies 
regarding efficacy.  
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 It is also important to note that both these types of expectancies will vary in 
strength. That is, one participant may have a very strong belief and feel certain that 
he/she has been allocated to receive active treatment, while another might have only a 
slight inclination that he/she is receiving active treatment. Similarly, a participant 
might believe very strongly that the active treatment is effective and expect large 
improvement, while another might believe that the treatment will have only a small 
effect. This makes the interaction between perceived treatment and expected efficacy 
more complicated because it is not necessarily clear what strength the perceived 
treatment must be to activate or deactivate the expected efficacy nor whether this 
relationship is additive. Nonetheless, if a participant does believe he/or she is on 
placebo, then this will likely diminish his/her overall expectancies regarding treatment 
outcome more than if he/she believed he/she was on active treatment regardless of 
strength. Expectancies for improvement are, therefore, likely to be stronger, on 
average, in those who believe they are receiving active treatment than those who 
believe they are on placebo.   
 
    
2.2.1 Failed blinding 
The first way in which expectancies can limit the validity of double-blind 
RCTs is when blinding fails. In these trials, accurate comparison between treatment 
and placebo is predicated on participants being unaware of their true treatment 
allocation so that expectancies do not bias outcomes in either arm. If blinding is not 
maintained, in that participants can guess their treatment allocation at a rate better 
than chance, then differences between the active treatment and placebo groups could 
occur as a result of the treatment alone, expectancy alone, or a combination of these 
two (Fergusson, Glass, Waring, & Shapiro, 2004; Fisher & Greenberg, 1993; 
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Swatzman & Burkell, 1998). This is because participants who know they are 
receiving active treatment are far more likely to expect improvement than participants 
who know they are receiving a placebo. Failed blinding, then, means that 
expectancies are not being adequately controlled and therefore presents a serious 
limitation to the internal validity of the trial. When blinding fails, the trial more 
closely resembles an open treatment versus no treatment comparison rather than the 
intended double-blind active treatment versus placebo comparison.  
 
Despite this possibility, very few researchers conducting double-blind RCTs 
assess whether blinding has been maintained. Several recent reviews have examined 
the frequency of checking for the success of blinding in a range of different RCTs.  
Karanicolas et al. (2008) found that only 3 (2%) of 171 double-blind RCTs of 
orthopaedic trauma published between 1995 and 2004 reported assessing whether 
blinding had been maintained. Fergusson et al. (2004) took a random sample of 100 
medical and 100 psychiatry double-blind RCTs published in selected high impact 
journals between 1998 and 2001 and found that only 15 (8%) of the 191 eligible trials 
reported that blinding had been assessed. These low rates are supported by researchers 
attempting to review common methods for assessing blinding finding only limited 
numbers of double-blind RCTs that have taken this precaution (e.g. Boutron, Estellat, 
& Ravaud, 2005; Fisher & Greenberg, 1993) 
 
One criticism of these reviews might be that blinding was assessed but not 
reported in some of these trials. If so, these reviews may underestimate the true rate of 
testing for blinding. Hróbjartsson, Forfang, Haahr, Als-Nelisen, and Brorson (2007) 
investigated this possibility in their review of all double-blind RCTs indexed in The 
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Cochrane Central Register of Controlled Trials and published in 2001. They identified 
1599 trials of which only 31 (2%) reported testing for the success or failure of 
blinding. They then took a random sample of 200 of the 1568 that did not report 
testing for blinding and sent questionnaires to the authors assessing whether blinding 
had been assessed but not reported. Of the 130 authors to respond, 15 (12%) did 
conduct some such test but failed to report the results. This suggests that assessing 
only published reports of testing for blinding does underestimate the true rate of 
testing, but only slightly. If Hróbjartsson et al.’s (2007) results are representative, then 
the number of double-blind RCTs that do test for blinding is around 14%, which is 
still very low considering the threat that failed blinding poses to the internal validity 
of these trials.  
 
 Perhaps even more alarming is that, when assessed, blinding is often found 
unsuccessful (e.g Margraf et al., 1991; Morin et al., 1995; Rabkin et al., 1986). 
Estimates from Fergusson et al. (2004), Hróbjartsson et al. (2007), and Karanicolas et 
al.’s (2008) reviews suggest that unsuccessful blinding occurs in anywhere between 
23%-60% of double-blind RCTs, with a high proportion of the remaining providing 
either insufficient or unclear data on the results of blinding. Many double-blind RCTs, 
therefore, cannot validly determine whether differences between active treatment and 
placebo result from the treatment itself or expectancy. Importantly, this is not to say 
that the active treatment is definitely ineffective in trials in which blinding is broken. 
In fact, participants’ ability to correctly guess their treatment allocation is often 
related to improvement in their symptoms (see Shapiro & Shapiro, 1997b for a 
review), which means that the probability of blinding being broken is actually likely 
to increase with the treatment’s efficacy (Sharpe, Ryan, Allard, & Sensky, 2003). 
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Nonetheless, failed blinding does mean that it is impossible to rule out expectancy as 
the cause of the active treatment’s observed superiority over placebo and this 
contradicts the aim of double-blind RCTs.    
 
 This concern is particularly relevant given increasing evidence that perceived 
treatment does impact on patient outcomes (e.g. Bausell et al., 2005; Dar et al., 2005; 
Lewis et al., 1975; McRae et al., 2004; Thomas et al., 2008). For example, in their 
double-blind RCT of dopamine transplantation and sham surgery for patients with 
Parkinson’s disease, McRae et al. (2004) found that perceived treatment predicted 
patient outcomes better than actual treatment allocation. Patients who believed they 
had received the transplantation demonstrated greater improvement in symptoms and 
reported higher quality of life than those who believed they had received the sham 
surgery, while there were only minimal differences between the dopamine 
transplantation and the sham surgery. Similarly, Bausell et al. (2005) observed no 
difference between real and sham acupuncture for pain following dental surgery in 
two single-blind RCTs, but found that those who believed they had received real 
acupuncture reported less pain than those who believed they had received sham 
acupuncture. These studies indicate that perceived treatment can be associated with 
participants’ treatment responses and reinforce the notion that failed blinding can 
invalidate double-blind RCTs. 
 
 Perhaps the most compelling evidence, however, comes from Dar et al.’s 
(2005) reanalysis of a double-blind RCT of nicotine replacement therapy for smoking 
cessation. The researchers conducting the original trial (Etter, Laszlo, Zellweger, 
Perrot, & Perneger, 2002) had observed that smokers receiving nicotine replacement 
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therapy smoked fewer cigarettes per day than those receiving placebo therapy and 
took this as evidence that nicotine replacement therapy is effective beyond the 
placebo effect. However, as with most double-blind RCTs, they had not considered 
participants’ perceived treatment beyond testing for the success of blinding at the end 
of the trial. When Dar et al. (2005) reanalysed the trial by including perceived 
treatment as a factor in addition to treatment allocation the difference between 
nicotine replacement therapy and placebo therapy disappeared. That is, the active 
treatment’s observed superiority over placebo was no longer evident when 
expectancies were controlled for. Furthermore, in both the active and placebo groups, 
participants who believed they were receiving nicotine smoked fewer cigarettes per 
day than those who believed they had been given a placebo, suggesting that perceived 
treatment was more important than actual treatment allocation.  
 
 While these findings demonstrate a strong association between perceived 
treatment and outcomes, there is some difficulty in interpreting the causal nature of 
this relationship. A placebo based interpretation would argue that participants who 
believe they are on active treatment will expect greater improvement than those who 
believe they are on placebo and that this will lead to greater improvement in the 
former. However, an alternative interpretation is that participants only come to 
believe they are taking active treatment because they experience improvement over 
the course of the trial. Here, improvement could result from the treatment itself or 
other factors, such as natural history. Thus, perceived treatment might influence 
treatment outcomes or treatment outcomes might influence perceived treatment.  
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 The studies described above are insufficient to differentiate between these two 
accounts because they are correlational in nature. While participants are randomly 
allocated to receive active treatment or placebo there is no control over whether 
participants believe they are receiving active treatment or placebo. Instead, 
participants are simply asked to retrospectively rate whether they believe they were 
given active treatment or placebo at the end of the trial. Although some studies have 
asked participants to rate their perceived treatment at multiple time points and as early 
as one week into the treatment (Margraf et al., 1991; Morin et al., 1995), there is still 
the possibility that some improvement has occurred by this time, not to mention that 
repeatedly questioning participants about their perceived treatment might affect their 
responses.  
 
 Even if the possible influence of treatment outcomes on perceived treatment 
could be ruled out, there are other factors that could account for perceived treatment’s 
effect on treatment outcomes. For example, those who believe they have been 
allocated to active treatment might be more compliant than those who believe they 
have been given placebo or might be more motivated to improve and engage in other 
beneficial activities.  
  
 While these concerns make it impossible to determine whether perceived 
treatment affects treatment outcomes, they do not eradicate the threat failed blinding 
poses to the internal validity of double-blind RCTs. The intention of double-blind 
RCTs is to control for the placebo effect and deduce whether any observed 
improvement results from the active treatment or expectancy. When blinding fails and 
participants can guess their allocation at a rate better than chance, expectancies are not 
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being properly controlled and this means that the researchers cannot be confident 
about the cause of any observed improvement in the treatment group.  
  
2.2.2 Expectancies masking the active treatment’s effect 
 The second way in which expectancies can limit the validity of double-blind 
RCTs concerns the possibility that the placebo effect could mask the active 
treatment’s effect. As discussed above, in double-blind RCTs the difference between 
the active treatment and placebo is believed to reflect the active treatment’s true 
efficacy beyond the effects of expectancy and other forms of bias. So, when blinding 
is maintained and those receiving active treatment show greater improvement than 
those receiving placebo, the active treatment is taken to be efficacious over and above 
any placebo effect. Conversely, when there is no difference between those receiving 
active treatment and placebo any improvement in those receiving active treatment is 
attributed to the placebo effect.  
 
 The central assumption on which this is based is that the treatment effect and 
placebo effect are additive. However, while treatment and placebo responses are often 
discussed as though the placebo effect simply adds onto the treatment effect, there are 
neither empirical nor theoretical reasons to support this view (Kirsch, 2000; Kirsch, 
Moore, Scoboria, & Nicholls, 2002). For example, Juliano and Brandon (2002) 
induced anxiety in briefly abstinent smokers and gave them cigarettes with either 
nicotine or no nicotine but told half of them that the cigarettes contained nicotine and 
the other half that the cigarettes were placebos. In those who received the placebo, 
smoking urges were lower for those who were told they would be receiving nicotine, 
indicating a placebo effect. In those given nicotine, however, there was an equal 
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reduction in smoking urges for those told to expect nicotine and those told to expect 
placebo. That is, nicotine reduced smoking urges without expectancy, but the addition 
of expectancy did not lead to further reductions despite evidence for a placebo effect. 
Importantly, this finding held when participants who did not believe the expectancy 
manipulation were excluded from the analysis. Evidence that placebo responses can 
differ to responses to hidden treatment (e.g. Hull & Bond, 1986) provides further 
support to the idea that active treatment and placebo effects may not be additive. A 
potential lack of additivity between treatment and placebo effects is perhaps 
unsurprising given that in classical conditioning some conditioned responses differ 
from the unconditioned response (e.g. Black, 1971; Glautier, Drummond, & 
Remington, 1992; Siegel, 1975).  
 
 If treatment and placebo responses are not additive, then the difference 
between the active treatment and the placebo will not accurately reflect the 
treatment’s effect without expectancy. This is particularly relevant when there is equal 
improvement in both the active treatment and placebo groups. In this instance, the 
most common conclusion would be that the active treatment only produced 
improvement via the placebo effect. An alternative explanation of this, however, is 
that the active treatment is efficacious without expectancy, but there were strong 
placebo effects in both the active and placebo groups that masked the active 
treatment’s effect. This possibility is a product of the fact that participant blinding 
attempts to evenly distribute expectancies regarding perceived treatment across the 
active treatment and placebo groups, as does randomisation for expectancies 
regarding treatment efficacy, rather than eradicating them. As such, participants will 
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still have expectancies regarding the trial outcome and this means that placebo effects 
within each arm are possible.  
 
 Linde et al.’s (2007) review of four double-blind RCTs comparing real 
acupuncture, placebo acupuncture, and a waitlist control for pain supports this 
possibility. While they found no differences between real acupuncture and placebo 
acupuncture, patients who had higher expectancies regarding the efficacy of 
acupuncture benefited more from the treatment than those who had low expectancies 
regarding acupuncture’s efficacy, regardless of what they actually received. Although 
they did not test for this possibility, Linde et al. (2007) argued that strong 
expectancies for improvement could create a ceiling effect whereby it is impossible to 
detect the effect of the treatment alone, i.e. without expectancy. If this is the case, then 
a lack of difference between the active treatment and placebo may not indicate that 
the active treatment has no unique effect. The same treatment delivered without 
participants’ awareness might lead to improvement, as with Juliano and Brandon’s 
(2002) study involving nicotine and denicotinised cigarettes administered with and 
without expectancy. This possibility limits the internal validity of double-blind RCTs 
because these trials cannot reliably determine whether the active treatment or the 
placebo effect has caused the improvement when there appears to be no difference 
between that active treatment and placebo groups.  
 
2.2.3 Differences between standard clinical practice and double-blind RCTs 
  The difference in expectancies that participants in double-blind RCTs are 
faced with compared with standard clinical practice reflects the third way in which 
double-blind RCTs can be limited. In double-blind RCTs participants will validly 
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question whether they have been allocated to receive active medication because they 
know there is a chance that they could receive a placebo. In standard clinical practice, 
however, it is highly unlikely that patients would doubt that they are receiving active 
medication (Barfod, 2005; Kirsch & Weixel, 1988; Nash, Holroyd, Rokicki, Kvaal, & 
Penzien, 2002). That is, while expectancies regarding the efficacy of the treatment can 
affect both participants in double-blind RCTs and patients receiving treatment in 
standard clinical practice, questions regarding perceived treatment are specific to 
participants in double-blind RCTs and other blinded placebo-controlled trials. If this 
translates into differences in overall expectancies regarding the outcome of the 
treatment, then one might expect greater efficacy for the same treatment in standard 
clinical practice, where there is no doubt that the treatment is active, compared with 
double-blind RCTs, where some doubt is likely, provided that the condition being 
treated is placebo-responsive. Outcomes found in double-blind RCTs may not, then, 
accurately reflect outcomes that would be found in standard clinical.  
 
 Relatively few studies have examined whether treatment responses differ 
under double-blind RCT administration compared with standard clinical practice.  
Skovlund (1991) compared the analgesic effect of paracetamol for uterine pain in 
postpartum women across two consecutive trials. The first trial was a double-blind 
RCT in which paracetamol was tested against placebo and, as such, women were 
aware that there was a possibility that they would receive a placebo. The second trial 
was also double-blind, but it was not placebo-controlled. Instead, paracetamol was 
tested against naproxen meaning that women in this trial, although unsure of the type, 
knew that they would be receiving an active analgesic, which approximates standard 
clinical practice. Women in the second trial reported lower uterine pain than those in 
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the first trial despite receiving the same dose of paracetamol. This supports the notion 
that treatment responses in double-blind RCTs can underestimate responses to the 
same treatment administered in standard clinical practice.  
 
 Rochon et al. (1999) compared receipt of nonsteroidal anti-inflammatory 
drugs for rheumatoid arthritis in 25 double-blind RCTs with 33 double-blind trials 
comparing the same treatment to another active treatment. As did Skovlund (1991), 
they found greater efficacy for the same treatment when participants knew they would 
be receiving an active treatment compared with when they knew there was a chance 
they were receiving a placebo. One limitation to both these studies, however, is that 
participants were not randomly allocated to the two types of treatment administration 
and this may have biased results.  
 
 Pollo et al. (2001) and Kirsch and Weixel (1988) conducted similar studies but 
used placebo treatment rather than active treatment and properly randomised their 
participants. Pollo et al. (2001) gave cancer patients recovering from thoracic surgery 
a continuous saline infusion. One group of patients was told that the infusion was a 
powerful painkiller, reflecting instructions analogous to standard clinical practice. A 
second group was told that the infusion might contain a powerful painkiller or saline, 
reflecting double-blind RCT administration. A third, control group was told that the 
infusion contained saline. Over the next three days, the patients who were told they 
were receiving a powerful painkiller required fewer analgesics compared with both 
those who were told they may receive a placebo and the control group, despite 
identical pain ratings. This implies a greater placebo effect in conditions analogous to 
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standard clinical practice compared with double-blind RCT administration, because 
fewer analgesics were required to achieve the same level of pain reduction.  
 
 Kirsch and Weixel (1988) administered decaffeinated coffee to their 
participants but told half that they were receiving caffeinated coffee, simulating  
instructions given in standard clinical practice, and told the other half that they were 
receiving either caffeinated or decaffeinated coffee, simulating double-blind RCT 
administration. As with Pollo et al. (2001) they found a larger placebo effect under 
standard clinical practice administration than double-blind RCT administration, in that 
mean heart rate was higher for those who were told they were receiving caffeine than 
those who were told they would receive either caffeine or placebo. 
 
Another small group of studies has examined whether there is an interaction 
between the instructions provided to participants and the treatment they receive, i.e. 
active or placebo, with less consistent results both within and across studies (Hughes, 
Gulliver, Amori, Mireault, & Fenwick, 1989; Kirsch & Rosadino, 1993; Nash et al., 
2002). For example, while Kirsch and Rosadino (1993) found that caffeinated coffee 
increased tension more than decaffeinated coffee only when participants were told 
they would be receiving caffeine and not when they were told they may receive 
caffeinated or decaffeinated coffee, they also found that caffeinated coffee increased 
alertness more than decaffeinated coffee regardless of whether participants were told 
they would be receiving caffeine or that they might receive caffeine or a placebo. 
  
 These inconsistent results are particularly difficult to disentangle given the 
general paucity of research in this area. What does seem clear, however, is that at least 
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under some circumstances double-blind RCT administration produces different 
treatment responses to standard clinical practice. Further, when this does occur, it 
seems that the most likely result is that double-blind RCT administration 
underestimates the magnitude of the treatment response that would be obtained in 
standard clinical practice (Kirsch & Rosadino, 1993; Kirsch & Weixel, 1988; Nash et 
al., 2002; Pollo et al., 2001; Skovlund, 1991 with only one exception, Hughes et al., 
1989). 
 
  While it is tempting to attribute any differences between double-blind RCTs 
and standard clinical practice to participant expectancies, there is another possible 
explanation. As mentioned earlier, the intention of participant blinding is to control 
for participant bias, such as demand characteristics and motivation to change, not just 
participant expectancies. This means that manipulating the instructions that 
participants receive about their treatment could also affect participant bias. For 
example, participants told that they have been given an active medication might feel 
more compelled to report improvement than participants who know there is a chance 
that they are receiving a placebo. This may seem like a particularly relevant 
possibility given that the majority of the above findings were for subjective outcomes. 
However, the higher heart rate in response to decaffeinated coffee for those who were 
told they were receiving caffeine compared with those who were told they would 
receive either caffeine or placebo observed by Kirsch and Weixel (1988) seems 
unlikely to have resulted from participant bias and points towards expectancy as a 
causal mechanism. There is also evidence from other studies that instructional 
expectancy manipulations can have a powerful effect on objective treatment responses 
(e.g. Benedetti, Maggi et al., 2003; Flaten, Simonsen, & Olsen, 1999). So it remains 
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likely that the differences in expectancies created in double-blind RCTs and standard 
clinical practice can cause differences in responses to the same treatment via the 
placebo effect in at least some circumstances.  
 
 There is, however, some caution required in interpreting the extent to which 
this limits double-blind RCTs. The primary aim of these trials is to determine the 
efficacy of an active treatment without expectancy, so the extent to which they 
replicate standard clinical practice is probably less important. It does, on the other, 
demonstrate that researchers and clinicians cannot reliably predict outcomes that 
would be achieved in standard clinical practice from double-blind RCTs. Further, it 
supports the notion that perceived treatment can impact on outcomes in these trials 
and that considering perceived treatment is essential for fully understanding treatment 
responses in double-blind RCTs.   
 
2.3 Alternatives to double-blind RCTs 
 In recognition of these limitations a number of alternatives to standard double-
blind RCTs have been suggested. These are 1) the balanced placebo design, 2) the 
‘open versus hidden’ design, and 3) the use of active rather than benign placebos as 
the control comparison. While each of these alternatives overcomes at least one 
problem associated with double-blind RCTs, they are not faultless. In most cases, 
overcoming one problem is associated with the introduction of another. Of course, 
some clinical trials avoid using placebo controls by comparing two active treatments, 
usually a standard treatment with established efficacy versus some new treatment. 
However, this approach is not considered as a true alternative to double-blind RCTs 
here, because these trials do not aim to determine the efficacy of a treatment above 
and beyond the placebo effect, they simply attempt to establish relative efficacy.  
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2.3.1 The Balanced Placebo Design 
 The balanced placebo design was developed by Ross, Krugman, Lyerly, and 
Clyde (1962). It consists of a 2x2 factorial design with treatment allocation and 
expected allocation as factors. Participants are allocated to receive the active 
treatment or a placebo and are either told that they have been given the active 
treatment or that they have been given a placebo. This produces four conditions as 
shown in Figure 2.1. One group (cell A) is given active treatment and are aware of 
this and, as such, should demonstrate the combined effects of the active treatment and 
the placebo effect. A second group (cell B) also receives active treatment but is told  
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Figure 2.1. The balanced placebo design: participants are allocated to receive either 
active treatment or placebo with half being told that they will receive active treatment 
and the others being told that they will receive a placebo.  
  
that they have been given a placebo. Any response to the treatment in this group 
should result from the active treatment alone. A third group (cell C) is given a placebo 
but is told they have been given the active treatment which means that any responses 
observed in this group should be the result of the placebo effect. Finally, a fourth 
group (cell D) receives a placebo and is aware of this. This group can, therefore, be 
considered a natural history group, in that no active treatment or placebo effects 
should occur. 
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 A number of studies investigating the effects of alcohol (see Hull & Bond, 
1986; Rohsenow & Marlatt, 1981 for reviews) and more recently nicotine (e.g. 
Gottlieb et al., 1987; Juliano & Brandon, 2002; Kelemen & Kaighobadi, 2007; 
Perkins et al., 2004) have employed the balanced placebo design. The main benefit of 
this method is that it can isolate the proportion of the treatment response that is 
uniquely attributable to the active treatment, the proportion of the treatment response 
that is uniquely attributable to the placebo effect, and, importantly, whether these two 
are additive (Kirsch et al., 2002). In this regard, the balanced placebo design is 
superior to double-blind RCTs because, without proof of additivity, the only 
conclusions the latter can validly draw is that the active treatment is more efficacious 
than placebo under double-blind RCT conditions. 
 
 The main problem with the balanced placebo design is that the deliberate 
deception inherent in this procedure is generally considered unethical (Kirsch et al., 
2002; Miller, Wendler, & Swartzman, 2005; Swatzman & Burkell, 1998; Waring, 
2008). While there has been ongoing debate regarding whether administering a 
placebo in double-blind RCTs is ethical  (Colloca, Lopiano, Lanotte, & Benedetti, 
2004; Shapiro & Shapiro, 1997b), there is no deception involved in these trials. 
Participants are informed that they will either receive active treatment or a placebo 
and this is exactly what happens (Miller et al., 2005; Waring, 2008). In the balanced 
placebo design, some participants are told they are receiving an active treatment when 
in fact they have been given a placebo and others are told they have been given a 
placebo, but are actually given active treatment. This makes double-blind RCTs much 
more ethically favourable than the balanced placebo design and is the most likely 
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reason that the balanced placebo design has only been used in healthy participants to 
date (Miller et al., 2005).  
 
2.3.2 The ‘Open versus Hidden’ Design 
 The ‘open versus hidden’ design involves comparing the efficacy of an active 
treatment in a group of participants who are aware that the treatment is being 
administered (open treatment), with a group of participants who are unaware that the 
treatment is being delivered (hidden treatment). The response to the hidden treatment 
is taken as the efficacy of the active treatment without expectancy and the response to 
the open treatment is taken as the active treatment plus any associated placebo effect. 
The main benefit of the ‘open versus hidden’ design, then, is that it can isolate the 
component of a treatment response that is attributable to the active treatment alone, 
which is not possible in double-blind RCTs. A second benefit, is that all participants 
receive active treatment, making it a better ethical alternative to both double-blind 
RCTs and the balanced placebo design (Benedetti, Maggi et al., 2003; Colloca et al., 
2004; Finniss & Benedetti, 2005; Kirsch, 2003). 
  
 Despite their greater ethical acceptability and usefulness for determining 
differences between an active treatment with and without expectancy, the ‘open 
versus hidden’ design is possible in only very limited circumstances (Colloca et al., 
2004). Most of the studies employing this design have been conducted in hospitals 
and involved intravenous injections delivered mechanically, a treatment context 
which is amenable to hidden administration (e.g. Amanzio, Pollo, Maggi, & 
Benedetti, 2001; Benedetti, Maggi et al., 2003; Gracely, Dubner, Wolskee, & Deeter, 
1983; Levine & Gordon, 1984). However, the majority of treatment will not be 
amenable. For example, it seems impossible to engineer hidden administration of oral 
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pills, a topical cream, or surgery. Further, comparing open and hidden treatment using 
this design does not control for the possibly confounding effects of participant bias. 
Participants receiving open treatment may be more subject to demand characteristics 
or more motivated to change than those receiving hidden treatment. Thus, not only is 
the ‘open versus hidden’ design impractical for the majority of treatments, it also re-
introduces the problem of participant bias.  
 
2.3.3 Active rather than benign placebos 
 The final alternative research design involves a slight modification to the 
standard double-blind RCT. It involves using an active placebo, which mimics the 
side effects of the active treatment, rather than a benign placebo as the control 
comparison. For example, atropine has been used as an active placebo for trials of 
tricyclic antidepressants (Gaudiano & Herbert, 2005). If participants’ guesses 
regarding their treatment allocation are influenced by side effects, then active 
placebos should make blinding harder to break because side effects should be 
equivalent in both groups (Edward, Stevens, Braunholtz, Lilford, & Swift, 2005; 
Fisher & Greenberg, 1993; Gaudiano & Herbert, 2005; Quitkin, 1999). As a result, 
active placebos may increase the internal validity of double-blind RCTs. 
 
 Although guesses about perceived treatment are not always based on side 
effects (e.g. Morin et al., 1995; Rabkin et al., 1986), in at least some cases they are 
(e.g. Margraf et al., 1991; Moscucci, Byrne, Weintraub, & Cox, 1987; or see Shapiro 
& Shapiro, 1997b for a review), which suggests that using active placebos may 
improve the success of blinding. A least one study has shown improved blinding as a 
result of using an active placebo (Turner, Jensen, Warms, & Cardenas, 2002). Further, 
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double-blind RCTs using active placebos tend to show diminished antidepressant 
effects compared with trials using benign placebos (Gaudiano & Herbert, 2005), 
which suggests that active placebos might ensure a more balanced distribution of 
expectancies across treatment arms.  
 
 Yet there are two important problems with employing active placebos: 
ethicality and practicality. Active placebos are used to emulate the adverse side 
effects of the active treatment and thereby produce adverse effects in those allocated 
to receive them. This means that participants in the active placebo group are likely to 
suffer at least some discomfort from their involvement in the trial in addition to being 
denied a potentially useful treatment (Boutron et al., 2006; Gaudiano & Herbert, 
2005; Max, 2007). As such, careful consideration must be given regarding the 
benefits and costs of administering an active placebo, which, in some circumstances, 
might undermine the ethicality of using these as controls in double-blind RCTs 
(Edward et al., 2005). The second criticism is that it might not always be easy to 
identify an appropriate active placebo and to be certain that its active component has 
no effect on the condition of interest (Max, 2007). If the active placebo does influence 
the condition being studied, whether positively or negatively, then the efficacy of the 
active treatment without expectancy cannot be validly determined.   
  
 In addition to these problems, double-blind RCTs that employ active placebos 
rather than benign placebos can still be limited because of the possibility that the 
placebo effect masks the active treatment and as a result of the difference in 
instructions between them and standard clinical practice. Further, although Turner et 
al. (2002) argued that their use of an active placebo improved blinding compared with 
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other trials employing benign placebos, 70% of their participants were still able to 
correctly guess that they had been allocated to receive active treatment. Thus, using 
active placebos does not necessarily overcome any of limitations introduced to 
double-blind RCTs as a result of participant expectancies. 
  
 
2.4 Conclusions 
 Double-blind RCTs do not eradicate expectancies, but simply aim to control 
for them. Participants in these trials will form expectancies both about the efficacy of 
the treatment (expected efficacy) and whether or not they have been allocated to 
receive active treatment or placebo (perceived treatment). There are a number of ways 
that these expectancies can undermine the validity of double-blind RCTs. Firstly, 
researchers conducting these trials rarely assess whether blinding has been maintained 
and, when they do, it is often found to be unsuccessful. This means that differences in 
perceived treatment could contribute to any observed differences between the active 
treatment and placebo groups and this thereby limits the internal validity of the trial. 
Secondly, double-blind RCTs do not test for the additivity of the active treatment’s 
effect and the placebo effect, which means that a failure to detect a difference 
between the active treatment and the placebo is not sufficient evidence that the active 
treatment in ineffective without expectancy. Thirdly, expectancies regarding 
perceived treatment are specific to double-blind RCTs and other trials that employ 
participant blinding, which means that double-blind RCTs may underestimate 
treatment outcomes that would be obtained in standard clinical practice.  
 
 By far the biggest limitation to understanding the full impact of expectancies 
in double-blind RCTs is that the research to date cannot determine whether perceived 
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treatment has a causal impact on actual treatment responses. The main reason for this 
is that there are relatively few studies investigating the role of perceived treatment in 
double-blind RCTs and, in those that have, there is very little attempt to control for 
other possible contributing factors, such as demand characteristics and motivation. 
Thus, while perceived treatment is often found to be related to treatment responses, it 
is unclear whether participants who believe they are taking active treatment 
experience improvement as a result of that expectation or whether experiencing 
improvement causes a participant to believe that he/she is taking active treatment. 
Equally possible is that any impact of perceived treatment on actual treatment 
responses is mediated by motivation or other similar psychological variables. For 
example, a person who believes he/she is taking active treatment may be more 
motivated to improve than a person who believes he/she is taking placebo and this 
increased motivation may result in greater improvement, not the expectancy.  
 
 In an attempt to overcome these limitations, I examined whether perceived 
treatment predicted actual treatment responses in a previous double-blind RCT of 
alcohol dependence in which blinding was maintained and after controlling for 
motivation to change (Chapter 3). In two experimental studies I also tested whether 
observable improvement affects perceived treatment and whether this, in turn, affects 
treatment responses. This involved conducting dummy (placebo only) double-blind 
RCTs and providing participants with false feedback about their performance in order 
to experimentally manipulate their perceived treatment (Chapter 4).  
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Chapter 3: Perceived Treatment in a Double-Blind RCT for 
Alcohol Dependence (Study 1) 
 
3.1 Introduction 
 This study investigated the relationship between perceived treatment and 
treatment outcomes in a double-blind RCT comparing acamprosate, naltrexone, and 
placebo for alcohol dependence. This consisted of reanalysing the trial as a 2x2 design 
with actual treatment and perceived treatment as factors. Of interest was whether 
perceived treatment was more reliably associated with the various indices of alcohol 
dependence and the number of adverse side effects than was actual treatment. As 
discussed in the previous chapter, this type of analysis has previously been conducted 
for double-blind RCTs of acupuncture for pain (Bausell et al., 2005), neurosurgery for 
Parkinson’s disease (McRae et al., 2004), smoking cessation (Dar et al., 2005; 
Thomas et al., 2008), and vitamin C for the common cold (Lewis et al., 1975). In all 
of these studies, participants who believed they were receiving active treatment 
showed greater improvement than participants who believed they were receiving a 
placebo, irrespective of the actual treatment they received.  
 
 The double-blind RCT reanalysed here was originally reported in Morley et al. 
(2006) and had a number of characteristics that made it particularly useful for 
exploring the relationship between perceived treatment and actual treatment 
responses. First, the researchers conducting the trial assessed participants’ perceived 
treatment at the end of the trial in order to test for the success for blinding, which 
made the current reanalysis possible. Second, blinding was maintained and there was 
no difference between the active treatments and placebo in the primary analysis. This 
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means that actual and perceived treatment should be relatively independent of each 
other compared with trials in which blinding fails. In all but one of the reanalyses 
mentioned above blinding was unsuccessful and that study (McRae et al., 2004) 
contained a very small sample who appeared overly optimistic about their chances of 
receiving the active treatment. Finally, the researchers assessed participants’ 
motivation to change before and after treatment which meant that this could be 
included as a covariate in the analysis. This was beneficial because perceived 
treatment could result in differences in motivation to change if, say, participants who 
believe they have been given a placebo become discouraged and feel that their 
participation in the trial will not benefit them. If this were the case, then poorer 
outcomes in these participants compared with those who believe they are taking active 
treatment could result from the former’s reduced motivation, rather than differences in 
expectancy.  
   
3.2 Methods 
 A full description of the methods used in the original trial can be found in 
Morley et al. (2006). A summary of these is given below, along with the design and 
data analysis for the current analysis. It should be noted that, despite assessing 
perceived treatment, the researchers conducting the original trial used this information 
only to test whether blinding had been achieved. As such, the analysis reported below 
is entirely novel with respect to the original study.  
 
3.2.1 Participants 
 One hundred and sixty-nine men and women diagnosed with alcohol 
dependence or abuse, according to the Diagnostic and Statistical Manual IV, took part 
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in the trial. They were recruited during attendance at an inpatient detoxification 
programme, an out-patient treatment follow-up, and via live and print advertisements.  
 
3.2.2 Design 
 The reanalysis was based on a 2x2 design with actual treatment and perceived 
treatment as factors. In order to achieve this, the four treatment types, naltrexone, 
acamprosate, naltrexone placebo, and acamprosate placebo were simplified into either 
active treatment, i.e. acamprosate and naltrexone, or placebo. This was justified on the 
basis that there were no differences found between acamprosate and naltrexone in the 
primary analysis of the original trial. Perceived treatment was based on participants’ 
guesses regarding their treatment allocation at the end of the trial, which could be 
either active or placebo. The dependent variables were days until first relapse, total 
number of days abstinent, total alcohol consumption during the trial, posttreatment 
alcohol dependency, posttreatment alcohol cravings, and number of adverse side 
effects.   
 
3.2.3 Measures 
 Drinks diary: Participants were required to complete a diary comprised of 
daily cards which assessed their alcohol consumption, compliance, and adverse side 
effects for each day they received treatment. Chick, Howlett, Morgan, and Ritson 
(2000), who were the first to use these daily cards, found a high level of consistency 
between them and serum -glutamyl transferase activity, an objective measure of 
alcohol consumption, suggesting they have good validity. The diary was used to 
derive the number of days until first relapse, the total number of days abstinent, total 
alcohol consumption during the treatment period, and number of adverse side effects.  
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 Alcohol dependence: was assessed via the Alcohol Dependence Scale (ADS: 
Skinner & Allen, 1982). The scale contains 25 items that assess alcohol withdrawal 
symptoms, impaired control over drinking, awareness of compulsion to drink, 
increased tolerance to alcohol, and strength of drink-seeking behaviour. Higher scores 
on the ADS correspond to greater alcohol dependence.  
 
 Alcohol cravings: were assessed using the Penn Alcohol Craving Scale 
(PACS: Flannery, Volpicelli, & Pettinati, 1999). The scale contains 5 items that assess 
the frequency, intensity, and duration of thoughts about drinking. Higher scores on the 
PACS indicate more alcohol cravings.  
 
 Motivation to change: was assessed with the Stages of Change Readiness and 
Treatment Eagerness Scale (SOCRATES: Miller & Tonigan, 1996). The scale was 
designed specifically for problem drinkers and contains 19 items that assess taking 
steps to overcome problem drinking, recognition of problem drinking, and 
ambivalence towards problem drinking. Higher scores on the SOCRATES correspond 
to greater motivation to change.  
 
3.2.4 Procedure 
 After informed consent was obtained, participants were required to remain 
abstinent from alcohol for a minimum of 3 days, but not more than 21 days, prior to 
the baseline assessment, which involved assessing demographics, alcohol 
consumption, alcohol dependence and cravings, and motivation to change. 
Participants were then randomised to receive naltrexone, acamprosate, naltrexone 
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placebo or acamprosate placebo for 12 weeks and occasional compliance therapy 
sessions. The compliance therapy involved discussing problems that might affect 
treatment compliance, such as, ambivalence and misconceptions about medications 
(Teesson et al., 2003). During the treatment period participants were asked to keep a 
drinks diary which was used to monitor their alcohol consumption and cravings. At 
the end of the 12 weeks, participants underwent a posttreatment assessment of alcohol 
dependence and cravings, motivation to change, compliance, and perceived treatment. 
The study was approved by the Human Ethics Review Committees of Central Sydney 
Area Health Service, South Eastern Sydney Area Health Service and Wentworth Area 
Heath Service.  
 
3.2.5 Statistical Analysis 
Analysis of variance (ANOVA) and Fisher’s exact test were used to assess 
whether there were differences in baseline characteristics across actual treatment and 
perceived treatment. These included age, sex, abstinence and average number of 
drinks per day before the trial, and pretreatment alcohol dependence, alcohol cravings 
and motivation to change. Analysis of co-variance (ANCOVA) was used to test for 
differences in compliance, the number of counselling sessions attended, and 
posttreatment motivation to change at the end of the trial, while controlling for age, 
sex, and pretreatment abstinence, average number of drinks and alcohol dependence. 
Blinding was confirmed via a Chi-square test of independence. 
 
ANCOVA was used to test the impact of actual treatment, perceived 
treatment, and their interaction on days until relapse, total days abstinent, total alcohol 
consumption, alcohol dependence, and alcohol cravings. Age, sex, baseline 
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abstinence, alcohol dependence and average number of drinks per day, number of 
pills involved in the treatment regimen, and posttreatment motivation to change were 
included as covariates. Alcohol cravings at baseline were also included as a covariate 
when posttreatment alcohol cravings was the outcome variable. ANCOVA also tested 
the impact of actual and perceived treatment on the number of adverse side effects. 
Here, age, sex, and number of pills involved in the treatment regimen were included 
as covariates. All statistical analyses were conducted using SPSS software (version 
15; SPSS Inc, Chicago, Ill) and results were considered significant when p<.05. 
  
3.3 Results 
3.3.1 Baseline characteristics 
 Of the 169 participants who were recruited, 116 (69%) completed the trial 
including responding to the question regarding their perceived treatment. They had a  
 
Table 3.1. Baseline characteristics across actual treatment and perceived treatment. 
Means (SE) are given for continuous variables, percentage male is given for sex, and 
* denotes p<.05.    
 Receive Active Receive Placebo 
 Believed Active Believed Placebo Believed Active Believed Placebo 
Age* 47.5 (1.3) 47.3 (1.8) 44.4 (1.9) 41.7 (1.7) 
Sex (% male) 67.4 76.9 52.4 65.7 
Abstinence 4.7 (.53) 5.2 (.71) 5.0 (.79) 4.6 (.80) 
Drinks/day 13.0 (1.1) 11.7 (1.4) 10.2 (1.6) 13.0 (1.5) 
ADS 20.5 (1.3) 19.5 (1.7) 19.4 (1.9) 21.6 (1.8) 
PACS 18.7 (1.1) 18.3 (1.4) 18.1 (1.6) 15.9 (1.5) 
SOCRATES 27.4 (.48) 25.8 (.63) 26.6 (.70) 27.0 (.67) 
 
 
mean age of 45.7 years (range 23-66) and the majority were male (66%). Table 3.1 
provides details of the baseline characteristics of these participants according to their 
actual treatment and perceived treatment. The only significant difference was for age, 
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which indicated that those receiving active treatment were significantly older than 
those receiving placebo treatment, F(1,112)=6.32, p=.01.  
 
3.3.2 The success of blinding 
 Table 3.2 shows the distribution of participants according to their actual 
treatment and perceived treatment. A Chi-square test of independence revealed that 
there was no significant association between actual treatment and perceived treatment 
indicating that blinding was maintained, χ2(df=1, n=116)=2.9, p=.07. There was, 
however, a tendency for those receiving active treatment to be more likely to believe 
they had been given active treatment than placebo.    
Table 3.2. Distribution of participants according to their actual treatment allocation 
and their perceived treatment allocation.  
  
  Perceived Treatment  
   Active Placebo 
Actual Treatment 
     Active 
     Placebo 
 
46 
 
26 
 
72 
21 23 44 
Total 67 49 116 
 
 
3.3.3 Total alcohol consumption 
 After controlling for baseline characteristics, number of pills, and motivation 
to change, the main effect of expectancy for total alcohol consumption was 
significant. As shown in Figure 3.1, participants who believed they had been allocated 
to receive active treatment reported consuming147 less drinks than participants who 
believed they had been allocated to receive placebo, F(1,89)=7.84, p<.01. There was, 
however, no main effect of actual treatment and no interaction between this and 
perceived treatment, highest F(1,89)=1.65, p=.20. 
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Figure 3.1. Covariate adjusted mean (+SE) total alcohol consumption by actual and 
perceived treatment. Those who believed they were receiving active treatment 
consumed significantly fewer drinks than those who believed they were receiving 
placebo. The main effect of actual treatment and the interaction were not significant. 
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Figure 3.2. Covariate adjusted mean (+SE) alcohol dependence score (ADS) across 
actual and perceived treatment. Those who believed they were taking active treatment 
reported significantly lower alcohol dependence than those who believed they were 
receiving placebo. No other differences were significant.  
 
 
 
Total Alcohol Consumption
0
50
100
150
200
250
300
350
400
450
Believed Active Believed Placebo
To
ta
l A
lc
oh
ol
ic
 D
rin
ks
 
Received Active
Received Placebo
p<.01
 56 
3.3.4 Alcohol dependence ratings 
 Alcohol dependence ratings at the end of the trial are presented in Figure 3.2. 
After controlling for baseline characteristics, number of pills, and motivation to 
change, the only significant difference was for perceived treatment. Participants who 
believed they received active treatment rated their alcohol dependence as 4.2 points 
lower than those who believed they had received the placebo, F(1,89)=4.48, p=.04. 
There was no significant effect of actual treatment on alcohol dependence ratings, nor 
a significant interaction, both F<1. 
 
3.3.5 Alcohol cravings 
 A similar pattern of results was found for alcohol cravings, as shown in Figure 
3.3. Participants who believed they had been given the active treatment reported 
alcohol cravings 5.6 points lower than participants who believed they had been given 
the placebo, after controlling for baseline characteristics, number of pills, and 
motivation to change, F(1,87)=8.77, p=.01. Again, there were no significant 
differences for actual treatment and no interaction, highest F(1,87)=1.28, p=.26. 
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Figure 3.3. Covariate adjusted mean (+SE) alcohol cravings (PACS). Those who 
believed they were on active treatment reported significantly lower cravings than 
those who believed they were on placebo. No other differences were significant.  
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3.3.6 Total number of days abstinent 
 Total number of days abstinent across actual and perceived treatment is shown 
in Figure 3.4. After controlling for baseline characteristics, number of pills, and 
motivation to change, both actual and perceived allocation were non-significant, both 
F<1. There was, however, a significant interaction which indicated that the difference 
in abstinence between expecting active treatment and expecting placebo was not the 
same for those receiving active treatment compared with those receiving placebo, 
F(1,89)=4.50, p=.04.  
 
Figure 3.4. Covariate adjusted mean (+SE) number of days abstinent across actual 
and perceived treatment. There were no main effects of actual and perceived 
treatment, although their interaction was significant.  
 
 
3.3.7 Number of days until relapse 
 The mean number of days until relapse across actual and perceived treatment 
is shown in Figure 3.5. While there were tendencies towards longer time until relapse 
for those who believed they had received active treatment compared with those who 
believed they had been given placebo and for those actually receiving active treatment 
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compared with those receiving placebo, these differences were not significant after 
controlling for baseline characteristics, number of pills, and motivation to change, 
highest F(1,89)=1.91, p=.17. There was also no interaction between perceived 
treatment and actual treatment for number of days until relapse, F<1.  
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Figure 3.5. Covariate adjusted mean (+SE) number of days until relapse across actual 
and perceived treatment allocation. No differences were significant. 
 
 
3.3.8 Number of adverse side effects 
 Number of adverse side effects showed the same pattern as total alcohol 
consumption, alcohol dependence, and alcohol cravings. As shown in Figure 3.6, after 
controlling for baseline characteristics, number of pills, and motivation to change, 
participants who believed they received active treatment reported significantly more 
adverse side effects than participants who believed they received a placebo, MD=.48, 
F(1,109)=4.00, p<.05. There were no differences in the number of adverse side effects 
reported between those who received active treatment and those who received 
placebo, nor was there a significant interaction , highest F(1,109)=2.32, p=.13. 
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Figure 3.6. Covariate adjusted mean (+SE) number of adverse side effects across 
actual and perceived treatment allocation. Participants who believed they received 
active treatment reported significantly more adverse side effects than those who 
believed they received placebo. No other differences were significant. 
 
3.3.9 Compliance, counselling, and posttreatment motivation to change  
 Means for number of days compliant, number of counselling sessions 
attended, and posttreatment motivation to change are presented in Table 3.3. There 
were no significant differences in any of these variables for actual treatment, 
perceived treatment, and their interaction after controlling for age, sex, abstinence and 
average number of drinks per day before the trial, and pretreatment alcohol 
 
Table 3.3. Mean (SE) number of days compliant with treatment instructions 
(compliance), number of counselling sessions attended (counselling), and 
posttreatment motivation to change (SOCRATES) by actual and perceived treatment. 
No differences were significant.   
  
 Receive Active Receive Placebo 
 Expect Active Expect Placebo Expect Active Expect Placebo 
Compliance 72.9 (3.0) 69.2 (4.4) 67.1 (4.0) 69.2 (4.3) 
Counselling 4.2 (.31) 4.4 (.46) 3.8 (.41) 3.2 (.44) 
SOCRATES 25.9 (.60) 25.9 (.91) 25.6 (.87) 27.3 (1.0) 
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dependence with relevant baseline characteristics controlled for. There was, however, 
a marginally non-significant trend for participants who believed they received active 
treatment to attend more counselling sessions than those who believed they received 
placebo, F(1,115)=3.64, p=.06, all others F<1.  
 
3.4 Discussion 
 As previously reported (Morley et al., 2006) there were no differences 
between those receiving the active treatment and those receiving the placebo. The 
new finding was that participants who believed they were given active treatment 
reported drinking less, being less alcohol dependent, and craving less alcohol than 
those who believed they were given a placebo. These effects were substantial, 
especially for total alcohol consumption. Here, participants who believed they 
received active treatment reported consuming half as many alcoholic drinks as 
participants who believed they received placebo. These effects were also not limited 
to positive outcomes. Participants who believed they received the active treatment 
also reported more adverse side effects than participants who believed they received a 
placebo. The lack of interaction between actual and perceived treatment for these 
outcomes suggests that the effect of perceived treatment was independent of the actual 
treatment participants were receiving. In fact, the only significant interaction between 
actual and perceived treatment was for total number of days abstinent.  
   
These findings are consistent with previous studies that have shown that 
perceived treatment is related to actual treatment responses (Bausell et al., 2005; Dar 
et al., 2005; Lewis et al., 1975; McRae et al., 2004; Thomas et al., 2008). The current 
reanalysis was, however, unique in that blinding was maintained and there was no 
 61 
effect of the active treatment compared with placebo. As a result, actual and perceived 
treatment were likely to have been independent of each other. Furthermore, the effects 
found here were after controlling for motivation to change, which suggests that 
motivation cannot account for the relationship between perceived treatment and actual 
treatment responses. This point is strengthened by the lack of significant differences 
observed between those who believed they received active treatment and those who 
believed they received placebo for compliance, number of counselling sessions 
attended, and posttreatment motivation.   
  
 There was, however, a fundamental limitation to this reanalysis. Because 
participants’ beliefs about their treatment were assessed retrospectively, it is 
impossible to determine the direction of causality between perceived treatment and 
actual treatment responses. As discussed in Chapter 2, participants who believe they 
are receiving active treatment are much more likely to expect improvement than those 
who believe they are receiving a placebo, and this may lead to greater improvement 
and adverse side effects in the former via the placebo effect. On the other hand, 
participants who noticed improvement as a result of spontaneous remission or random 
fluctuations in their symptoms may have simply concluded that they were taking 
active treatment. The same applies for adverse side effects. Importantly, this is a 
limitation that applies to all retrospective reanalyses of perceived treatment in double-
blind RCTs. A second limitation is that all outcomes assessed here were self reported 
and therefore subject to participant bias. Particularly concerning is the possibility for 
demand characteristics, which could have contributed to the observed differences in 
outcomes between those who believed they received active treatment and those who 
believed they received a placebo. This is also a limitation that applies to all previous 
 62 
reanalyses, with the exception of Thomas et al. (2008),who verified the higher rates of 
smoking cessation in participants who believed they received active treatment by 
assessing carbon monoxide and cotinine.   
 
 Overall, this reanalysis adds to the literature by confirming the strong 
relationship between perceived allocation and actual treatment responses, in this case, 
for treatment for alcohol dependence and adverse side effects. The success of blinding 
and the active treatment’s lack of efficacy suggest that these findings were not 
contaminated by a strong relationship between active and perceived treatment. The 
inability to determine the causal direction of the relationship between perceived 
allocation and treatment outcome highlights an important limitation to these types of 
studies as does the potential for participant bias, particularly demand characteristics. 
In the next chapter, I address these limitations by using feedback to experimentally 
manipulate participants’ perceived treeatment and incorporating objective outcome 
variables in two dummy (placebo only) double-blind RCTs for cognitive 
performance. In later chapters, I also explore the relationship between expectancy and 
adverse side effects.   
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Chapter 4 – Perceived Treatment, False Feedback, and 
Cognitive Performance: Two Dummy Double-Blind RCTs 
(Study 2) 
 
4.1 Introduction 
 The reanalysis conducted in the previous chapter demonstrated a strong 
relationship between perceived treatment and actual treatment responses in a double-
blind RCT for alcohol dependence. This is consistent with other similar reanalyses 
(Bausell et al., 2005; Dar et al., 2005; Lewis et al., 1975; McRae et al., 2004; Thomas 
et al., 2008). The two advantages of my reanalysis were that blinding was maintained, 
meaning that there was likely to be a smaller relationship between actual and 
perceived treatment, and the ability to control for motivation to change. However, it 
also highlighted two important limitations that apply to these types of studies. They 
are: 1) the inability to determine the direction of causation between perceived 
treatment and actual treatment responses and 2) the predominant use of self reported 
outcomes that allow for participant bias, particularly demand characteristics.  
 
 While the problem of self reported outcomes can be overcome by the inclusion 
of objective outcome measures, the inability to determine the causal nature of the 
relationship between perceived treatment and actual treatment responses reflects a 
more significant problem. This concerns whether participants improve because they 
believe they have been given active treatment or whether they believe they have been 
given active treatment because they improved. The reanalyses conducted in Chapter 3 
and elsewhere cannot differentiate between these two possibilities because they are 
retrospective. They make no attempt to manipulate participants’ perceived treatment 
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but simply measure the association between these beliefs and participants’ treatment 
responses. Although there is also evidence that perceived treatment appears to be 
influenced by improvement (see Shapiro & Shapiro, 1997b for a review), this is also 
retrospective and is equally insufficient. The only difference between this and the 
reanalyses mentioned above is the choice to use treatment response as the independent 
variable and perceived treatment as the dependent variable. In essence, they are 
assessing the same relationship but from a different point of view.  
  
 By far the biggest hindrance to determining the direction of causation between 
perceived treatment and actual treatment responses is the lack of experimental studies 
in this area. The only experimental studies that I am aware of which consider 
perceived treatment have compared instructions given as in double-blind RCTs with 
those given in standard clinical practice (Hughes et al., 1989; Kirsch & Rosadino, 
1993; Kirsch & Weixel, 1988; Nash et al., 2002; Pollo et al., 2001). To my 
knowledge, there have been no experimental studies that have assessed whether 
differences in perceived treatment lead to differences in actual treatment responses 
within double-blind RCTs.  
 
 With this in mind, the following two experiments were aimed at developing an 
experimental model in which the relationship between perceived treatment and actual 
treatment responses could be examined more closely. This involved dummy double-
blind RCTs in which participants received placebo treatment under the guise of a 
double-blind RCT for cognitive performance. The first advantage of this was that any 
potential confound between active treatment and perceived treatment was eliminated 
because all participants received placebo. The second advantage was that the feedback 
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participants received about their cognitive performance could be manipulated. This 
meant that I could directly test whether observable improvement, albeit bogus, 
influenced participants’ perceived treatment. The third advantage was that I could 
assess whether perceived treatment predicted cognitive performance beyond any 
effect of the feedback manipulation itself. In the second experiment, this was taken 
further by comparing the influence of feedback in participants undergoing the dummy 
double-blind trial, that is when it was likely to induce beliefs about treatment 
allocation, with another group of participants who were told they were controls in a 
trial for cognitive performance and received no treatment, where no such beliefs could 
be expected. This meant that I could ensure that any effect of perceived treatment was 
due to participants’ beliefs, rather than the feedback manipulation itself.   
 
4.2 Experiment 1 
 Experiment 1 was a dummy double-blind RCT of caffeine for cognitive 
performance. Participants were asked at the end of the trial whether they believed they 
had been given caffeine or a placebo and asked to rate their confidence regarding this 
belief. There were three main points of interest. The first was whether participants 
who received false feedback indicating improvement as a result of their treatment 
would be more likely to believe they had consumed caffeine than those who received 
false feedback indicating no change as a result of their treatment. The second was 
whether perceived treatment predicted actual cognitive performance, independently of 
any effect of the false feedback. The third was whether confidence ratings regarding 
perceived treatment accounted for more variation in cognitive performance than did 
forced choice perceived allocation, if perceived treatment did predict cognitive 
performance.  
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4.3 Methods 
4.3.1 Participants 
 Thirty-one (18 female) first year psychology students from the University of 
Sydney participated in order to gain course credit. The participants had a mean age of 
18.7 (SD=.98) and drank an average of less than one cup of caffeinated coffee per day 
(mean=0.85, SD=.80).  
 
4.3.2 Design 
 Experiment 1 involved a single factor, 2 level design. Participants were told 
that they were taking part in a double-blind RCT of caffeine for cognitive 
performance (see Appendix 3a), but were all given a benign placebo (lactose). The 
experimental manipulation was the false feedback participants were given about their 
performance before and after receiving the placebo. As shown in Figure 4.1, 
participants completed a cognitive task three times. The first represented their 
baseline performance, the second represented their performance after treatment but 
before feedback (pre-feedback), and the third reflected their performance after both 
treatment and the feedback manipulation (post-feedback). Half of the participants 
were given feedback indicating that their cognitive performance had improved from 
baseline after receiving treatment on the two subsequent tests (positive feedback). The 
other half of the participants received feedback indicating no change from baseline as  
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Figure 4.1. Design for Experiment 1. Participants in the positive feedback group 
received false feedback indicating that they improved by 20% from baseline after the 
treatment was delivered on the two subsequent tests. Participants in the no change 
feedback group received false feedback indicating that there was no change in their 
cognitive performance after the treatment was delivered.  
 
a result of their treatment (no change feedback). In both cases the feedback was 
independent of the participants’ actual performance. After the final cognitive task, 
participants were asked about their perceived treatment. The study was single-blind 
and participants were randomly allocated to either positive or no change feedback.  
 
4.3.3 Materials  
Placebo Pills: The placebo pills were made from lactose and were white 
coated. They were prepared by the Faculty of Pharmacy, University of Sydney.  
 
Cognitive Task: The cognitive task used rapid visual information processing 
(RVIP) to assess sustained attention. This was based on the RVIP task used by 
Yeomans, Ripley, Davies, Rusted, and Rogers (2002) who found that caffeine 
improved accuracy and decreased reaction times. Numbers ranging from 1-8 were 
presented in the middle of a computer screen at a rate of 120/min. The participants 
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were required to press the space bar as quickly as possible as soon as they identified 
either three consecutive even or three consecutive odd numbers. Participants had 1.5s 
to make a correct response with all responses outside this time considered false 
alarms. Each version of the task lasted 5min and the sequence of numbers was semi-
random such that there were 8 targets every minute. The programme recorded the 
number of correct responses (hits), the number of incorrect responses (false alarms; 
FA), and the reaction time for a correct response. A non-parametric measure of 
accuracy was calculated, namely                        (McNicol, 1972), so that a single 
score considered both hits and false alarms. To avoid the influence of outliers, the 
median reaction time for a hit was taken as the measure of reaction time. 
  
 Feedback: The feedback manipulation was incorporated into the cognitive 
task. At the end of each test participants received feedback regarding their 
performance. This was in the form of a bogus percentage accuracy score such that all 
baseline scores varied randomly from 40-60%. Then, those receiving positive 
feedback received scores indicating a 20±2% increase from baseline on the two 
posttests while participants receiving neutral feedback received scores indicating no 
change from baseline, that is a 0±2% change.  
  
 Beliefs Questionnaire (Appendix 3b): This was a study-specific questionnaire 
containing a forced choice question that asked participants whether they believed they 
had received caffeine or placebo. This question read ‘Do you think that you were 
given the caffeine pill or the placebo pill?’. The next question asked participants to 
rate how confident they were about their perceived medication using an 11-point (0 to 
10) Likert-type scale. This read ‘On a scale from 0-10, how certain are you that this is 
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the treatment you received?’. The scale was anchored by ‘Not at all’, a confidence 
rating of 0, and ‘Extremely certain’, a confidence rating of 10. These confidence 
ratings served two purposes. First, they allowed for the assessment of differences in 
the strength of confidence about perceived treatment between those who believed they 
had received caffeine and those who believed they had received placebo. Second, this 
scale was used as a predictor of cognitive performance by converting the 11-point 
scale to a 21-point scale (-10 to 10) that reflected perceived treatment and confidence 
simultaneously. This was done by allocating those who believed they received the 
placebo a negative score for this question while those who believe they received 
active treatment maintained positive scores. As such, the original 11-point scale can 
be thought of as the strength of perceived treatment, while the 21-point scale can be 
thought of as perceived treatment ratings.  
 
4.3.4 Procedure 
 Participants attended a single one hour session. The information sheet (see 
Appendix 3a) explained that the study was a double-blind RCT of caffeine aimed at 
confirming that caffeine increases cognitive performance. After informed consent was 
gained, the experimenter described the RVIP task to the participants and gave them an 
opportunity to practise on two 30s trial versions with no feedback given. In order to 
make the feedback manipulation meaningful, participants were told that university 
students of the same age typically scored between 40-60% on the cognitive task. After 
this, the participants completed an initial 5min version of the RVIP task which 
constituted their baseline accuracy. At the end of this task all participants received 
feedback indicating accuracy between 40-60%, regardless of their actual score.  
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 Participants were then given the placebo pill under the guise of a double-blind 
RCT of caffeine as a cognitive enhancer. Specifically, they were given a placebo pill 
packaged in a numbered envelop and told that the envelope contained either caffeine 
or placebo, but that they would not know which one they had been allocated to 
receive. They were also told that the experimenter delivering the envelope was 
unaware of whether it contained caffeine or the placebo. Participants were then given 
a 10min rest, which they were told was to allow the treatment to have its effect. 
During this time they were allowed to read general interest magazines. After 10min, 
the participants completed a second version of the RVIP task which constituted their 
pre-feedback performance. Upon finishing this task, half of the participants received 
positive feedback indicating that their cognitive performance had improved from 
baseline, while the other half received feedback indicating no change from baseline. 
Following another 10min rest period, the participants completed a third and final 
version of the RVIP task, which constituted their post-feedback performance. 
Feedback for this test mimicked that of the previous test. That is, those who received 
positive feedback after the pre-feedback test also received positive feedback on the 
third test that indicated sustained improvement from baseline. Participants who had 
received feedback indicating no change from baseline on the pre-feedback test, again 
received feedback indicating no change since baseline. Finally, participants completed 
the beliefs questionnaire which contained questions regarding their perceived 
treatment allocation. Participants were tested either alone or in pairs. These 
procedures were approved by the University of Sydney’s Human Research Ethics 
Committee.  
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4.3.5 Statistical analysis  
A Chi-square test of independence assessed whether positive feedback led 
participants to believe they had been given caffeine more frequently than feedback 
indicating no change did. The strength of confidence regarding perceived treatment 
was compared using an independent samples t-test. Given that the feedback 
manipulation could itself affect cognitive performance (see Kluger & DeNisi, 1996 
for a review) it was desirable to test the impact of perceived treatment on cognitive 
performance while controlling for feedback. However, it was not possible to include 
feedback and perceived treatment in a simultaneous regression in the current 
experiment because they were too strongly correlated and this led to problems with 
multicollinearity (see Cohen, Cohen, West, & Aiken, 2003 for a discussion of this 
problem). As a result, simple linear regression was used to examine the impact of 
feedback and perceived treatment on cognitive performance separately. This involved 
testing accuracy and reaction times across feedback and forced choice perceived 
treatment at 1) baseline, 2) pre-feedback while controlling for baseline, and 3) post-
feedback while controlling for pre-feedback scores as well as perceived treatment 
ratings on accuracy and reaction times on the post-feedback test controlling for pre-
feedback performance. Because they occurred before feedback the first two tests, 
baseline and pre-feedback, were simply to ensure that there were no initial differences 
in cognitive performance across groups. The important test in terms of assessing the 
possible impact of perceived treatment was the post-feedback test. All statistical 
analyses were conducted using SPSS software (version 15; SPSS Inc, Chicago, Ill) 
and results were considered significant when p<.05. 
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4.4 Results and discussion 
4.4.1 Feedback on perceived treatment 
 Figure 4.2 displays forced choice perceived treatment by feedback. Seventy-
three percent of participants who received feedback indicating improvement as a 
result of their treatment believed they had been given caffeine compared with only 
6.3% of those given feedback indicating no change,  χ2=14.7, df=1, n=31, p<.01. This  
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Figure 4.2. Experiment 1. Feedback on forced choice (FC) perceived treatment. 
Participants who were given positive feedback about their cognitive performance 
were significantly more likely to believe they had been given caffeine compared with 
participants who were given no change feedback. 
 
indicates that the positive feedback was generally successful at inducing participants 
to believe they had been allocated to receive caffeine as was the no change feedback 
at inducing participants to believe they had been allocated to receive the placebo. 
Using the original 11-point scale, there were no differences in strength of beliefs 
between participants who believed they had been given caffeine (M=5.1, SD=2.4) and 
those who believed they had been given the placebo (M=5.9, SD=2.6), t(29)=.88, 
p=.39.  
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4.4.2 Feedback on cognitive performance 
 Mean accuracy and reaction times by feedback for the three tests are presented 
in Figure 4.3. There were no significant differences between those receiving positive 
feedback and those receiving no change feedback on accuracy or reaction time on the 
baseline and pre-feedback tests, highest t(28)=1.11, p=.28. Importantly, there were  
 
Figure 4.3. Experiment 1. Mean (±SE) accuracy (A) and reaction time (B) for those 
who received positive feedback and those who received no change feedback. No 
differences were significant at any stage. 
 
also no differences in accuracy or reaction time between those receiving positive 
feedback and those receiving no change feedback on the post-feedback test 
controlling for performance on the previous test, highest t(28)=1.02, p=.35. This lack 
of a significant difference on the post-feedback test indicates that the feedback 
manipulation in and of itself did not predict cognitive performance. That is, there was 
no evidence to suggest that receiving positive feedback, in and of itself, led to better 
cognitive performance than receiving negative feedback did.  
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4.4.3 Perceived treatment on cognitive performance 
 As shown in Figure 4.4A, for forced choice perceived treatment there were no 
differences in accuracy on the baseline and pre-feedback tests between those who 
believed they received caffeine and those who believed they received the placebo, 
highest t(28)=1.35, p=.19. On the post-feedback test, however, participants who 
believed they received caffeine scored 12.3% higher than those who believed they 
received placebo controlling for performance on the previous test, t(28)=2.26, p=.03.  
Figure 4.4. Experiment 1. Mean (±SE) accuracy (A) and reaction time (B) based on 
participants forced choice perceived treatment. On the post-feedback test, participants 
who believed they received caffeine had significantly higher accuracy than those who 
believed they received the placebo. No other differences were significant.  
 
This suggests that participants who believed they received caffeine performed better 
than participants who believed they received the placebo on the post-feedback test. 
When confidence ratings were analysed, a 1-point increase in perceived treatment 
rating corresponded to a 1.2% increase in accuracy on the post-feedback test, 
t(28)=2.62, p=.01, which further supports the predictive power or perceived treatment 
on cognitive performance. The ratings uniquely accounted for 9.6% of the variance in 
accuracy at the second posttest, while the forced choice measure accounted for 7.4% 
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of the variance. Although this is only a small difference it might suggest that 
perceived treatment ratings are a more sensitive measure than forced choice perceived 
treatment. There were no differences in reaction time as a result of any measure of 
perceived treatment on any of the tests, see Figure 4.4B, all F<1, suggesting that the 
relationship between perceived treatment and cognitive performance was confined to 
accuracy.  
  
4.5 Experiment 2 
The feedback manipulation employed in Experiment 1 was successful at 
inducing beliefs about treatment allocation. Participants who received positive 
feedback after receiving treatment were much more likely to believe they had been 
given caffeine than those who received no change feedback. Further, participants who 
believed they received caffeine demonstrated higher accuracy on the final test than 
those who believed they received placebo. Although the feedback itself did not 
predict cognitive performance, Experiment 1 could not completely rule out the 
possibility that the false feedback contributed to some of perceived treatment’s effect 
on cognitive performance. This was because perceived treatment and false feedback 
were so strongly related.  
 
Experiment 2 aimed to overcome this limitation by comparing the impact of 
false feedback when it induced beliefs about perceived treatment with false feedback 
when no such beliefs could be expected. This was done by adding a control group that 
underwent exactly the same procedures described in Experiment 1, but was told that 
they had been allocated to a no treatment group in an open trial for cognitive 
performance. If it is positive feedback in and of itself that leads to improved cognitive 
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performance, then participants who receive positive feedback should demonstrate 
better cognitive performance than those receiving no change feedback regardless of 
whether they receive placebo treatment disguised as a double-blind RCT or whether 
they are told they are controls in an open trial and receive no treatment. On the other 
hand, if it is the belief about being on active treatment (which the positive feedback 
induces) that leads to improved cognitive performance, then those who believe they 
have been given active treatment because they received positive feedback should 
demonstrate better cognitive performance than those who believe they have been 
given placebo because they receive no change feedback. In this case, minimal, if any, 
differences between positive and no change feedback would be expected in those 
receiving no treatment because there are no such beliefs about treatment allocation.  
 
 A second, more minor modification was the use of piracetam as the bogus 
active treatment rather than caffeine. Caffeine is the world’s most commonly used 
psychoactive substance (Fredholm, Battig, Holmén, Nehlig, & Zvartau, 1999). This 
means that participants are likely to have strong preconceived expectancies about 
caffeine’s effects. Piracetam on the other hand is a nootropic which is likely to be 
relatively unknown by first year psychology students and should elicit less 
preconceived expectancies about its effects. If so, using piracetam rather than caffeine 
as the bogus active treatment should make the information provided in the 
experiment, including the feedback manipulation, more salient because participants 
are less likely to enter the experiment with preconceived notions about its effect.  
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4.6 Methods 
 Except where stated otherwise, the methods used in Experiment 2 were 
identical to those of Experiment 1.  
 
4.6.1 Participants 
 Forty-eight (33 female) first year psychology students from the University of 
Sydney participated in order to gain course credit. The participants had a mean age of 
18.8 (SD=1.0).  
 
4.6.2 Design 
 The main change in Experiment 2 was the addition of a control group that 
received the same feedback manipulation but received no treatment. This involved a 
2x2 design with feedback and treatment as factors. The design is shown in Figure 4.5. 
Participants were told that they were taking part in a double-blind RCT of piracetam 
for cognitive performance, but, as with Experiment 1, all participants actually 
received a benign placebo (lactose). Also as with Experiment 1, half of the 
participants received bogus feedback indicating that their cognitive performance 
improved from baseline while the other half received bogus feedback indicating no 
change from baseline. The new aspect of this experiment was the treatment 
manipulation. Participants were randomly allocated to receive the placebo pill under 
double-blind instructions (double-blind group; see Appendix 3c) or they were told 
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Figure 4.5. Design for Experiment 2. After baseline participants were randomised to 
receive a placebo under the guise of a double-blind RCT or were told they were in the 
no treatment group of an open-trial. Participants were further randomised to receive 
either positive feedback or feedback indicating no change about their cognitive 
performance as per Experiment 1.  
 
that they were controls in a trial of piracetam and would not be receiving treatment 
(no treatment group; see Appendix 3d). This randomisation was done with a 3:2 ratio 
such that 60% of participants were allocated to the double-blind group and 40% of 
participants were allocated to the no treatment group.  
 
4.3.3 Materials 
Placebo Pills: The placebo pills were still made from lactose but were red 
coated in Experiment 2. They were also prepared by the Faculty of Pharmacy, 
University of Sydney.  
 
Beliefs Questionnaire (Appendices 3e and 3f): was identical to Experiment 1 
except that participants were asked whether they believed they had received piracetam 
or placebo rather than caffeine or placebo for those in the double-blind group. Those 
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in the control group were simply asked to note whether they had been given piracetam 
or no treatment.  
 
4.3.4 Procedure 
 The procedure was identical to Experiment 1 except that participants were 
now randomly allocated to receive placebo treatment under the guise of a double-
blind RCT of piracetam or to receive no treatment under the guise of being controls in 
a trial of piracetam. Because of this, participants were randomly allocated to the 
treatment condition in pairs so that when two people were tested simultaneously they 
were in the same treatment group.   
 
 
4.3.5 Statistical analysis  
There were two parts to the statistical analysis. The first sought to replicate the 
findings from Experiment 1 by testing the impact of the feedback manipulation on 
perceived treatment and whether feedback and/or perceived treatment predicted 
cognitive performance in only those who received the double-blind placebo treatment. 
The analysis conducted to achieve this was identical to that of Experiment 1.  
 
The second part examined whether perceived treatment or the feedback 
manipulation affected cognitive performance. As with the analysis above, the 
important test in terms of assessing this was the post-feedback test, because this was 
after the first feedback manipulation. Therefore, ANCOVA assessed the impact of 
feedback and treatment on cognitive performance on the post-feedback test 
controlling for scores from the pre-feedback test. Any significant interactions found 
were investigated further by tests of simple effects using Fisher’s LSD procedure. 
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This analysis included all participants in the no treatment group, but only included 
participants in the double-blind group whose perceived allocation matched their 
feedback, that is, believed piracetam after receiving positive feedback or believed 
placebo after receiving negative feedback. This was done because the critical question 
was whether positive feedback led to better cognitive performance regardless of 
treatment type or whether the belief about being on piracetam induced by positive 
feedback led to better cognitive performance. By excluding the 5 (17%) participants 
in whom the feedback failed to induce matched beliefs about perceived allocation, the 
only difference between positive feedback in the double-blind group and positive 
feedback in the no treatment groups was that the former believed they had been given 
an active treatment while the latter knew they were not receiving any treatment. 
Similarly, the only difference between no change feedback across treatment groups 
was that participants in the double-blind group believed they were taking placebo and 
participants in the no treatment group knew were not receiving treatment. As such, 
this meant that I could directly test whether the effects of positive treatment on 
cognitive performance, if any, were constant across treatment or whether 
improvement only occurred when participants believed they had been given active 
treatment. All statistical analyses were conducted using SPSS software (version 15; 
SPSS Inc, Chicago, Ill) and results were considered significant when p<.05. 
 
4.7 Results and discussion 
 The following 3 sub-sections (4.7.1-4.7.3) refer to the analysis conducted on 
the double-blind group only. This analysis tested whether the results found in 
Experiment 1 were replicable.   
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4.7.1 Feedback on perceived treatment  
As shown in Figure 4.6, based on the forced choice question, 86% of 
participants in the double-blind group who received positive feedback believed they 
had been given piracetam, the bogus active treatment, while only 19% of those who 
received no change feedback believed they had been given piracetam, χ2=13.4, df=1, 
n=30, p<.01. This replicates the results of Experiment 1 and indicates that feedback, 
albeit false, influences perceived treatment. Using the original 11-point scale, 
participants who believed they had been given piracetam had a mean confidence of 
5.2 (SD=2.0) while those who believed they had been given the placebo had a mean 
confidence of 4.9 (SD=2.6) which were not significantly different, t(28)=.33, p=.75.   
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Figure 4.6. Experiment 2. Feedback on forced choice (FC) perceived treatment. 
Participants who were given positive feedback about their cognitive performance 
were significantly more likely to believe they had been given piracetam compared 
with participants who were given no change feedback.  
 
4.7.2 Feedback on cognitive performance  
 Mean accuracy and reaction times by feedback for only those in the double-
blind group are shown in Figure 4.7. As with Experiment 1, controlling for 
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performance on the previous test where applicable, there were no significant 
differences in accuracy or reaction times between participants who received positive 
feedback and those who received no change feedback, highest t(27)=1.17, p=.25. 
There were also no significant differences in accuracy, t(27)=1.54, p=.14, or reaction 
times as a function of feedback, although the tendency towards faster reaction times in 
those who received positive feedback compared with those who received no change 
feedback was marginally non-significant, t(27)=1.82, p=.08.  This also replicates the 
findings of Experiment 1 and indicates that feedback manipulation in and of itself is 
not a significant predictor of cognitive performance.  
Figure 4.7. Experiment 2. Mean (±SE) accuracy (A) and reaction time (B) for those 
who received positive feedback and those who received no change feedback. No 
differences were significant on any test.   
 
4.7.3 Perceived treatment on cognitive performance 
 Figure 4.8 displays mean accuracy and reaction time by perceived treatment. 
Also as with Experiment 1, controlling for performance on the previous test as 
appropriate, there were no differences in accuracy or reaction times between those 
who believed they received piracetam and those who believed they received placebo 
on the baseline and pre-feedback tests, highest t(27)=1.10, p=.32. Unlike Experiment 
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1, there was no difference in accuracy on the post-feedback test between those who 
believed they received piracetam and those who believed they received placebo on 
either the forced choice or 21-point ratings of perceived treatment, both F<1. This 
reflected a failure to replicate the finding from Experiment 1 that perceived allocation 
predicted accuracy on the cognitive task. However, participants who believed they 
received piracetam had significantly faster reaction times on the post-feedback test 
than those who believed they had been give the placebo, MD=34.5, t(27)=2.18, p=.04.  
Figure 4.8. Experiment 2. Mean (±SE) accuracy (A) and reaction time (B) based on 
participants forced choice perceived treatment. On the post-feedback test, participants 
who believed they received piracetam had significantly faster reaction times than 
those who believed they received the placebo. No other differences were significant.  
 
Similarly, a 1-point increase in perceived treatment ratings significantly predicted a 
3ms decrease in reaction times, t(27)=2.18, p=.04. This suggests that perceived 
treatment did significantly predict one aspect of cognitive performance, albeit 
different to the one predicted in the previous experiment. Possible reasons for this 
difference are discussed further below. There were minimal differences in the 
proportion of variation that the forced choice question and ratings accounted for in 
reaction times, 9.7% and 9.3% respectively, suggesting that there was no real 
difference in their predictive power.  
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4.7.4 Perceived treatment versus feedback 
 Mean accuracy and reaction time by feedback for those in the double-blind 
group and those in the no treatment group are shown in Figure 4.9. Controlling for 
performance on the previous test, the two-way ANCOVA revealed that there were no 
main effects of either perceived treatment or feedback on the post-feedback test for 
accuracy and for reaction time, all F<1. The interaction for accuracy was also non-
significant, F(1,38)=1.07, p=.3. There was, however, a significant interaction between 
perceived treatment and feedback for reaction time, F(1,38)=8.86, p<.01. This 
indicated that the differences between positive and no change feedback were not the 
same for those in the double-blind group as they were for those in the no treatment 
group. Test of simple effects revealed that, for the no treatment group, positive 
feedback actually led to significantly slower reaction times than did negative 
feedback, F(1,38)=4.36, p=.04. For the double-blind group, however, positive 
feedback led to significantly faster reaction times than those who received negative 
feedback, F(1,38)=4.57, p=.04.   
  
The crucial difference between feedback in the double-blind group and the no 
treatment group was that it induced beliefs about perceived treatment in the former. 
That is, participants who were told they were taking part in a double-blind RCT and 
received positive feedback believed they had been given piracetam, the bogus active 
treatment, and those that received no change feedback believed they had been given a 
placebo. No such beliefs could be expected in the no treatment group because these 
participants knew that they were not receiving treatment. This suggests that the faster 
reaction times for those who received positive feedback and believed they were on 
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active treatment compared with those who received negative feedback and believed 
they were on placebo resulted from differences in beliefs, not feedback. Without 
beliefs about treatment allocation, positive feedback actually led to slower reaction 
times than negative feedback.  
 
Figure 4.9 Experiment 2. Mean (+SE) accuracy (A) and reaction time (B) on the 
post-feedback test by feedback for those who were in the double-blind group and 
those in the no treatment group. Test of simple effects revealed that positive feedback 
led to significantly faster reaction times in the double-blind group but actually 
increased reaction times in the no treatment group.  
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4.8 General Discussion 
 This study used dummy (placebo only) double-blind RCTs for cognitive 
performance to explore the relationships between feedback, perceived treatment, and 
actual treatment responses. In both experiments, participants’ perceived treatment was 
influenced by the feedback they received. Participants who received feedback 
indicating they had improved as a result of their treatment generally believed they had 
been given active treatment while those given feedback indicating no improvement 
generally believed they had been given a placebo. If the positive feedback used here is 
a sufficient analogy for improvement that participants may experience during real 
double-blind RCTs, then these findings clearly demonstrate that observable 
improvement leads participants to believe they are on active treatment much more 
frequently than when they observe a lack of improvement. While this is consistent 
with correlational evidence that improvement is related to perceived treatment (e.g. 
Margraf et al., 1991; Morin et al., 1995), this is the first study to show experimentally 
that observable improvement does influence perceived treatment.   
  
 Participants who believed they received active treatment demonstrated better 
cognitive performance than those who believed they received the placebo. This is 
consistent with my reanalysis of a double-blind RCT for alcohol dependence in 
Chapter 2 and those previously conducted in other areas (Bausell et al., 2005; Dar et 
al., 2005; Lewis et al., 1975; McRae et al., 2004; Thomas et al., 2008). Feedback did 
not significantly predict cognitive performance in either experiment in the participants 
who received placebo treatment under the guise of a double-blind RCT. This seemed 
to suggest that perceived treatment was the most important determinant of actual 
treatment responses. That is, it seemed to be the belief that one was on active 
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treatment that led to better cognitive performance rather than simply receiving 
positive feedback.  
 
 The addition of a control group that received the same feedback manipulation 
but that received no feedback in Experiment 2 provided the most important finding. 
That is, while positive feedback led to better cognitive performance than negative 
feedback after placebo treatment administered under the guise of a double-blind RCT, 
the opposite was true when no treatment was given. This suggests that the differences 
in cognitive performance between those who believed they received active treatment 
and those who believed they received the placebo cannot be explained by the different 
feedback they received. Instead, it seems likely that it was the participants’ beliefs 
about their treatment allocation that influenced their cognitive performance. This 
supports a placebo based interpretation of the relationship between perceived 
treatment and actual treatment responses. That is, participants who believed they were 
taking active treatment expected to perform better than those who believed they were 
given the placebo and these expectations for greater improvement led to better 
cognitive performance. Importantly, the observed improvement was for an objective 
outcome which greatly reduces the possibility that these differences arose from 
participant bias and further supports a placebo effect based interpretation.  
 
There seemed to be minimal differences between the use of forced choice and 
ratings of perceived treatment. This contradicted suggestions that confidence ratings 
might capture more variation in beliefs about treatment allocation than the commonly 
used forced choice questions (e.g. Margraf et al., 1991; Sharpe et al., 2003). However, 
the marginal increase in variability accounted for by the ratings in Experiment 1 may 
 88 
imply that it is worth including these when assessing perceived treatment given how 
easily they can be incorporated.  
 
 There are a number of important implications of these findings. The finding 
that observable changes influenced perceived treatment reinforces Sharpe et al.’s 
(2003) concern that the probability of blinding being broken is likely to increase with 
the magnitude of the treatment’s efficacy. This presents a significant problem for 
double-blind RCTs because it produces an unsatisfactory situation whereby these 
trials cannot validly assess efficacious treatments. This is because the more 
efficacious the treatment is the more likely it will produce improvement that enables 
participants to determine whether they have been allocated to active treatment or 
placebo. Another important implication concerns the interplay between observable 
changes, perceived treatment, and actual treatment responses. The possibilities that 
either observing improvement causes perceived treatment or that perceived treatment 
causes improvement need not be mutually exclusive. In the current study false 
feedback suggesting either improvement or no change strongly influenced perceived 
treatment and perceived treatment, in turn, appeared to influence actual treatment 
responses. This suggests that observing some improvement may trigger a belief about 
being on active treatment which may cause more improvement via the placebo effect.  
 
 There are also some potential limitations to the current study. The fact that 
perceived treatment significantly predicted accuracy in Experiment 1 but predicted 
reaction times in Experiment 2 might raise questions regarding the true replicability of 
these findings. Importantly, this difference between Experiments 1 and 2 cannot be 
explained by processes such as speed-accuracy trade-off. In Experiment 1, when 
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perceived treatment predicted accuracy there were no significant differences in 
reaction times. Similarly, in Experiment 2, when perceived treatment predicted 
reaction times there were no differences in accuracy. One possible explanation for the 
difference is that changing the bogus active treatment from caffeine (Experiment 1) to 
piracetam (Experiment 2) created differences in how the participants’ expected their 
cognitive performance to be affected. When caffeine was the bogus active treatment 
participants may have expected their accuracy to improve, whereas when piracetam 
was the bogus active treatment participants may have expected their reaction times. 
However, because I did not assess participants expectancies regarding the efficacy of 
their treatment I was unable to test this possibility.  
 
  As with many other studies (e.g Basoglu, Marks, Livanou, & Swinson, 1997; 
Bausell et al., 2005; Dar et al., 2005; Rabkin et al., 1986), perceived treatment was 
only assessed after the outcome of interest was measured, in this case cognitive 
performance on the post-feedback test. Although this was done intentionally in an 
attempt to ensure that participants did not question the purpose of the study, it remains 
possible that some participants may have noticed improvement on the post-feedback 
test and that this led them to believe they had been allocated to receive the active 
treatment. However, given the success at which feedback induced beliefs about 
treatment allocation, this possibility seems to rest upon unsuccessful randomisation or 
highly spurious increases in cognitive performance which coincided with receiving 
positive feedback.   
 
 Overall, this study provides firm evidence that participants in double-blind 
RCTs use available cues, in this case feedback, in order to determine whether they 
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have been allocated to receive active treatment or a placebo. Although this has been 
suggested by correlational evidence from previous studies (see Shapiro & Shapiro, 
1997b for a review) this is the first study to show this effect by experimentally 
manipulating observable changes via false feedback. Further, there was a clear 
relationship between perceived treatment and cognitive performance. Participants 
who believed they received active, albeit bogus, treatment performed better than 
participants who believed they received the placebo and these differences could not be 
explained by the feedback manipulation itself or self report bias. This suggests that 
perceived treatment can influence outcomes in double-blind RCTs via the placebo 
effect. Finally, the use of dummy (placebo only) double-blind RCTs also ruled out the 
potential for confounding relationships between active treatment and perceived 
treatment and may serve as a very useful model for exploring these issues further.  
Attention now turns to the possible contribution of the placebo effect to treatment side 
effects.  
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Chapter 5: Review of Placebo-Induced Side Effects 
 
  
 The earlier finding that participants taking part in a double-blind RCT for 
alcohol dependence who believed they were given active treatment reported more side 
effects than participants who believed they were given a placebo (see Chapter 3) 
suggests that the placebo effect may contribute to treatment side effects. While this 
possibility has been raised by a number of other researchers (e.g. Barsky et al., 2002; 
Myers, Cairns, & Singer, 1987; Roscoe et al., 2006; Shapiro, Chassan, Morris, & 
Frick, 1974), it has received surprisingly little research attention, with the majority of 
placebo studies focusing on beneficial outcomes.  
 
 In addition to being inherently unpleasant, adverse side effects often lead to 
poorer compliance with and in some cases discontinuation of treatment, which, in 
turn, leads to worse treatment outcomes (e.g. chemotherapy: Demissie, Silliman, & 
Lash, 2001; antidepressants: Schatzberg, 2007). Determining if and how the placebo 
effect contributes to these adverse effects may, therefore, be useful in guiding 
interventions to reduce the burden of side effects and improve treatment outcomes. 
The limited evidence for placebo-induced side effects to date can be categorised into: 
1) experimental studies assessing negative placebo effects, 2) adverse side effects in 
placebo groups from double-blind RCTs, 3) studies assessing the relationship between 
pretreatment expectancies and post-chemotherapy nausea, and 4) experimental studies 
assessing whether warning patients about side effects actually leads to more adverse 
side effects. This chapter reviews the aetiology and evidence for placebo-induced side 
effects. 
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5.1 Possible Causes of Placebo-Induced Side Effects 
 As discussed in Chapter 1, placebo-induced side effects are any responses to a 
treatment other than those for which the treatment has been administered and that are 
not attributable to the inherent properties of the treatment itself. Placebo-induced side 
effects are, therefore, best considered as a subset of the placebo effect, with the same 
underlying mechanisms. In this way, placebo-induced side effects are learned 
responses that could result from information and/or classical conditioning. Note that 
this is not to say that placebo-induced side effects and all other placebo effects are 
produced by the same biological processes, as this is not even the case for positive 
placebo effects. For example, Amanzio and Benedetti (1999) found that placebo 
analgesia induced by verbal information could be reversed by naloxone, while 
placebo analgesia induced by conditioning with keterolac was unaffected by 
naloxone, suggesting that the former but not the latter was mediated by endogenous 
opioids. Instead, it simply means that placebo-induced side effects could occur as a 
result of the information patients receive about their treatment’s side effects as well as 
any previous experience they have had with that treatment or even with similar 
treatments.  
 
 Patients in standard clinical practice and participants in double-blind RCTs 
receive information about their treatment that usually includes a warning about 
possible side effects. This is important so that the patient or participant can make an 
informed decision about whether he or she wishes to receive the treatment, known as 
the process of informed consent. There is, however, the possibility that this 
information might cause patients and participants to expect and therefore experience 
the side effects they have been warned about (Barsky et al., 2002; Myers et al., 1987; 
 93 
Shapiro et al., 1974). Thus, informing patients or participants about potential side 
effects may cause placebo-induced side effects.  
 
Patients are also likely to draw on information from sources other than their 
health professionals, including their family and friends, the media, and the internet. 
This may be particularly so for more prevalent illnesses and their treatments. For 
example, there are innumerable internet sites that provide information about 
chemotherapy and its side effects and chemotherapy-induced alopecia and nausea are 
often portrayed on television and in movies. This information may also lead to 
placebo-induced side effects if it elicits sufficiently strong expectancies for these 
effects.  
 
Patients will often have had prior experience with their treatment or other 
similar treatments and this provides opportunities for classical conditioning that may 
also lead to placebo-induced side effects. The clearest example of classical 
conditioning producing a side effect-like response is anticipatory nausea. Studies in 
this area have shown that the severity of post-chemotherapy nausea predicts the 
severity of anticipatory nausea (Andrykowski & Redd, 1987; Stockhorst, 
Klosterhalfen, Klosterhalfen, Winkelmann, & Steingrueber, 1993) and that 
anticipatory nausea is subject to processes of classical conditioning, such as 
overshadowing (Stockhorst et al., 1998). This means that evaluating placebo-induced 
side effects requires consideration of both the information the patient or participant 
has received about their treatment and any prior experience they have had with the 
treatment or with similar treatments.  
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5.2 Evidence for Placebo-induced Side Effects 
5.2.1 Experimental studies on negative placebo effects  
 As with positive placebo effects, most research on negative placebo effects has 
been on pain. These studies have shown that placebo administration with the 
suggestion of hyperalgesia can cause increased pain sensitivity compared with natural 
history (e.g. Benedetti, Amanzio, Casadio, Oliaro, & Maggi, 1997; Benedetti, 
Amanzio, Vighetti, & Asteggiano, 2006; Colloca, Sigaudo, & Benedetti, 2008; Kong 
et al., 2008), with one exception (Johansen, Brox, & Flaten, 2003). For example, 
Colloca et al. (2008) told healthy volunteers that a sham electrode would increase the 
intensity of a painful stimulus and that activation of this electrode was signalled by a 
green screen, whereas deactivation was signalled by a red screen. The participants 
consistently rated their pain as higher when they saw the green screen compared with 
the red screen, even though the actual pain intensity was kept constant.  The lack of 
evidence for placebo hyperalgesia in Johansen et al.’s (2003) probably resulted from 
the high intensity of the painful stimulation they used. In their study, average pain 
ratings for the natural history were over nine out of ten, which likely led to a ceiling 
effect whereby any additional pain in the negative placebo group could not be 
detected.  
 
There is also some preliminary evidence to suggest that such placebo 
hyperalgesia is mediated by cholecystokinin systems in the opposite direction to 
placebo analgesia (Benedetti et al., 1997; Benedetti et al., 2006). Although far from 
conclusive, this seems to indicate that the effect has physiological underpinnings and 
exists beyond subjective bias. Information has also been shown to induce placebo 
headaches, which is perhaps an extension of placebo hyperalgesia. In these studies, 
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participants told that a sham electrode applied to their head will cause headaches 
reported headaches twice as often as those told that the electrode would not be 
switched on (Bayer, Baer, & Early, 1991; Schweiger & Parducci, 1981).  
 
 There is some evidence of placebo allergic reactions. In perhaps the most 
striking study on negative placebo effects, Ikemi and Nakagawa (1962) found that 
Japanese men who were allergic to lacquer trees reacted to resin from harmless trees 
when they were told that the resin was from a lacquer tree. The adverse reactions to 
the normally harmless trees were quite severe, with participants developing skin 
irritation and rashes that lasted for up to 11days. Unfortunately there appears to have 
never been an attempt to replicate this study. More robust evidence comes from 
Luparello and colleagues (Luparello, Lyons, Bleecker, & McFadden, 1968; 
McFadden, Luparello, Lyons, & Bleecker, 1969) who have shown twice that 
informing asthmatics that a placebo inhalant, nebulised saline, contains an allergen 
leads to bronchoconstriction. Interestingly, they also found that this placebo 
bronchoconstriction could be reversed by administration of the same placebo inhalant, 
but with suggestion that it is a bronchorelaxant. The fact that the placebo effect can 
cause allergic reactions may not be entirely surprising given evidence of immuno-
conditioning studies which produce placebo-like effects (see Pacheco-López et al., 
2006 for a review). It is also worth noting that in both these cases the participants had 
a history of allergic reactions and that this experience likely contributed to the placebo 
effects observed.  
 
 In other areas, Flaten et al. (1999) found that both a stimulant and a placebo 
pill led to higher ratings of tension in participants who were told to expect stimulation 
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in the form of increased metabolism and bodily activity compared with those given no 
information about the treatment. This suggests that the placebo effect can increase the 
magnitude of an adverse response to an active treatment as well as inducing an 
adverse response to an otherwise inactive treatment. Similarly, studies using the ‘open 
versus hidden’ design (see Chapter 2) have shown that people with Parkinson’s 
disease show poorer motor performance when they are aware that stimulation of their 
subthalmic nucleus has ceased compared with when they are unaware of this 
(Benedetti, Maggi et al., 2003; Mercado et al., 2006; Pollo et al., 2002). In this case, 
the information that the stimulation has ceased increases the decline in performance 
associated with the lack of stimulation. Again, this implies that the placebo effect can 
worsen adverse treatment outcomes and points towards negative placebo effects.  
 
 Overall, these studies are important for showing that suggestion of adverse 
outcomes can lead to negative placebo effects, whether as a result of this information 
alone or previous experience. However, to a certain extent, they provide only indirect 
evidence for placebo-induced side effects. This is because they involve suggestion 
about a sole action of the treatment being delivered, whether active or placebo. In the 
pain studies for example, a placebo is administered and hyperalgesia is suggested. 
This is somewhat different to placebo-induced side effects, which are placebo effects 
in response to the treatment, other than those for which it has been given. In this 
sense, these studies do not necessarily indicate that information or experience with 
treatment side effects can cause placebo-induced side effects. Instead, these types of 
negative placebo effects might be considered as primary placebo effects, whereas 
placebo-induced side effects might be conceived of as secondary placebo effects. As a 
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result, they provide important evidence that negative placebo effects do occur, but 
they do not directly test for placebo-induced side effects.  
  
5.2.2 Side effects in placebo groups in double-blind RCTs 
 One source of evidence often cited for placebo-induced side effects are 
placebo groups in double-blind RCTs, as it quite common for these participants to 
report side effects. In the double-blind RCT reanalysed in Chapter 3, 48% of 
participants in the placebo group reported at least one side effect. The most common 
of these side effects was headaches, which was reported by 20% of participants 
receiving placebo (Morley et al., 2006). Interestingly, the occurrence of headaches 
was actually significantly higher in the placebo group than it was in the group 
receiving acamprosate (4%), suggesting possible interaction between drug effects and 
placebo-induced side effects. In a double-blind RCT of gabapentin for panic disorder, 
Pande et al. (2000) also found a high rate of side effects reported by the 51 
participants receiving placebo. In all, 24% reported headaches, 18% reported 
somnolence, 16% reported nausea, and 14% reported asthenia and dyspepsia. These 
rates were very similar to the side effects reported by participants receiving 
gabapentin. Remarkably, two (4%) of the participants on placebo actually withdrew 
from the study because of these adverse effects. In another trial, Preston, Materson, 
Reda, and Williams (2000) found slightly lower rates of side effects in 187 
participants receiving placebo in a double-blind RCT of six anti-hypertensive 
medications. In all, 12% of the placebo group in their study reported at least one side 
effect and the most common of these was again headaches. Even more remarkably 
than Pande et al.’s (2000) finding, 7% of the participants receiving placebo withdrew 
from the trial because of adverse effects.  
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 These examples of side effects in the placebo groups of double-blind RCTs 
appear representative according to at least two reviews. In the first, Rosenzwieg, 
Brohier, and Zipfel (1993) assessed side effects in 1228 healthy volunteers allocated 
to receive placebos in 109 double-blind RCTs. They found that 20% of these 
participants reported at least one side effect in response to their placebo treatment. 
Headaches were the most commonly reported side effect with 7% of participants 
reporting headaches. They also found that participants receiving repeated placebo 
treatments reported more side effects than those receiving a single placebo treatment 
(26% vs 16%, respectively). This is interesting because it parallels evidence that more 
invasive treatment regimens produce larger placebo effects (de Craen et al., 1999; de 
Craen et al., 2000). In the second review, Weihrauch and Gauler (1999) analysed 
double-blind RCTs for stroke, angina pectoris, diabetes, anxiety, and gastro-duodenal 
lesions conducted by a pharmaceutical company. Overall, they found that between 2-
62% of participants receiving placebo reported at least one side effect. These side 
effects also tended to mimic those reported by participants receiving active treatment.  
 
 The relatively frequent rate of side effects reported by participants receiving 
placebo treatment in double-blind RCTs supports the possibility that the placebo 
effect might contribute to treatment side effects. This is particularly so given that the 
side effects reported in these participants seem to mimic those reported by participants 
receiving active treatment, which all participants have presumably been warned about. 
There are, however, two important limitations to this type of evidence. Firstly, none 
of these trials included a no treatment control group. This means that they did not 
adequately control for the natural history of the condition being treated. As such, it is 
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impossible to determine whether the side effects reported by the participants receiving 
placebo directly resulted from the placebo treatment or whether they would have 
occurred regardless of treatment and were simply misattributed to the treatment.  
Therefore, the frequency of side effects found in these types of studies might 
overestimate placebo-induced side effect.  
 
 On the other hand, given that participant blinding is often found to be 
unsuccessful in these types of trials (see Chapter 2), it may be the case that they 
underestimate the occurrence of placebo-induced side effects. As discussed in detail 
in Chapter 2, participants who know they are receiving placebo treatment are much 
less likely to expect the treatment to affect them and may, therefore, have only weak 
expectancies for side effects. This makes it very difficult to determine the true extent 
to which side effects are associated with placebo treatment in double-blind RCTs. As 
a result, the occurrence of side effects in the placebo groups of double-blind RCTs is 
insufficient to determine whether the placebo effect contributes to treatment side 
effects, however suggestive it may be.  
 
5.2.3 Expectancies and post-chemotherapy nausea 
 A number of studies have assessed the relationship between chemotherapy 
patients’ pretreatment expectancies for nausea and their actual experience of nausea 
posttreatment. Generally, these studies have employed the same basic design, 
involving asking first time chemotherapy patients to rate their expectancies for nausea 
and then to report their experience of nausea following one or more infusions. A 
summary of these studies and their limitations is provided in Table 5.1. Nine out of 
the eleven studies identified found that higher pretreatment expectancies for nausea 
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were associated with greater posttreatment nausea, with expectancies accounting for 
up to 32% of the variability in post-chemotherapy nausea. This suggests that some of 
the nausea chemotherapy patients experience after treatment might be attributable to 
the placebo effect. If so, this would provide evidence for a placebo-induced side 
effect. However, there are a number of methodological limitations to these studies that 
make it difficult to determine whether expectancies have a causal impact on post-
chemotherapy nausea, or whether they are simply correlated.  
 
 From the outset, studies assessing pretreatment expectancies and post-
chemotherapy nausea might be considered a weaker source of evidence for placebo-
induced side effects because they are correlational in nature. However, correlational 
studies can provide evidence regarding the causal nature of relationships if other 
potentially confounding factors are adequately controlled for. To this end, the method 
of statistical analysis used in these studies is integral in determining whether 
expectancies cause, or at least worsen posttreatment nausea. Unfortunately, almost all 
of the studies identified here are limited in this respect, as can be seen in Table 5.1.   
 
 Firstly, the majority of these studies consisted of relatively small samples 
given their correlational nature, with only three involving more than 100 patients 
(Rhodes, Watson, McDaniel, Hanson, & Johnson, 1995; Roscoe et al., 2004; Shelke 
et al., 2008). Secondly, five of the studies did not control for history of nausea in other 
settings (Andrykowski & Gregg, 1992; Cassileth et al., 1985; Olver, Taylor, & 
Whitford, 2005; Rhodes et al., 1995; Shelke et al., 2008), which is problematic 
because expectancies for nausea might simply reflect patients’ knowledge of their risk 
of experiencing nausea. Thirdly, in four out of the five studies that did control for  
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Table 5.1. Summary of studies assessing the relationship between first time chemotherapy patients’ expectancies and post-chemotherapy nausea. In all studies expectancies were assessed prior 
to the first infusion. In each case the patients, statistical analysis, measure of nausea, significance of expectancy, and limitations are described. Where more than one statistical test was used, 
multivariate analysis was favoured over univariate analysis. Other predictors included (hierarchical) or entered (stepwise) into the regression models that significantly predicted nausea are 
italicised. If provided by the authors, the unique proportion of variability (ΔR2
 
) expectancy accounted for in post-chemotherapy nausea is given.  
Authors Patients Statistical Analysis Nausea  Significant Limitations 
Andrykowski & 
Gregg (1992)  
 
65 mixed cancer 
patients 
Hierarchical regression  
(state anxiety) 
Average nausea severity over   
2-4 infusions  
No  Small sample size 
No control for history of nausea  
Cassileth et al. 
(1985) 
 
 
56 mixed cancer 
patients 
Chi-square test of independence Severity of nausea 
experienced prior to 3rd 
infusion    
No   Small sample size 
No control for history of nausea or 
any other variable 
Haut et al. 
(1991) 
36 breast cancer 
patients  
Hierarchical regression   
(number of treatments, emetic potential, 
no. of anticancer drugs, anti-emetics, 
motion sickness, state anxiety)1 
a) Frequency of nausea, i.e. 
proportion of infusions 
followed by any nausea 
b) Average nausea severity 
across all infusions 
[No. of infusions not 
specified]  
   
Yes – R2=.32 
 
 
Yes – R2=.24 
 
Very small sample size 
Over-fitted model 
Jacobsen et al. 
(1988) 
45 breast cancer 
patients 
Stepwise regression  
(age, Karnofsky status, state anxiety, 
trait anxiety, history of nausea for food, 
anxiety, pregnancy, and motion 
sickness, chemotherapy agentsx3)2 
a) Any nausea over 6 
infusions 
b) Frequency of nausea, i.e. 
reported after <4 infusions 
versus 4 or more infusions  
c) Mean nausea severity over 
the 6 infusions 
d) Mean duration of nausea 
 
Yes  
 
No  
 
 
Yes  
 
Yes  
Very small sample size 
Used stepwise regression 
 
Montgomery & 
Bovbjerg 
(2000)4 
 
 
52 breast cancer 
patients 
Stepwise regression 
(age, education, employment, ethnic 
group, marital status, tumour size, no. 
of positive lymph nodes, stage, 
chemotherapy regimen, nausea after 6th 
infusion, frequency of nausea for 
infusions 1-5, no. of side effects after 
infusion 6, any anticipatory nausea on 
any infusion) 
 
Any nausea following 7th 
infusion  
Yes  Small sample size 
Used stepwise regression 
Olver et al. 
(2005) 
87 mixed cancer 
patients  
Hierarchical regression 
(nurses toxicity ratings of regimen 
and patients’ activity)3 
 
Severity of nausea after 1st 
infusion 
Yes – R2=.05 Small-moderate sample size 
No control for history of nausea or 
any other variable 
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Table 5.1. Summary of studies assessing the relationship between first time chemotherapy patients’ expectancies and post-chemotherapy nausea (continued). 
Authors Patients Statistical Analysis Nausea  Significant Limitations 
Rhodes et al 
(1995) 
329 mixed cancer 
patients 
Chi-square test of independence Any nausea in the 48hrs 
following 1st infusion 
 
Yes No control for history of nausea or 
any other variable 
Roscoe et al. 
(2000) 
Study 1: 36 
ovarian cancer 
patients 
 
 
Study 2: 86 
mixed cancer 
patients 
 
Hierarchical regression 
(emetic potential, chemotherapy agent, 
anti-emetics, age <50,  motion sickness, 
nausea during pregnancy) 
 
Hierarchical regression 
(emetic potential, no. of chemotherapy 
agents, anti-emetics, chemotherapy 
agentsx5, age <50,  motion sickness, 
nausea during pregnancy) 
 
a) Average nausea severity in 
the 60hrs following 1st and 
2nd infusions 
 
b) Average nausea severity in 
the 60hrs following 1st and 3rd 
infusions 
Yes - R2=.18 
 
 
 
Yes - R2=.09 
Very small sample 
Over-fitted model 
 
 
Small sample size 
Over-fitted model 
Roscoe et al. 
(2004) 
 
 
194 breast cancer 
patients 
Hierarchical regression 
(age, nausea during pregnancy) 
a) Average nausea in the 5 
days from 1st infusion 
onwards 
 
b) Any severe nausea (6 or 7 
out of 7) in the 5 days from 
1st infusion onwards 
 
No (but p=.054) 
 
 
 
Yes  
Limited covariates included 
Shelke et al 
(2008)5 
 
 
322 mixed cancer 
patients 
Bivariate correlation a) Average nausea in the 5 
days from 1st infusion 
onwards 
 
b) Peak nausea rating in the 5 
days from 1st infusion 
onwards 
 
I: Yes - R2=.07 
C: Yes – R2=.03 
 
I: Yes - R2=.09 
C: Yes – R2=.09 
No control for history of nausea or 
any other variable  
 
1Haut et al. (1991) provide insufficient information to determine which of the other variables were significant, however, they do state that motion sickness and state anxiety did not significantly 
predict post-chemotherapy nausea.  
2Predictors significant on at least one of the nausea outcomes.  
3No information provided about whether the other predictors were significant or not.  
4Alhtough Montgomery & Bovbjerg (2000) assessed and analysed expectancies before the 1st infusion, they conducted their regression analysis using expectancies assessed before the 7th 
infusion.  
5Shelke et al.’s (2008) study was an intervention study with participants in the intervention group (I, n=159) receiving additional information about their anti-emetic treatment and those in the 
control group (C, n=163) receiving no additional information. Expectancies were assessed before and after information was given. Those reported here are for the pre-intervention expectancies 
as these were the best predictors of posttreatment nausea.  
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history of nausea the regression models were either over-fitted (Haut, Beckwith, 
Laurie, & Klatt, 1991; Roscoe, Hickok, & Morrow, 2000) or were based on stepwise 
procedures (Jacobsen et al., 1988; Montgomery & Bovbjerg, 2000). 
 
 Over-fitting a regression model occurs when there are less than 10-20 
participants for each predictor included in the analysis. This leads to overestimation of 
the total amount of variability the model accounts for as well as increasing the 
probability of finding spurious results for individual predictors (Harrell, 2001). Thus, 
the significant findings in these studies may be unreliable. Stepwise regression is 
often erroneously used to overcome this problem (Millis, 2003). This type of 
regression analysis identifies the best predictor of the dependent variable without 
controlling for the other variables, enters this variable in a first step, and then repeats 
this procedure controlling for any variables entered in previous steps up until the 
significance of the predictor to be entered exceeds some criterion for inclusion, e.g. 
p<.10. Any remaining predictors that do not meet this criterion are excluded from the 
model. This procedure is associated with a number of problems and its use in 
psychology has been heavily criticised (Harrell, 2001; Mernard, 2003; Millis, 2003; 
Thompson, 1995). One of these problems is that stepwise regression capitalises on 
error variance, thereby increasing spurious findings and making the results highly 
sample dependent and often difficult to replicate. Further, it may lead to elimination 
of predictors that are theoretically important and which should be controlled for, but 
that do not meet the criterion for inclusion. As a result, stepwise regression can only 
test for prediction rather than cause and is, therefore, inappropriate for testing theories 
(Mernard, 2003). As such, results from the studies employing stepwise regression are 
useful in terms of confirming the relationship between expectancies for nausea and 
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actual nausea, but they are insufficient to rule out other possible causes of this 
relationship.  
 
 Only one study on expectancy and post-chemotherapy nausea conducted to 
date avoids all of these limitations. In this study, Roscoe and colleagues (2004) asked 
194 first time chemotherapy patients with breast cancer to rate their pretreatment 
expectancies in a number of different ways after speaking with their physician. The 
expectancy assessment involved asking participants to rate 1) retrospectively how 
likely they believed they were to experience nausea before speaking to their 
physician, 2) how certain they were that they would experience nausea after speaking 
with their physician, and 3) the highest level of nausea they expected after speaking 
with their physician. The patients then received their first chemotherapy infusion and 
were given diaries to report the severity of nausea in the morning, afternoon and 
evening for 5 days from the initial infusion. The diaries were used to calculate 
average nausea across the 5 days and whether the patient experienced severe nausea, 
classified as a nausea rating of 6 or 7 out of 7 at any time point. Hierarchical 
regression controlling for age and nausea during pregnancy found that patients’ 
retrospective expectancies (reported in Table 5.1) significantly predicted the 
occurrence of severe nausea. A similar analysis, however, revealed that none of the 
expectancy measures were significantly associated with average nausea over the 5 
days.  
 
 The two studies which had sufficiently large sample sizes, but failed to control 
for any other potentially confounding variables, both found significant relationships 
between expectancies and post-chemotherapy nausea (Rhodes et al., 1995; Shelke et 
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al., 2008). In the three with small sample sizes, but that were not limited by their 
method of statistical analysis (Andrykowski & Gregg, 1992; Cassileth et al., 1985; 
Olver et al., 2005), only one found a significant relationship between expectancies 
and post-chemotherapy nausea (Olver et al., 2005). The remaining four that employed 
statistical analyses that may have overestimated the importance of expectancy all 
found significant relationships between expectancy and posttreatment nausea (Haut et 
al., 1991; Jacobsen et al., 1988; Montgomery & Bovbjerg, 2000; Roscoe et al., 2000), 
perhaps indicative of the statistical analysis employed. 
 
 These findings are clearly inconclusive. In the most methodologically rigorous 
study (Roscoe et al., 2004), a relationship between expectancies and post-
chemotherapy nausea was only evident for one of three methods of assessing 
expectancy and only for the occurrence of severe nausea. Further, although age and 
nausea during pregnancy were included as covariates in their analysis, susceptibility 
to motion sickness was not. The authors based this decision on the lack of correlation 
between motion sickness and posttreatment nausea. However, motion sickness 
remains an important variable to control for, regardless of whether or not its 
correlation with posttreatment nausea is significant, as it has often been found to 
predict nausea in other studies (e.g. Jacobsen et al., 1988; Morrow, 1985; Roscoe et 
al., 2000) and it may account for some of the variance in expectancies. The other, less 
rigorous studies seemed to provide relatively consistent evidence for an association 
between expectancies and post-chemotherapy nausea, but due to their limitations, they 
cannot determine whether expectancies actually contribute to or are merely correlated 
with this nausea. Hence, as with studies on the negative placebo effects and side 
effects in the placebo groups of double-blind RCTs, the results of the studies that have 
 106 
assessed the relationship between expectancies and post-chemotherapy nausea can 
only be considered suggestive of placebo-induced side effects.  
 
It is worth noting that Sohl, Schmur, and Montgomery (2009) recently 
conducted a meta-analysis assessing the relationship between expectancy and 
treatment-related side effects in cancer patients that included some studies measuring 
post-chemotherapy nausea. Their analysis indicated a moderate positive relationship 
between expectancy and adverse symptoms in these patients. However, rather 
strangely, they only included effect sizes for bivariate associations between 
expectancy and adverse symptoms, meaning that there was no control for other 
potentially confounding variables, such as a history of nausea in other settings. As a 
result, their meta-analysis can also only be considered suggestive of placebo induced 
side effects.  
 
5.2.4 Experimental studies on information and side effects 
 Eight studies have investigated placebo-induced side effects by manipulating 
whether participants are warned about possible side effects or not. The experimental 
nature of these studies means that they are best designed to determine whether the 
placebo effect contributes to treatment side effects, especially because they control for 
natural history. These studies have produced conflicting results, with half finding that 
warning participants about side effects does lead to more side effects being reported 
(Gibbs, Waters, & George, 1989b; Mondaini et al., 2007; Myers & Calvert, 1984; 
Myers et al., 1987) and the other half finding no effect of the warning (Gibbs, Waters, 
& George, 1989a; Howland, Baker, & Poe, 1990; Morris & Kanouse, 1982; Myers & 
Calvert, 1973).  
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 In terms of studies finding evidence in support of placebo-induced side effects, 
Myers and Calvert (1984) found that providing information only about the beneficial 
effects of the treatment led to less side effects being reported than when patients were 
warned about treatment side effects or when they received no information at all.  In 
perhaps the most remarkable study in this area, Myers et al. (1987) compared side 
effects in participants in a multicentre double-blind RCT for unstable angina who 
were warned about the possibility of gastrointestinal discomfort with those reported 
by participants who were not warned about this possibility. Those who received the 
warning subsequently reported much higher rates of gastrointestinal discomfort and 
were six times more likely to withdraw from the study because of this. It is worth 
noting, however, that this study was only quasi-experimental because participants 
were not randomised to receive the warning or not. Instead, the difference in warnings 
arose from differences in ethical requirements between the participating centres. Two 
out of the three participating centres’ ethics committees required participants to be 
warned about possible gastrointestinal discomfort, while the others did not. Further, 
participants in this study received aspirin, sulfinpyrazone, or placebo and the authors 
did not report on whether the warning interacted with type of treatment or not. Of 
most interest would have been whether the warning affected participants receiving 
placebo treatment. 
 
 The most compelling evidence for the effect of information on side effects 
comes from Mondaini et al. (2007), who investigated whether information affects side 
effects in men with prostatic hyperalgesia. These men were treated with finasteride 
for one year, a medication which is associated with side effects to do with sexual 
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function, including decreased libido, erectile dysfunction, and ejaculation disorders. 
Mondaini et al. (2007) randomised half of the men to be warned about these possible 
side effects and the other half to receive no such warning.  At the end of the treatment 
period, reported occurrence of these side effects was much more frequent in men who 
were warned about possible side effects compared with those not warned. 
Specifically, 31% of men warned that finasteride could affect their sexual function 
reported erectile dysfunction, 24% reported decreased libido, and 16% reported 
ejaculation disorders compared with 10%, 8%, and 6%, respectively, in men not 
warned about this possibility. 
  
 In terms of the studies failing to find an effect of warnings about side effects, 
Howland et al. (1990) found no difference in side effects between general practice 
patients receiving erythromycin, an antibiotic, who were warned about possible side 
effects, including abdominal cramping and discomfort, and those not warned. 
Similarly, Myers and Calvert (1973) found no differences in side effects or 
withdrawal rates in patients with depression given amitriptyline and either warned or 
not warned about possible dizziness, dry mouth sweating, and constipation. Morris 
and Kanouse (1982) also failed to find an effect of warning patients given thiazide for 
hypertension about possible fatigue, skin rash or hives, dry mouth, dizziness, light-
headedness, and headaches. Although, they did note that there was a trend towards 
those warned about side effects actually reporting more side effects. 
 
 One possible explanation for the studies failing to find an effect of providing 
information about side effects is that the studies involved various treatments with 
different possible side effects. In general, the placebo effect seems to affect some 
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conditions but not others (Evans, 2003). If so, some adverse effects may be more 
amenable to placebo-induced side effects than others and this may explain the 
differences in results across studies. Two studies conducted by Gibbs and her 
colleagues (1989a; 1989b) support this possibility. In both these studies, general 
practices in small towns in England were randomised, across towns, to provide their 
patients with prescription information leaflets or to provide no additional information. 
The information leaflets contained warnings about side effects relevant to the 
treatment being delivered. The first study (Gibbs et al., 1989a) involved patients given 
non-steroidal anti-inflammatory drugs, β-adrenoceptor antagonists, or bronchodilators 
and found no evidence that the information leaflet affected the side effects reported. 
The second study (Gibbs et al., 1989b), involving patients given penicillins, diuretics, 
or benzodiazepines, found that the information leaflet led to greater side effects in 
patients given benzodiazepines. Importantly, in each case the information led to 
increased knowledge of side effects, so these differences cannot be accounted for by 
differences in awareness of side effects. Instead, it may be that the treatment or 
symptoms related to benzodiazepines were amenable to placebo-induced side effects 
while the others were not. However, replication of the studies finding an effect of 
informing patients about treatment side effects would be required before these 
conflicting results could be attributed to whether or not the condition is placebo 
responsive. 
 
 There are also a number of general limitations to these studies. Firstly, they all 
involved active treatments. As discussed in Chapter 2, it is not yet known whether 
active treatment and placebo effects are additive. If they are not, then it may not be 
possible to isolate any placebo-induced side effects in studies involving active 
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treatment. In the studies that failed to find an effect of warning participants about side 
effects, for example, it could be that the side effects directly attributable to the active 
treatment might have produced a ceiling effect whereby no placebo-induced side 
effects could be detected. The only study that included a placebo treatment was that of 
Myers et al. (1987), but as mentioned above, they did not assess the effect of warning 
participants about side effects separately for those receiving active treatment and 
those receiving placebo. Secondly, all of these studies only considered the incidence 
of side effects and ignored their frequency and severity. This may not fully capture 
the variation in the side effects experienced by patients. For example, equal numbers 
of patients warned and not warned about side effects might experience one of these 
adverse symptoms, but the warning might increase the frequency or severity of the 
side effect.  
 
These first two limitations suggest these studies were not maximally sensitive 
to placebo-induced side effects. However, a third limitation is that all of the side 
effects assessed in these studies were self reported. This means that the higher 
reporting of side effects found in some of these studies might simply have resulted 
from demand characteristics. This is a difficult limitation to overcome in these types 
of studies, because it is often not possible to objectively measure side effects, such as, 
headaches, dizziness, or dry mouth. Thus, while experimental studies on placebo-
induced side effects provide at least some evidence that information about treatment 
side effects can lead to higher reporting of these side effects, they cannot determine 
whether this results from the placebo effect or some other process.  
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5.3 Conclusions 
 Studies showing that expectancies for adverse outcomes can produce negative 
placebo effects support the possibility that the placebo effect may contribute to 
treatment side effects. However, this type of evidence might only be considered 
indirect evidence for placebo-induced side effects as it involves expectancies 
regarding the primary action of the placebo, whereas placebo-induced side effects are 
secondary effects. Evidence that placebo groups in double-blind RCTs often report 
side effects is suggestive of placebo-induced side effects, but is limited in that these 
trials do not control for natural history. The fact that first time chemotherapy patients’ 
expectancies for nausea often predict their actual experience of post-chemotherapy 
nausea is equally suggestive. However, in the most methodologically rigorous study 
in this area, the results were ambiguous, with only one type of expectancy 
significantly predicting severe nausea, after history of nausea in some other settings 
was controlled for. Finally, at least four studies have shown that warning patients 
about side effects leads to a higher report of these side effects, but there are an equal 
number of studies that failed to find such an effect. Further, all of these studies 
involved active treatment, making it difficult to isolate the placebo effect, and they all 
only considered the incidence of side effects, rather than also examining their 
frequency and severity. Overall then, there seems to be evidence of a relationship 
between expectancies and side effects, but it remains unclear whether or to what 
extent the placebo effect actually contributes to treatment side effects.  
 
 With this in mind, the two following studies aimed to test for placebo-induced 
side effects by improving on some of the methodological limitations of the studies 
discussed in this chapter. In the first, I conducted a series of experiments to test 
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whether information about treatment side effects leads to greater side effects when 
only placebos were administered. To do this, I manipulated the side effect warnings 
given to otherwise healthy volunteers suffering from sleep difficulty who were told 
that they were taking part in a trial of a new medication designed to improve their 
sleep quality, but were actually given placebos. In the second study, I investigated 
whether first time chemotherapy patients’ pretreatment expectancies uniquely 
accounted for a significant proportion of variability in their posttreatment nausea, in a 
large sample (n>600) of cancer patients and after controlling for a number of other 
possibly confounding variables.  
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Chapter 6 – Information and Placebo-Induced Side Effects: 
Three Dummy Trials for Sleep Difficulty (Study 3) 
 
6.1 Introduction 
This study investigated whether providing information about possible 
treatment side effects leads to more side effects via the placebo effect. This involved a 
series of three dummy (placebo only) trials for sleep difficulty. Sleep difficulty was 
chosen because there is already some evidence for placebo effects in this area (e.g. 
Fratello et al., 2005; McCall, D'Agostino, & Dunn, 2003; Suetsugi et al., 2007) and it 
was expected to be relatively common in the student population from which 
participants were recruited, given prevalence of up to 35% in the general population 
(Stein, Belik, Jacobi, & Sareen, 2008). In these dummy trials, participants suffering 
from mild sleep difficulty were allocated to receive placebo treatment under the guise 
of a new medication for sleep difficulty or to a no treatment control group. The 
information participants received about bogus possible side effects was manipulated 
such that some participants were warned about side effects and others were not 
(Experiment 1) or such that the side effects participants were warned about were 
counterbalanced (Experiments 2 and 3). In the latter case this involved suggesting 
different sets of side effects to two groups of participants receiving placebo treatment.   
 
The design of these experiments had a number of advantages over previous 
studies in this area. As discussed in Chapter 5, all experimental studies investigating 
placebo-induced side effects to date have involved active treatments (Gibbs et al., 
1989a, 1989b; Howland et al., 1990; Mondaini et al., 2007; Morris & Kanouse, 1982; 
Myers & Calvert, 1973, 1984; Myers et al., 1987). If the active treatment produces 
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side effects in and of itself, then this may create a ceiling effect whereby any placebo-
induced side effects cannot be detected. Using placebo treatment avoids this 
possibility and thereby increases sensitivity for detecting placebo-induced side effects. 
The previous studies also only assessed the incidence of side effects as present or 
absent. Such crude measures of assessment may be insufficient to fully capture the 
impact of information on treatment side effects. For example, informing participants 
about side effects might cause a placebo effect that increases the frequency or severity 
of the symptom rather than increasing its occurrence. For this reason, the current 
study also included assessment of the frequency and severity of each side effect. 
Further, the inclusion of a no treatment group allowed for assessment of natural 
history, in that the occurrence, frequency, and severity of the suggested side effects 
could be observed in participants not receiving placebo treatment.  
 
 
6.2 Experiment 1 
 Experiment 1 piloted the design for the current study. The main aim was to 
determine whether the placebo treatment would elicit a placebo effect for sleep 
difficulty: without such an effect it would be unrealistic to expect placebo-induced 
side effects. A secondary aim was to determine whether warning participants about 
side effects had any impact on the occurrence, frequency, or severity of the suggested 
side effects. However, because only a small number of participants were involved in 
this experiment, it was highly unlikely that differences in side effects, if any, would 
reach statistical significance.  
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6.3 Method 
6.3.1 Participants 
Twenty-six first year (16 female, mean age=18.9, SD=1.3) psychology 
students from the University of Sydney experiencing mild difficulty sleeping 
participated in this study. Interested participants responded to an advertisement placed 
on ‘Experimtrix’, the School of Psychology, University of Sydney’s recruitment 
website for first year psychology students. Potential participants were excluded if they 
were under 18, had received treatment for sleep difficulty in the previous 3 months, 
were lactose intolerant, or were currently taking prescription medication other than 
the contraceptive pill. Participants received course credit for completing the study.  
 
6.3.2 Design 
Table 6.1 summarises the design of Experiment 1. The experiment employed a 
simple one factor, three level between-subjects design. One group received placebo 
treatment which they were told was a new herbal medication that would help them 
with their sleep difficulty. They also received an information sheet that suggested that 
the treatment may have three minor side effects: being more sleepy than usual when 
waking up, having a dry mouth, and mild headaches. A second group also received 
 
Table 6.1. Design of Experiment 1. Participants were allocated to receive placebo 
treatment or no treatment (control). Half of those allocated to receive placebo 
treatment were warned  about three possible side effects (suggestion) while the other 
half were not (no suggestion). 
 
Group Treatment Information 
Suggestion 
(n=9) 
Placebo pills (lactose) New treatment for sleep 
difficulty that may cause side 
effects, i.e. headaches, dry 
mouth, sleepy in the morning 
No Suggestion 
(n=8) 
Placebo pills (lactose) New treatment for sleep 
difficulty but no mention of side 
effects 
Control                             
(n=9) 
No treatment Controls in a trial of a new 
treatment for sleep difficulty 
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placebo treatment which they were told was a new herbal medication that would help 
them with their difficulty sleeping but received an information sheet that made no 
mention of side effects. Finally, a third group, the control group, did not receive 
treatment, but were told that they were acting as controls for a trial of a new sleep 
difficulty treatment. The dependent variables for sleep difficulty were global sleep 
difficulty, number of minutes taken to fall asleep (sleep latency), and total sleep time. 
The dependent variables for placebo-induced side effects were free and cued report of 
the occurrence, frequency, and severity of the suggested side effects. 
 
6.3.3 Materials 
Placebo Pills: The placebo pills were made from lactose and were red coated. 
They were prepared by the Faculty of Pharmacy, University of Sydney.  
  
 Pittsburgh Sleep Difficulty Index (Amended; PSQI-A): This is a standardised 
19-item questionnaire developed by Buysse, Reynolds, Monk, Berman, and Kupfer 
(1989). It consists of seven components assessing subjective sleep difficulty, sleep 
latency, total sleep time, habitual sleep efficiency, sleep disturbances, use of 
medications, and daytime dysfunction over the previous month. Summing these 7 
components provides a global sleep difficulty score ranging from 0-21 with higher 
scores indicating more sleep difficulty. Two amendments were made to this 
questionnaire. First, the component regarding the use of sleep medications was 
removed because part of the experimental manipulation involved administering 
treatment to some participants, but not others. This meant that total scores could range 
from 0-18 instead of 0-21. Secondly, because participants only received treatment for 
one week the questionnaire was amended such that participants rated their sleep 
difficulty over the previous week, rather than the previous month.   
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 Posttreatment Questionnaire (Appendix 4b): This was a study-specific 
questionnaire given only to those who received the placebo treatment. It assessed side 
effects as well as other aspects of the treatment, such as, perceived efficacy and 
compliance. The side effect question asked participants to rate whether or not they 
had experienced any side effects during the treatment period and, if so, to specify 
what these side effects were as well as rate their severity. This provided their free 
report of side effects. The perceived efficacy question required participants to rate 
how effective they found the treatment was for reducing their sleep difficulty on a 
scale from 0, ‘Not at all’ to 10, ‘Very effective’. In terms of compliance, participants 
were asked whether or not they had taken all of the pills given to them. If they had 
not, they were asked to report on how many nights they had failed to take the pill and 
whether there was a reason for this.  
  
 Adverse Symptom Checklist (Appendix 4c): This was also a study-specific 
questionnaire. It assessed general adverse health symptoms and had the three target 
symptoms, sleepiness in the mornings, headaches, and dry mouth, embedded in it. 
This questionnaire required participants to rate 1) whether or not they had experienced 
the symptom in the previous week (occurrence), 2) the number of days on which the 
had experience the symptom (frequency), and 3) how severe the symptom had been 
(severity). The latter was on an 11-point Likert-type scale anchored by ‘Not at all 
severe’ to ‘Extremely severe’. The checklist reflected participants’ cued report of side 
effects and was given to all participants.  
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6.3.4 Procedure 
Participants attended an initial session lasting approximately 20min in which 
they were given the information sheet and consent form. The information sheet 
(Appendix 4a) included a background section which described the experiment as a 
trial of a new herbal medication, labelled SX3752, believed to be effective for 
reducing sleep difficulty and stated that they may be allocated to receive the treatment 
or to a group that would not receive treatment. Half of the information sheets 
contained a warning about possible side effects under a section titled ‘Risks’. This 
warning stated:  
“Some people who take SX3752 report some minor side effects. These may 
include feeling more sleepy than usual when you awaken, having a dry mouth, 
and mild headaches. If you do experience these side effects, they will go away 
completely when you stop taking SX3752”  
The remaining information sheets did not contain this section and made no mention of 
possible side effects. After informed consent was gained participants were asked to 
provide some demographic information and complete a questionnaire about their 
sleeping habits over the past week (PSQI-A). This constituted their baseline sleep 
difficulty. Participants were then informed about whether they would be receiving the 
treatment or not. Those who were in one of the two treatment groups were given 7 
placebo pills (lactose) and told to take one each night for the next week about 15 
minutes before going to bed. Those in the no treatment group were told that they were 
acting as controls and would not be receiving treatment. Participants returned one 
week later to complete the follow-up assessment which lasted approximately 15min. 
In this session, participants were asked to complete the PSQI-A which assessed their 
level of sleep difficulty over the treatment period. Those who received treatment were 
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then given the posttreatment questionnaire which assessed side effects via free report, 
perceived efficacy of the treatment, and compliance. All participants were then given 
the adverse symptom checklist which had the three suggested side effects embedded 
in it. At the end of the session participants were debriefed and given information 
about the ‘Quarter of an Hour Rule’ (Bootzin, Epstein, & Wood, 1991), which is a 
behavioural strategy that can be used to reduce sleep difficulty. These procedures 
were approved by the University of Sydney’s Human Research Ethics Committee.  
 
6.3.5 Statistical Analysis 
 Two orthogonal contrasts tested whether placebo treatment reduced sleep 
difficulty compared with no treatment at the follow-up session and whether there were 
differences in sleep difficulty between the suggestion and no suggestion groups. This 
was done on posttreatment scores for global sleep difficulty, sleep latency, and total 
sleep time, controlling for baseline scores. Only a few participants freely reported side 
effects and the symptoms varied from one participant to another making it impractical 
to compare frequency and severity. As a result, only the occurrence of any adverse 
effects was considered when comparing freely reported side effects and this was done 
using a Chi-square test of independence. For cued report of side effects, Chi-square 
tests of independence assessed the occurrence of the suggested side effects across all 
groups. Orthogonal contrasts were then used to assess the frequency and severity of 
each suggested side effect in those reporting these symptoms for placebo treatment 
versus no treatment and the suggestion versus no suggestion groups. All statistical 
analyses were conducted using SPSS software (version 15; SPSS Inc, Chicago, Ill) 
and results were considered significant when p<.05. 
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6.4 Results and Discussion 
6.4.1 Sleep Difficulty  
 Figure 6.1 displays mean global sleep difficulty before and after treatment 
across groups. Global sleep difficulty decreased by an average of 4.7 (SD=2.5) points 
for those in the suggestion group, 3.0 (SD=2.0) points for those in the no suggestion 
group, and 2.1 (SD=3.7) points for those in the control group. Contrast analysis 
revealed that posttreatment global sleep difficulty was significantly lower for those 
who received placebo treatment compared with no treatment, after controlling for 
baseline scores, F(1,22)=5.29, p=.03, but that there was no significant difference in 
global sleep difficulty among the two treatment groups, F<1. 
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Figure 6.1. Experiment 1. Mean (+SE) global sleep difficulty across treatment group. 
Placebo treatment significantly reduced sleep difficulty but there was no significant 
difference in sleep quality between the suggestion and no suggestion groups.  
 
 
 Mean sleep latency and total sleep time for each group are shown in Figure 
6.2. There was a tendency for a greater reduction in sleep latency for those receiving 
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placebo treatment compared with the control participants, which was only marginally 
non-significant after controlling for baseline sleep latency, F(1,22)=4.26, p=.051. 
There was also a tendency for increased total sleep time for participants receiving 
placebo compared with those receiving no treatment, however, this was also non-
significant after controlling for baseline total sleep time, F<1. There were no 
differences between the suggestion and no suggestion groups on either of these 
measures of sleep difficulty, both F<1. This pattern of results suggests a placebo 
effect for global sleep difficulty and tendencies towards the same for sleep latency 
and total sleep time, but that this placebo effect was unaffected by whether or not 
participants were warned about side effects.  
 
Figure 6.2. Experiment 1. Mean (+SE) sleep latency (A) and total sleep time across 
groups. There were non-significant tendencies towards better sleep quality for those 
receiving placebo treatment compared with those receiving not treatment. There were 
no significant differences between the suggestion and no suggestion groups. 
 
6.4.2 Side effects – Free report 
Six out of the seventeen (35%) participants who received placebo treatment 
freely reported experiencing at least one side effect. The rate of these side effects was 
almost identical with three participant reporting at least one side effect in the 
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suggestion group (33%) and three participants in the no suggestion group (38%), 
χ2<1. In the suggestion group two of the participants reported side effects consistent 
with the warning: one participant reported all three suggested side effects (tiredness in 
the morning, headaches, and dry mouth) while the second reported only dry mouth. 
The third participant in this group reported experiencing stomach cramps on the last 
night of taking the tablet. The side effects reported by two of the participants in the no 
suggestion group were also consistent with the target side effects even though these 
participants received no warning: they were, tiredness during the day and headaches. 
The third participant in the no suggestion group reported experiencing difficulty 
concentrating. This suggests that participants receiving placebo treatment report 
experiencing side effects, but that the warning they received that had no affect on the 
type of these side effects.  
 
6.4.3 Side effects – Cued report 
Figure 6.3 displays the occurrence of target symptoms as a function of 
treatment group. A higher proportion of participants in the suggestion group reported 
sleepiness in the morning and headaches than the no suggestion group while the 
opposite was true for dry mouth. The occurrence of these symptoms was quite high in 
the control group with at least 50% of these participants reporting each of the three 
target symptoms. Chi-square tests, however, revealed that there were no significant 
differences in occurrence of these three target symptoms between groups, highest 
χ2(df=2, n=26)=1.65, p=.44. 
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Figure 6.3. Experiment 1. Occurrence (%) of target symptoms across treatment 
groups. No differences were significant.  
 
  
As shown in Figure 6.4, sleepiness in the mornings and dry mouth were rated 
as being slightly more frequent in the suggestion group compared with the no 
suggestion group, but these differences were not significant, both F<1. For headaches, 
however, the no suggestion group actually reported this side effect as more frequent 
than the suggestion group, although this was marginally non-significant, F(1,8)=4.64, 
p=.06. Frequency of side effects in the control group was lower than both treatment 
groups, with the exception of headaches in the suggestion group. These tendencies 
towards less frequent side effects in the control group were not significant, highest 
F(1,14)=3.04, p=.11. 
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 Figure 6.4: Experiment 1. Mean (+SE) frequency in days each target symptom 
occurred across treatment group. No differences were significant. 
 
 
 Figure 6.5 shows a small tendency for those in the suggestion group to report 
greater symptom severity than those in the no suggestion group, however none of 
these differences were statistically significant, all F<1. The mean severity of the three 
target symptoms did not differ significantly between those receiving placebo 
treatment and those in the control group, all F<1. Taken together, the findings for 
occurrence, frequency, and severity of the target side effects indicate that the warning 
had minimal, if any affect on these adverse symptoms.  
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Figure 6.5. Experiment 1. Mean (+SE) severity rating for target symptoms across 
treatment condition. No differences were significant.  
 
 
 
6.4.4 Summary  
Even with this small sample there was clear evidence of a placebo effect for 
sleep difficulty. Participants who received a placebo pill but were told that they were 
receiving an active medication reported significantly less global sleep difficulty at the 
end of the treatment period compared with participants who received no treatment. 
This was supported by tendencies towards reduced sleep latency and increased total 
sleep time in the placebo treatment groups compared with the control group. In 
relation to side effects, the suggestion that the treatment may result in increased 
tiredness in the morning, mild headaches, and dry mouth appeared to have minimal, if 
any, effect on the occurrence, frequency, or severity of these symptoms, however. It 
was interesting that one third of the participants receiving placebo treatment reported 
at least one side effect via free report, regardless of whether they were warned about 
side effects or not. This may provide some evidence for placebo-induced side effects 
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as these participants may have expected and therefore experienced adverse symptoms 
as a result of these expectancies. On the other hand, these participants may have 
misattributed the random occurrence of these adverse symptoms during the 
experiment to the treatment. The fact that the control group, who never received 
treatment, often reported similar occurrence, frequency, and severity of the target side 
effects supports this possibility. However, this group had the highest level of sleep 
difficulty, which may have contributed to their high level of reported adverse 
symptoms. 
 
 
6.5 Experiment 2 
 Overall, the results obtained in Experiment 1 were promising. They 
demonstrated that the design was sufficient to produce a placebo effect for sleep 
difficulty. The placebo treatment led to some side effects being reported via free 
report, but whether these were placebo-induced side effects or were simply 
misattributed could not be determined. There were some small tendencies towards 
increased occurrence, frequency, and severity of the target side effects in the 
suggestion group compared with the no suggestion group. Importantly, the differing 
patterns of results for side effect occurrence, frequency, and severity, support the use 
of more sophisticated analysis of side effects than those used in previous studies (e.g. 
Gibbs et al., 1989a, 1989b; Howland et al., 1990; Mondaini et al., 2007; Morris & 
Kanouse, 1982; Myers & Calvert, 1973, 1984; Myers et al., 1987).  
 
 A number of potential limitations were revealed during this pilot experiment. 
Some participants in the treatment groups questioned whether they had received a 
placebo at the end of the study period. This was surprising because participants were 
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told that they would receive either active treatment or no treatment, with no mention 
of placebos. This doubt regarding type of treatment might have weakened 
expectancies for reduced sleep difficulty and/or side effects and may, therefore, have 
detracted from the placebo effect for either of these outcomes. A second limitation 
was the high level of target symptoms in the control group, as noted above. This made 
it impossible to determine whether the side effects freely reported in the treatment 
groups occurred as a result of the placebo effect or of misattribution. Finally, the side 
effect manipulation may not have been strong enough to induce expectancies for these 
adverse effects. That is, participants in the suggestion group may not have attended to 
the warning contained in the information sheet sufficiently to cause an expectation for 
these adverse effects. If so, placebo-induced side effects would be unlikely.  
 
Experiment 2 employed a similar design to Experiment 1, but a number of 
changes were made in an attempt to increase its sensitivity to both the placebo effect 
and placebo-induced side effects. The most significant of these was counterbalancing 
the side effects which the suggestion group were warned about. Participants in the 
suggestion group were informed that they might experience drowsiness, dry mouth, 
and nausea (Set A) or dizziness, blurred vision, and sore eyes (Set B). This provided a 
more sensitive measure of the influence of information on side effects because it 
allowed for a within-subjects comparison of suggested versus non-suggested side 
effects. Participants in the suggestion group also received a verbal warning about 
these possible, but bogus, side effects when they were given their treatment, in 
addition to the written warning contained in the information sheet. This was done to 
increase attention to the side effect warning. A question was also added to the end of 
the posttreatment questionnaire asking participants in the treatment groups whether 
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they remembered being warned about side effects or not, and, if so, which side effects 
they had been warned about in order to check the side effect manipulation. Finally, 
the information that the treatment was a new herbal medication was removed. Instead 
participants were simply told that the trial was for a new medication designed to 
reduce their sleep difficulty. This was aimed at increasing expectancies for both 
improved sleep quality and treatment side effects as some participants might expect 
herbal treatments to be less effective, or at least less toxic, than other types of 
treatment.  
 
6.6 Methods 
 Except where otherwise stated, the methods used in Experiment 2 were the 
same as Experiment 1.  
 
6.6.1 Participants 
Participants were 57 (mean age=20.1, SD=3.9, female=44) first year 
psychology students from the University of Sydney who reported difficulty sleeping. 
Recruitment and eligibility criteria were identical to Experiment 1.  
 
6.6.2 Design 
 The side effects which the suggestion group (n=18) were warned about were 
now counterbalanced. This meant that half of the participants in the suggestion group 
were warned about drowsiness, dry mouth, and nausea (Set A; Appendix 4d) while 
the other half were warned about dizziness, blurred vision, and sore eyes (Set B; 
Appendix 4e). Allocation to Set A or Set B side effects was random. As with 
Experiment 1, the no suggestion group (n=21) received placebo treatment but were 
not warned about side effects and the control group (n=18) did not receive treatment.  
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6.6.3 Procedure 
All participants were told that they were taking part in an open trial of a new 
medication for sleep difficulty that did not contain a placebo group. Participants in the 
suggestion group received a verbal warning about either Set A or Set B side effects 
when they received their medication in addition to the warning contained in the 
information sheet.  
 
6.6.4 Materials  
 Adverse Symptom Checklist (Appendix 4f): The version described in 
Experiment 1 was altered to include all six side effects (Sets A and B) plus some other 
non-suggested adverse effects, e.g. restlessness.  
  
 Posttreatment Questionnaire (Appendix 4g): This contained the extra question 
asking participants to rate whether they remembered being warned about side effects, 
and if so, to list these. This question occurred at the end of the questionnaire. 
 
6.6.5 Statistical Analysis 
 Statistical analysis for the placebo effect for sleep difficulty and free report of 
side effects was identical to Experiment 1. The counterbalancing of side effects 
allowed for both within- and between-groups analysis for cued report of side effects 
in the suggestion group. For the within-subjects analysis, the total number of target 
and non-target side effects and their mean frequency and severity were calculated for 
each participant. Paired samples t-tests were then used to determine whether there 
were differences in the reporting of target versus non-target side effects. For the 
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between-subjects analysis, the occurrence, frequency, and severity of each adverse 
symptom were compared when they were suggested with when they were not 
suggested via Chi-square tests of independence and independent samples t-tests.  
 
6.7 Results and discussion 
 
6.7.1 Sleep Difficulty 
Figure 6.6 displays global sleep difficulty before and after treatment for each 
group. Sleep difficulty decreased by an average of 3.1 (SD=3.0) points in the 
suggestion group, 3.0 (SD=1.6) points in the no suggestion group, and 0.8 (SD=2.1) 
points in the control group. Controlling for baseline sleep quality, posttreatment sleep 
difficulty was significantly lower in those who received treatment compared with 
controls, F(1,53)=10.6, p<.01, but again there was no significant difference in global 
sleep quality between the treatment groups, F<1.  
Figure 6.6: Experiment 2. Mean (+SE) global sleep difficulty before and after 
treatment for each group. Placebo treatment significantly reduced sleep difficulty 
compared with no treatment. There was no significant difference between the two 
treatment groups (suggestion vs no suggestion). 
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This pattern of results was the same for total sleep time, as shown in Figure 
6.7B. Mean total sleep time increased by 33.5 (SD=56.3) minutes in the suggestion 
group and 22.9 (SD=40.1) minutes in the no suggestion group but only increased by 
1.7 (SD=90.0) minutes in the control group. The increase in total sleep time for 
participants receiving placebo treatment was significantly higher than for those in the 
control group, after controlling for baseline total sleep time, F(1,53)=4.4, p=.04. 
There was, however, no significant difference between the two treatment groups, F<1. 
As can be seen in Figure 6.7A, there were no significant differences between groups 
for sleep latency after controlling for baseline scores, highest F(1,53)=1.94, p=.17. 
The improved sleep quality in participants allocated to receive placebo treatment for 
global sleep difficulty and total sleep time was consistent with the findings of 
Experiment 1 and provides further evidence for a placebo effect for sleep difficulty. 
 
Figure 6.7. Experiment 2. Mean (+SE) sleep latency (A) total sleep time (B) and by 
treatment group. The only significant difference was that total sleep time was greater 
in those that received placebo treatment compared with controls.  
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6.7.2 Side effects – Free report 
Overall 12 out of 39 participants who received placebo treatment reported 
experiencing at least one side effect via free report. These were approximately equally 
distributed between the suggestion and no suggestion groups, 33.3% and 28.6%, 
respectively, χ2<1. The side effects reported in the suggestion group were not related 
to the warning. In fact, only two of these participants reported a target side effect and 
of these two, one also reported a non-target side effect. Combining the two treatment 
groups, the most common side effects reported were headaches and drowsiness with 
each being reported four times. Interestingly, one participant claimed to have vomited 
in response to the pill on her final night of treatment. Thus, as in Experiment 1, 
participants receiving placebo treatment for sleep difficulty freely reported side 
effects in response to their treatment, but these were not related to whether or not they 
had been warned about side effects.  
 
6.7.3 Side effects – Cued report 
Figure 6.8 displays average occurrence, frequency, and severity of target 
versus non-target symptoms reported by the suggestion group via cued report. 
Although there was a slight tendency for more target symptoms to be reported by the 
suggestion group than non-target symptoms and for the target symptoms to be more 
frequent and severe, paired t-tests revealed that none of these differences were 
significant, all t<1. In general, the mean occurrence, frequency, and severity of both 
target and non-target symptoms were quite low. 
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Figure 6.8: Experiment 2. Mean (+SE) occurrence (total number of symptoms, A), 
frequency (B), and severity (C) of target symptoms versus non-target symptoms 
reported by the suggestion group. No differences were statistically significant.  
 
 As shown in Figure 6.9, between-subjects analysis of each of the six target 
symptoms when suggested versus not suggested showed a similar pattern to the 
within-subjects analysis above. That is, there was a general tendency for symptoms to 
have greater occurrence, frequency, and severity when they were suggested than when 
they were not suggested. The only exceptions to these were occurrence, frequency, 
and severity of dizziness and occurrence of drowsiness. Chi-square tests of 
independence and independent samples t-tests revealed that none of these differences 
were statistically significant, all χ2<1 or t<1. As can also be seen in Figure 6.9, the 
occurrence, frequency, and severity of each of these side effects were relatively high 
in the control group. Thus, these results indicate a similar pattern to those of 
Experiment 1, in that there were small tendencies for increased side effects when 
suggested, but that none of these differences were statistically significant. 
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Figure 6.9. Experiment 2. Occurrence (A) and mean (+SE) frequency (B) and 
severity (C) of each symptom in the suggestion group when suggested (target), in the 
suggestion group when not suggested (non-target), and in the control group (control). 
No differences were statistically significant.  
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6.7.4 Recall of side effect warning  
 Recall of the side effect warning was poor. Only one participant (6%) in the 
suggestion group correctly recalled all three of the side effects contained in the 
warning and, as shown in Figure 6.10, almost two thirds of these participants could 
only correctly recall one or less of the side effects that they had been warned about. 
One third of these participants also incorrectly reported being warned about a 
symptom that they had, in fact, not been warned about.  
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Figure 6.10. Experiment 2. Correct recall of side effects contained in the warning 
given to participants in the suggestion group.  
 
 
6.7.5 Summary 
Experiment 2 demonstrated further evidence for a placebo effect for sleep 
difficulty. Participants who received placebo treatment showed significantly lower 
levels of global sleep difficulty and had longer total sleep time than those who 
received no treatment. The warning about side effects did not significantly increase 
occurrence, frequency, or severity of side effects via free or cued report. There were 
tendencies in this direction, but they were only small. It was again interesting to note, 
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however, that approximately 30% of all participants who received the placebo 
treatment reported at least one side effect when asked. Perhaps most importantly, it 
was clear that the majority of participants could only remember being warned about 
one side effect or less at the end of the treatment period. This suggests that 
participants either failed to attend to the warning about side effects when given or that 
substantial forgetting occurred during the treatment period. Given such poor recall, it 
is not surprising that the warning had no impact on participants’ report of side effects.   
 
 
6.8 Experiment 3 
 Poor recall of the warning was a major and unexpected limitation to 
Experiment 2. To develop expectancies for suggested side effects participants must 
first attend to and retain the information contained in the warning. The poor recall was 
unexpected because participants received an extra verbal warning in the experiment. 
One possible explanation is that participants received a large amount of information in 
a relatively small amount of time. The fact that participants remembered being 
warned about possible side effects, for the most part, but forgot which specific side 
effects they had been warned about supports this. Although the participants were 
given the information sheet to take home with them, it is unlikely that they would 
have re-read the information during the treatment period.  
 
 Experiment 3 addressed this limitation by reducing the warning to contain 
only one side effect, rather than three. This was intended to reduce the memory load 
on participants regarding the warning and, thereby, to increase their expectancies for 
the suggested side effect. Three other modifications were made to the design of 
Experiment 3. The first was that the side effects participants were warned about were 
changed to either increase in appetite or decrease in appetite. The advantage of this 
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was that these symptoms are symmetrical, in that an increase in appetite precludes a 
decrease in appetite and vice versa. Unfortunately, there were no data on occurrence, 
frequency, and severity of change in appetite likely in the control group from the 
previous experiments, as this was not included on either of the adverse health 
checklists. The second was that the no suggestion group was omitted. This was done 
because the counterbalancing of the side effect warning allowed for a within-groups 
comparison of suggested versus non-suggested side effects in the suggestion group. 
The control group was maintained, however, as it was important to confirm the 
placebo effect for sleep difficulty and to determine the extent to which increased or 
decreased appetite was reported by participants not receiving treatment. Finally, the 
colour of the placebo pills was changed to blue, rather than red. This was based on 
evidence indicating that blue pills are associated with greater hypnotic effects than red 
pills (Blackwell, Bloomfield, & Buncher, 1972; Buckalew & Coffield, 1982; de 
Craen, Roos, Leonard de Vries, & Kleijnen, 1996) and that increasing the placebo 
effect for sleep difficulty might increase expectancies for treatment side effects.  
 
6.9 Methods 
 
 Except where otherwise stated, the methods used in Experiment 2 were the 
same as Experiment 2.  
 
6.9.1 Design 
 The no suggestion group was omitted from this study. Therefore, participants 
were either allocated to receive placebo treatment under the guise of new medication 
aimed at reducing their sleep difficulty or to a no treatment control group. Half of the 
participants received both a written and verbal warning that the treatment might cause 
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increased appetite (Appendix 4h), while the other half received a written and verbal 
warning that the treatment might cause a decrease in appetite (Appendix 4i). This 
occurred whether or not participants received treatment so as to avoid any potential 
sampling bias which may have arisen if the warning deterred participants from joining 
the study. Therefore, half of the participants in the control group were also given an 
information sheet that warned of possible increased appetite in response to the bogus 
treatment, while the other half received an information sheet that warned of possible 
decreased appetite. Participants were allocated to the suggestion or control group on a 
3:2 ratio to ensure a sufficient sample size in the experimental group, which resulted 
in 31 participants in the suggestion group and 17 participants in the control group.  
 
6.9.2 Participants 
Participants were 48 (mean age=20.1, SD=5.1, female=37) first year 
psychology students from the University of Sydney who reported difficulty sleeping. 
Eligibility criteria were identical to Experiment 2.  
 
6.9.3 Procedure 
The procedure used was the same as Experiment 2, with the exception that 
participants were either warned about increase in appetite or decrease in appetite.  
 
6.9.4 Materials  
Placebo Pills: The placebo pills were made from lactose and were blue 
coated. They were prepared by the Faculty of Pharmacy, University of Sydney.  
  
 Adverse symptom checklist (Appendix 4k): The version used in Experiment 2 
was altered to include a question asking whether the participant had experienced a 
change in appetite, and if so to describe this and to rate its severity. The direction of 
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the change in appetite was derived from the description participants provided. Due to 
experimenter error, the question regarding the frequency of change in appetite was 
unintentionally omitted, so only the occurrence, direction, and severity of change in 
appetite were assessed.  
 
6.9.5 Statistical Analysis 
 ANCOVA was used to test whether participants receiving placebo treatment 
had lower levels of sleep difficultly at the follow-up compared with those receiving 
no treatment and after controlling for baseline levels. For side effects via cued report, 
a nonparametric measure was calculated which indicated appetite changes as follows: 
1) consistent with the warning, 2) inconsistent with the warning, and 3) no change in 
appetite. A Chi-square test of independence was used to determine whether the 
pattern of changes in appetite differed among those in the suggestion group and those 
in the control group. A Chi-square test for goodness of fit assessed whether there was 
an overall effect of the warning, regardless of treatment, by comparing the proportion 
of consistent changes in appetite with those that were inconsistent in all participants 
reporting a change in appetite. An independent samples t-test was used to compare the 
severity of consistent changes in appetite across the suggestion and control groups. 
Two participants in the control group failed to answer the question regarding changes 
in appetite so they were omitted from the analysis of side effects based on cued report. 
No statistical analysis was conducted on free report of side effects because only four 
participants reported side effects in response to this question.  
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6.10 Results and discussion 
6.10.1 Sleep difficulty 
 The pattern of results for sleep difficultly replicated the placebo effect found 
in Experiment 2. As shown in Figure 6.11, controlling for baseline scores, placebo 
treatment significantly reduced global sleep difficulty by 1.6 points and increased 
total sleep time by more than no treatment and increased to 26min compared with the 
control group who received no treatment, F(2,45)=4.69, p=.04 and F(2,45)=8.02, 
p<.01, respectively. There was again no significant difference in sleep latency 
between the suggestion and control groups, F(2,45)=2.01, p=.16. Thus, there was 
further evidence for a placebo effect for sleep difficulty.  
Figure 6.11. Experiment 3. Mean (+SE) global sleep difficulty (A) and total sleep 
time before and after treatment for the suggestion and control group. In both cases, 
placebo treatment led to significantly better posttreatment sleep quality.  
  
 
6.10.2 Side effects – Free report 
 Only four (13%) of the participants receiving placebo treatment freely 
reported a side effect. Two of these participants reported a change in appetite and on 
both occasions these were consistent with the warning these participants had received.  
The third participant reported migraines and drowsiness, while the fourth reported 
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difficulty waking up and strange dreams. The proportion of participants freely 
reporting side effects was clearly lower in this experiment than in the previous two 
experiments (approx 30%).  
 
6.10.3 Side effects – Cued report  
 Figure 6.12 displays the proportion of participants reporting consistent, 
inconsistent, or no change in appetite for the suggestion group and the control group. 
Eight (26%) participants in the suggestion group reported a change in appetite and 
these were all in the direction of the warning they had received. This suggested a 
strong impact of the warning on appetite. However, four participants in the control 
group also reported a change in appetite and three (20% overall) of these were 
consistent with the warning contained in the information sheet that these participants 
received. A Chi-square test of independence revealed no significant difference in the 
pattern of changes in appetite for the suggestion group compared with the control 
group, χ2(df=2, n=46)=2.21, p=.33. A post hoc Chi-square test for goodness of fit 
showed that, regardless of treatment condition, the direction of changes in appetite 
was significantly associated with the warning participants had received, χ2(df=1, 
n=12)=8.33, p<.01. Taken together, this implied that there was an overall effect of 
suggestion whereby participants reporting a change in appetite did so in the direction 
which they had been warned about, but that this was not significantly related to 
whether or not they actually received the placebo treatment. This finding was rather 
unexpected and is discussed in more detail below.  Figure 6.13 displays severity 
ratings of the changes in appetite for the suggestion and control groups. There were 
no significant differences between these two groups, t<1.   
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Figure 6.12. Experiment 3. Proportion and direction of changes in appetite for 
participants in the suggestion and control groups. No differences were statistically 
significant.  
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 Figure 6.13. Experiment 3. Mean (+SE) severity of changes in appetite for 
participants in the suggestion and control groups. There was no statistically 
significant difference.  
 
6.10.4 Recall of the side effect warning 
 Recall of the side effect warning was near perfect. All but one participant in 
the suggestion group recalled being warned about side effects. Further, all of the 
participants who remembered being warned about side effects correctly identified the 
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direction of change in appetite that had been suggested. This indicates an important 
improvement over Experiment 2, where almost two thirds of the participants could 
only remember being warned about one or less side effects from a possible three.  
 
6.10.5 Summary 
 Experiment 3 replicated the placebo effect for sleep difficulty found in 
Experiment 2, with those receiving placebo treatment reporting significantly lower 
global sleep difficulty and increased total sleep time posttreatment compared with 
control participants. There was a smaller proportion of side effects freely reported in 
this experiment (13%) compared with the two previous experiments (about 30%). The 
findings for changes in appetite when cued were rather odd, in that there seemed to be 
an overall effect of warning participants about possible changes in their appetite, but 
that this was unrelated to whether or not the participants actually received placebo 
treatment. The warning about side effects was recalled much better in this experiment 
than in Experiment 2, with virtually all of the participants in the suggestion group 
remembering the side effect they had been warned about.  
 
 
6.11 General Discussion 
 There was consistent evidence for a placebo effect for sleep difficulty in all 
three experiments. In Experiments 1, 2 and 3, placebo treatment led to significantly 
lower global sleep difficulty than no treatment and in Experiments 2 and 3 placebo 
treatment also significantly increased total sleep time. This supports previous 
evidence for placebo effects in sleep difficulty (e.g. Fratello et al., 2005; McCall et al., 
2003; Suetsugi et al., 2007). It is worth noting that the control groups consistently 
demonstrated reductions in their sleep difficulty, even though they did not receive 
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treatment. Post hoc analysis of pooled data from the control groups in each 
experiment demonstrated that these reductions were significant for global sleep 
difficulty and sleep latency. It is not clear why this was the case. It may reflect 1) an 
initial reporting bias during, 2) that taking part in the trial itself improved their sleep 
quality, or 3) that there was regression to the mean. Regardless of the reason, it re-
emphasises the need to control for natural history when investigating the placebo 
effect.  
 
 In relation to placebo-induced side effects, the first two experiments provided 
no statistically significant evidence that warning participants about possible side 
effects actually influenced their reports of these adverse symptoms. However, this is 
perhaps unsurprising given the poor recall of the suggested side effects found in 
Experiment 2. In Experiment 3, in which almost all participants correctly recalled the 
side effect they had been warned about, 26% of participants who received placebo 
treatment reported the suggested side effect, either increase or decrease in appetite. 
Further, no participants in this group reported a change in appetite that was 
inconsistent with the warning. Although this result may suggest that the warning 
affected side effects, this pattern was not significantly different to the control group, 
in which changes in appetite also generally appeared consistent with the warning, 
even though these participants did not receive treatment. As such, this implies an 
overall effect of warning participants about potential side effects that was independent 
of whether participants actually received treatment or not. However, the control group 
only consisted of seventeen participants and only four of these participants reported a 
change in appetite, so it is difficult to determine whether this result would hold in a 
larger sample. 
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 Despite the lack of convincing evidence for placebo-induced side effects 
caused by the warning, a number of participants receiving placebo treatment reported 
experiencing at least one side effect in response to their treatment. In the first two 
experiments approximately 30% of participants receiving placebo treatment reported 
at least one side effect, whereas only 13% did in the final experiment. This may 
provide evidence for placebo-induced side effects, if participants entered the 
experiment with preconceived expectancies for side effects. The difference in rates of 
freely reported side effects in Experiments 1 and 2 versus Experiment 3 is potentially 
interesting. The two major differences between these experiments were that the 
former involved a warning about three possible side effects and that the placebo pills 
were red, while the latter involved a warning about only one possible side effect and 
the placebo pills were blue. Perhaps being warned about a greater number of side 
effects created more generalised expectancies for adverse outcomes than only being 
warned about one side effect. Equally plausible is that red pills might be more readily 
associated with toxicity compared with blue pills and this may have led to stronger 
expectancies for side effects. Of course, caution is required here as the high rate of 
adverse symptoms in the control group implies that the side effects reported by the 
treatment groups might have simply been misattributed to the treatment, rather than 
actually being caused by the placebo effect.  
 
 Overall then, there was generally little evidence for placebo-induced side 
effects, which is consistent with previous studies that have failed to find evidence that 
information about side effects increases their occurrence (Gibbs et al., 1989a; 
Howland et al., 1990; Morris & Kanouse, 1982; Myers & Calvert, 1973). However, 
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given the small but consistent tendencies towards increased side effects in the 
suggestion groups, it might be the case that placebo-induced side effects do exist, but 
that they are relatively weak effects. As discussed in the previous chapter, placebo-
induced side effects might be considered secondary placebo effects because they are 
responses made to the treatment other than those for which it has been administered 
and that are not attributable to the inherent properties of the treatment itself. As such, 
participants might develop much stronger expectancies for the primary outcome of 
their treatment, in this case reduced sleep difficulty, than they do for side effects. This 
certainly seems plausible given the strong evidence for a placebo effect for sleep 
difficulty in the current study. Further, it may explain why there is more convincing 
evidence for negative placebo effects than there is for placebo-induced side effects 
(see Chapter 5).     
 
 There are at least two important implications of this possibility, both of which 
are discussed in more detail in Chapter 8. Firstly, if placebo-induced side effects do 
exist but are only weak, then detecting these effects will require very large sample 
sizes, which, despite employing a highly sensitive design, the current study lacked. 
Secondly, the fact that participants appear to benefit more from the suggestion of 
positive outcomes than the suggestion of adverse outcomes implies that providing 
information about a treatment, its aims, likely efficacy, and side effects will produce 
more benefit via the placebo effect than it will harm. This means that, in addition to 
allowing for increased patient autonomy, informed consent might improve outcomes 
via the placebo effect substantially more than it increases adverse side effects.  
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 The current study also highlights a general limitation to experimental studies 
assessing the influence of warning participants about side effects. That is, these types 
of studies do not directly assess expectancies for side effects. Such assessment was 
deliberately avoided in the current study because questioning participants about their 
expected side effects might influence their expectancies or it might have undermined 
the credibility of the bogus trial and hinted towards the true purpose of the study. As a 
result, it was impossible to determine whether participants actually expected to 
experience side effects as result of the warning, beyond recall of the side effects 
listed. If no such expectancies were elicited, then no placebo-induced side effects 
could be expected. Therefore, while experimental studies involving manipulating 
information about treatment side effects are best able to determine whether this has a 
causal impact on actual side effects, they are entirely reliant on the side effect warning 
producing expectancies for side effects, which for the above reasons is difficult to 
check.  
 
   In an attempt to explore the possibility that placebo-induced side effects do 
exist but only have small effects, the following study investigated whether 
expectancies contribute to treatment side effects in a large sample of first time 
chemotherapy patients. An advantage of this was that the relationship between 
expectancy and side effects could be assessed directly.   
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Chapter 7 – Expectancy and Posttreatment Nausea in First 
Time Chemotherapy Patients (Study 4) 
 
7.1 Introduction 
 This study examined the relationship between expectancy and nausea in a 
large sample of first time chemotherapy patients in a trial comparing antiemetic 
regimens for delayed nausea. Although methods for the prevention and control of 
emesis have improved greatly, nausea continues to be a significant burden to patients 
undergoing chemotherapy, with the vast majority of these patients experiencing 
nausea at some point during their chemotherapy treatment (Roscoe et al., 2000). As 
discussed in Chapter 5, a number of studies have shown that stronger pretreatment 
expectancies for nausea predict greater posttreatment nausea (Haut et al., 1991; 
Jacobsen et al., 1988; Montgomery & Bovbjerg, 2000; Olver et al., 2005; Rhodes et 
al., 1995; Roscoe et al., 2004; Roscoe et al., 2000; Shelke et al., 2008). While such 
studies are suggestive of placebo-induced side effects, the majority of these studies 
have methodological flaws limiting the conclusions which can be drawn from them. 
For example, many did not adequately control for other potentially confounding 
variables, particularly history of nausea, and/or used statistical techniques that may 
have overestimated the role of expectancy. This makes it difficult to determine 
whether expectancy actually contributes to post-chemotherapy nausea or whether the 
two are simply correlated.  
 
 In the only study that avoided all of the above limitations (Roscoe et al., 2004) 
the results were equivocal. Here, patients’ retrospective ratings of their expectancies 
before speaking to their oncologist significantly predicted the occurrence of severe 
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nausea in the 5 days following their first infusion, but not average nausea. Further, 
despite measuring susceptibility to motion sickness, which has been shown to relate to 
post-chemotherapy nausea (Jacobsen et al., 1988; Morrow, 1985; Roscoe et al., 2000), 
the authors did not control for this potentially confounding variable.  
   
The current analysis aimed to overcome these limitations in order to determine 
whether expectancy contributes to post-chemotherapy nausea and, thereby, provide 
evidence for placebo-induced side effects. To do this, I used hierarchical regression to 
evaluate whether first time chemotherapy patients’ pretreatment expectancies were 
significantly associated with their posttreatment nausea, over and above other possible 
factors, such as age, gender, diagnosis, susceptibility to motion sickness, and 
pretreatment quality of life (QoL). Importantly, the large sample size meant that the 
study was well powered to detect even small effects. Further, there was a large sub-
sample of previously pregnant women, which enabled me to assess whether including 
nausea during pregnancy as a covariate influenced the relationship between 
expectancy and post-chemotherapy nausea.  
 
 An interesting possibility not addressed in previous studies is that the 
relationship between expectancy and post-chemotherapy nausea may be non-linear. If 
it is not linear, then a certain level of expectancy may be required to produce an 
effect. For instance, patients with particularly high levels of expectancy might 
experience more nausea than those with moderate and low levels of expectancy with 
little difference between the lower levels themselves. Conversely, having very low 
expectancies for nausea might have a protective effect and result in less nausea 
compared with those who have moderate or high levels of expectancy with little 
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difference between the higher levels. This possibility was addressed by categorising 
patients into groups according to their level of expectancy and investigating whether a 
particular level of expectancy either heightened or protected against post-
chemotherapy nausea.  
 
 Predictors of patients’ expectancies for nausea were also examined in order to 
determine whether a history of nausea in other areas is associated with expectancies 
for post-chemotherapy nausea. In the only previous study addressing this, 
Montgomery and Bovbjerg (2003) found that patients’ lifetime history of nausea, 
including susceptibility to motion sickness and nausea during pregnancy, were 
unrelated to their expectancies for post-chemotherapy nausea. However, this analysis 
was based on only 31 patients. Finally, the inclusion of a measure of quality of life 
allowed me to assess the relationship between post-chemotherapy nausea and quality 
of life. Nausea is often rated as one of the most severe and debilitating side effects of 
chemotherapy (Carelle et al., 2002; Griffin et al., 1996; Klastersky, Schimpff, & 
Senn, 1999) and has been shown to reduce quality of life (Ballatori & Roila, 2003; 
Ballatori et al., 2007; Cohen et al., 2007; Lindley, Hirsch, O'Neill, Transau, & et al., 
1992; Osoba et al., 1997). However, no study to date has simultaneously investigated 
expectancies, post-chemotherapy nausea, and quality of life in cancer patients.  
 
7.2 Methods 
7.2.1 Participants 
Participants were first time chemotherapy patients taking part in a multicentre 
trial comparing antiemetic regimens for the treatment of delayed nausea. They were 
enrolled from 18 private practice oncology groups in the USA between June 12, 
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2001 and June 11, 2004. Eligible patients were 18 years or older with any cancer 
diagnosis, regardless of stage, and were about to receive their first chemotherapy 
treatment containing doxorubicin and antiemetic prophylaxis with a 5-HT-receptor 
antagonist, ondansetron, granisetron, or dolasetron plus dexamethasone or the 
equivalent dose of intravenous methylprednisolone on the day of treatment.   
 
7.2.2 Design 
 This study examined the relationship between expectancies and post-
chemotherapy nausea in a trial comparing antiemetic regimens for the treatment of 
delayed nausea. First time chemotherapy patients completed a questionnaire about 
their expectancies for nausea before their first infusion and then recorded their 
nausea over four consecutive days following their treatment. As part of the trial, 
patients were randomised to one of three antiemetic regimens for the second and 
third days following their first chemotherapy infusion: Arm 1-prochlorperazine 10mg 
p.o. every 8 hours, Arm 2-any first generation 5-HT3 RA using standard dosage, or 
Arm 3-prochlorperazine 10 mg p.o. as needed. However, only minimal differences 
were observed among study arms (see Hickok et al., 2005 for additional details) and 
this variable was controlled for as appropriate in the following analysis.  
 
7.2.3 Measures 
On-study Interview: During an interview conducted at the time of recruitment 
patients were asked to provide information regarding demographics, diagnosis, 
previous cancer-related treatment, and their history of nausea. The two questions 
concerning history of nausea asked whether the patients were susceptible to motion 
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sickness and whether they experienced nausea during pregnancy. The latter question 
was scored as ‘Not applicable’ if the participant was male or had never been pregnant.  
 
Expectancy Questionnaire: This questionnaire has previously been used by 
Roscoe et al. (2003) and contained questions assessing patient expectancies for 
posttreatment nausea, vomiting, fatigue, and hair loss. Four of these questions 
assessed expectancies for nausea. One required the patients to rate the likelihood that 
they would experience nausea after their chemotherapy treatment on a 5-point scale 
ranging from 1 (“I am certain I will not have this”) to 5 (“I am certain I will have 
this”). A second question required the patients to rate the expected severity of their 
post-chemotherapy nausea as “very mild or none at all”, “mild”, “moderate”, 
“severe”, “very severe”, or “intolerable”. A third question asked the patients to rate 
their perceived susceptibility to nausea compared with their friends and family as 
either “more”, “less”, or “the same”. A final question required patients to rate the 
likelihood of experiencing chemotherapy-related nausea compared with other cancer 
patients with the same diagnosis and undergoing the same treatment, again as “more”, 
“less”, or “the same”. These four expectancy questions were then combined by 
averaging z-scores to produce a single expectancy measure.  
 
Functional Assessment of Cancer Therapy Scale-General (FACT-G; version 
4): This measure was used to assess patients’ quality of life. It contains 27-items 
assessing wellbeing across four domains: physical, functional, social/family, and 
emotional. The scores for each item are summed to produce an overall measure of 
global quality of life. The FACT-G is a widely used and well validated measure for 
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assessing quality of life in cancer patients undergoing chemotherapy treatment (Cella 
et al., 1993).  
 
Post-chemotherapy Nausea: was assessed via a 4-day patient diary developed 
by Burish et al. (1987) and Carey and Burish (1988) specifically for this purpose. The 
diary required the patients to rate the severity of their nausea on a 7-point scale 
ranging from 1 (“not at all nauseated”) to 7 (“extremely nauseated”) for the morning, 
afternoon, evening, and night separately for each day. The diary was then used to 
calculate average nausea over the four days posttreatment as well as peak nausea, the 
highest severity rating for nausea at any time in the four days following treatment.  
 
7.3.4 Procedure 
For a full description of the procedures see Hickok et al. (2005). Briefly, after 
informed consent was gained, patients completed the on-study interview, the FACT-
G, and the expectancy questionnaire. Patients then received their first chemotherapy 
infusion. Immediately following this they were given the 4-day diary to record their 
nausea. At the end of the fourth day the patients returned this diary and were given the 
FACT-G to complete for a second time. The study was approved by the institutional 
review board of the University of Rochester and every participating site approved the 
protocol in accordance with an assurance filed with and approved by the US 
Department of Health and Human Services.  
 
7.3.5 Statistical Analyses 
Two hierarchical regressions were used to determine the predictors of post-
chemotherapy average and peak nausea in all patients. Age, gender, and susceptibility 
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to motion sickness comprised the first step, then diagnosis, followed by study arm, 
then pretreatment QoL, and finally expectancy. Diagnosis was dummy coded using 
breast cancer as the reference group and combining myeloma, endometrial, sarcoma, 
and bladder cancer patients into a single group because of their low numbers (see 
below). Nausea during pregnancy could not be included in this analysis because this 
question was only valid for previously pregnant women. In order to test whether this 
variable influenced the relationship between expectancy and nausea, the above 
analysis was repeated with the sub-sample of women who had been pregnant. Gender 
was excluded from this analysis as only women were involved. To assess the impact 
of level of expectancy on nausea four approximately equal groups were created using 
quartiles based on the combined expectancy measure. The groups were classified as 
not expectant (0-25th percentile), slightly expectant (26-50th percentile), somewhat 
expectant (50-75th percentile), and highly expectant (76-100th percentile). ANCOVA 
was then used to compare these groups with follow-up pairwise comparisons using 
Fisher’s LSD procedure.  
 
A simultaneous regression was used to assess predictors of expectancy. This 
included age, gender, diagnosis, pretreatment quality of life, and susceptibility to 
motions sickness as possible predictors. As above, both of these analyses were 
repeated for the sub-sample of the previously pregnant women so as to determine 
whether the inclusion of nausea during pregnancy influenced the results. Finally, a 
hierarchical regression used to assess the impact of average and peak post-
chemotherapy nausea on quality of life. Here, age and gender were entered as the first 
step, followed by diagnosis and study arm, then pretreatment quality of life, and then 
average and peak nausea in the final step.  All statistical analyses were conducted 
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using SPSS software (version 15; SPSS Inc, Chicago, Ill) and results were considered 
significant when p<.05.  
7.3 Results 
7.3.1 Sample Characteristics  
Six hundred and ninety-one patients enrolled in the study, of whom 671 
provided evaluable data. Participants had an average age of 53 (range 25-90). The 
majority were female (94%), white (88%), and had received some college education 
(59%). Ninety percent had breast cancer, 9% had lymphoma, and the remaining 1% 
was a mix of myeloma, endometrial, sarcoma, and bladder cancer patients.  
 
7.3.2 Overview of Nausea 
Five hundred and sixty-two (84%) patients reported at least some nausea in the 
four days following treatment and 165 (25%) reported severe nausea (rating of 6 or 7 
on the 7-point scale). Overall, average nausea over the four days following 
chemotherapy was 2.2 (SD=1.2) and the mean peak nausea was 4.0 (SD=2.1). Before 
their first chemotherapy treatment patients had a mean quality of life of 86.3 
(SD=13.0), which decreased to 76.3 (SD=15.8) after the treatment. 
 
7.3.3 Expectancy and Nausea 
Table 7.1 shows the final step in the hierarchical regressions for average and 
peak nausea with all patients included. For average nausea, the overall model with 
age, gender, diagnosis, susceptibility to motion sickness, pretreatment quality of life, 
and expectancy included was significant and accounted for 16.7% of the variance, 
R2=.17, F(8,653)=14.6, p<.001. Expectancy had a significant impact on average 
nausea. Specifically, an increase of one standard deviation on the expectancy measure 
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was associated with a .27 increase in average nausea after controlling for all other 
variables in the model, b=.27, t(653)=4.44, p<.001. This meant that expectancy  
Table 7.1. Final step in the hierarchical regression of predictors of post-
chemotherapy nausea for all participants. †Dummy coded with breast cancer as the 
reference group. ††
 
Dummy coded with Study Arm 1 as the reference group 
*Significant at p<.05, **Significant at p<.01,***Significant at p<.001. 
A) Average Nausea b   SE  β   Sig. 
Age***   -.029 .004 -.273  <.001 
Gender   -.019 .252 -.004 .94 
Motion Sickness .033 .095 .013 .73 
Lymphoma†* -.478 .201 -.117 .02 
Other Diagnosis† .571 .637 .032 .37 
Study Arm 2†† .161 .003 .064 .12 
Study Arm 3†† .046 .104 .018 .66 
Pretreatment QoL* -.008 .103 -.086 .03 
Expectancy*** .271 .061 .176 <.001 
B) Peak Nausea b SE β Sig. 
Age***   -.050 .007 -.262 <.001 
Gender   -.280 .459 -.030 .54 
Motion Sickness .100 .173  .022 .57 
Lymphoma†** -.950 .366 -.129 .01 
Other Diagnosis† .782 1.16 .025 .50 
Study Arm 2†† .173 .006 .038 .36 
Study Arm 3†† .236 .189 .052 .21 
Pretreatment QoL* -.013 .189 -.076 .048 
Expectancy*** .431 .111 .155 <.001 
 
uniquely accounted for 2.5% of the variance in average nausea. Age, pretreatment 
quality of life, and having lymphoma were also significant predictors. Specifically, an 
increase in age of 10yrs corresponded to a decrease of 0.3 points on average nausea, 
b=-.03, t(653)=7.32, p<.001. A 10-point increase in pretreatment quality of life 
corresponded to a .1 decrease in average nausea, b=-.008, t(653)=2.25, p=.03. 
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Lymphoma patients reported average nausea that was .48 points lower than breast 
cancer patients, b=-.478, t(653)=2.38, p=.02.  
 
When this analysis was repeated in the sub-sample of women who had been 
pregnant, expectancy remained a significant predictor, although it uniquely accounted 
for slightly less variance in average nausea, R2 change=.019, b=.25, t(537)=3.65, 
p<.001. Nausea during pregnancy itself was significant, with those having 
experienced nausea during pregnancy reporting average nausea as .33 points higher 
than those who did not experience nausea during pregnancy, b=.33, t(537)=3.35, 
p=.001. The one difference in this analysis was that pretreatment quality of life was 
no longer significantly associated with average nausea, t(537)=1.51, p>.05. 
 
For peak nausea, the overall model was also significant and accounted for 
14.8% of the variance F(8,653)=12.6, p<.001. Expectancy was again significant after 
controlling for all other variables. Here, an increase of one standard deviation on the 
expectancy measure corresponded to a .43 increase in peak nausea, b=-.43, 
t(653)=3.87, p<.001. In this instance, expectancy uniquely accounted for 2.0% of the 
variance in peak nausea. As with average nausea, age, pretreatment quality of life, and 
having lymphoma were also significant predictors. A 10yr increase in age was 
associated with a .50 decrease in peak nausea, b=-.05, t(653)=6.95, p<.001. A 10-
point increase in pretreatment quality of life corresponded to a .13 decrease in peak 
nausea, b=-.013, t(653)=1.98, p<.048. Lymphoma patients reported .95 points less 
peak nausea than breast cancer patients, b=-.95, t(653)=2.60, p=.01.  
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As above, when this analysis was repeated on the sub-sample of previously 
pregnant women, expectancy remained a significant predictor and uniquely accounted 
for slightly less variance in peak nausea than when nausea during pregnancy was not 
included, R2 change=.018, b=.42, t(537)=3.41, p=.001. Nausea during pregnancy was 
also significant. Women who experienced nausea during pregnancy had peak nausea 
.41 points higher than those not experiencing nausea during pregnancy, b=.41, 
t(537)=2.28, p=.02. Again, pretreatment quality of life failed to reach significance in 
this analysis, t(537)=1.18, p>.05. 
 
7.3.4 Level of Expectancy and Nausea 
Figure 7.1A shows average nausea across the different levels of expectancy. 
The ANCOVA, with age, gender, susceptibility to motion sickness, diagnosis, 
pretreatment quality of life, and study group as covariates, revealed that average 
nausea differed significantly as a function of level of expectancy, F(3,653)=8.9, 
p<.001. Pairwise comparisons using Fisher’s LSD revealed that, highly expectant 
patients reported significantly higher levels of average nausea than all other levels of 
expectancy. Specifically, highly expectant patients reported average nausea as .59 
points higher than not expectant patients, t(653)=4.51p<.001, .58 points higher than 
slightly expectant patients, t(653)=4.54,  p<.001, and .47 points higher than somewhat 
expectant patients, t(653)=3.78, p<..001. There were no significant differences in 
average nausea between somewhat expectant, slightly expectant, and not expectant 
patients, highest t(653)=1.02, p=.31. The pattern of results was identical when the 
analysis when nausea during pregnancy was controlled for in the sub-sample of 
previously pregnant women.  
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Figure 7.1. Covariate adjusted mean (+SE) average (A) and peak (B) nausea by level 
of expectancy for all participants. Highly expectant individuals reported both more 
average nausea and higher peak nausea than all other expectancy levels, **p<.01, 
***p<.001. No other differences were significant. 
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Figure 7.1B shows peak nausea for each level of expectancy. As with average 
nausea, the ANCOVA revealed significant differences in peak nausea across the 
different levels of expectancy after controlling for age, gender, motion sickness, study 
arm, diagnosis, and pretreatment quality of life, F(3,653)=6.93, p<.001. Highly 
expectant patients reported peak nausea .94 points higher than not expectant patients, 
t(653)=3.94, p<.001, .96 points higher than slightly expectant patients, t(653)=4.13, 
p<.001, and .65 higher than somewhat expectant patients, t(653)=2.90, p=.004. Again 
there were no differences between somewhat expectant, slightly expectant, and not 
expectant patients in terms of peak nausea, highest t(653)=1.41, p=.16. Also as with 
average nausea, this pattern of results was identical in the sub-sample of previously 
pregnant women. 
 
7.3.5 Predictors of Expectancy 
 Table 7.2 displays the simultaneous regression predicting expectancies for 
nausea based on all participants. The overall model including age, gender, motion 
sickness, diagnosis, and pretreatment quality of life was significant and accounted for 
18.6% of the variance in expectancy, F(6,656)=24.9, p<.001. The only two significant 
predictors were susceptibility to motion sickness and pretreatment quality of life. 
Controlling for all other variables, patients who reported being susceptible to nausea 
were, on average, .45 standard deviations higher on the expectancy measure than 
patients who reported not being susceptible to motion sickness, b=.45, t(656)=7.75, 
p<.001. An increase of 10 points in pretreatment quality of life predicted a decrease 
of .17 standard deviations on the expectancy measure, b=.17, t(656)=7.75, p<.001. 
This pattern did not change when the analysis was repeated for women who had been 
pregnant. However, nausea during pregnancy was also a significant predictor of 
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expectancy, such that women who had experienced nausea during pregnancy had 
expectancies for nausea that were .32 standard deviations higher, on average, than 
women who did not experience nausea during pregnancy, b=.32, t(540)=5.12, p<.001. 
 
Table 7.2. Simultaneous regression of predictors of expectancy for nausea. †
 
Dummy 
coded with breast cancer as the reference group. ***Significant at p<.001. 
Predictors b   SE  β   Sig. 
Age -.004 .003 -.060 .10 
Gender .239 .161 .072 .14 
Motion Sickness*** .451 .058 .276 <.001 
Lymphoma† .195 .128 .074 .13 
Other Diagnosis† .570 .407 .050 .16 
Pretreatment QoL*** -.017 .002 -.279 <.001 
 
 
7.3.6 Nausea and Quality of Life 
The overall model, with age, gender, pretreatment quality of life, average 
nausea, and peak nausea included was significant and accounted for 55% of the 
variability in post-chemotherapy quality of life, R2=.55, F(8,657)=89.4, p<.001. 
Average nausea, peak nausea, and pretreatment quality of life were all significant 
predictors of posttreatment quality of life. This means that, even after controlling for 
age, gender, diagnosis, pretreatment quality of life, study group, and peak nausea, a 1-
point increase in average nausea corresponded to a 5.2 point decrease in post-
chemotherapy quality of life, b=-5.1, t(656)=8.4, p<.001. Similarly, a 1-point increase 
in peak nausea was associated with a .76 decrease in post-chemotherapy quality of 
life, b=-.76, t(656)=2.22, p=.03. A 1-point increase in pretreatment quality of life 
predicted a .58 increase in posttreatment quality of life, b=.58, t(656)=17.6, p<.001. 
Together, average and peak nausea uniquely accounted for 19.4% of the variability in 
post-chemotherapy quality of life, R2 change=.19, F(2,656)=142, p<.001. Comparing 
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the standardised regression coefficients for average and peak nausea it was clear that 
average nausea had a much larger effect on post-chemotherapy nausea, β= -.389 and 
β=-.102 respectively.  
  
7.4 Discussion 
In this study, stronger pretreatment expectancies for nausea were significantly 
associated with higher average and peak nausea posttreatment. Importantly, this result 
was obtained after controlling for age, gender, susceptibility to motion sickness, and 
pretreatment quality of life in all patients and was maintained in the sub-sample in 
whom nausea during pregnancy could be included as a covariate. As such, these 
results show an independent contribution of expectancy to post-chemotherapy nausea 
and, thereby, provide strong support for expectancy as a causal factor in 
chemotherapy-related nausea. Although the current findings are consistent with 
previous studies that have found a relationship between expectancy and post-
chemotherapy nausea (Haut et al., 1991; Jacobsen et al., 1988; Montgomery & 
Bovbjerg, 2000; Olver et al., 2005; Rhodes et al., 1995; Roscoe et al., 2004; Roscoe et 
al., 2000; Shelke et al., 2008), such studies have generally failed to adequately control 
for other potentially confounding variables and/or have used statistical techniques 
likely to overestimate the strength of this relationship. Thus, the current study 
provides the most convincing evidence to date that expectancies contribute to post-
chemotherapy nausea.  
 
A novel and interesting finding was that patients classified as highly expectant 
of nausea experienced higher levels of both average and peak nausea than all other 
levels of expectancy and that none of the other levels, somewhat expectant, slightly 
expectant, and not expectant, differed significantly from one another. This suggests 
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that patients who are highly expectant of experiencing nausea are particularly at risk 
of actually experiencing nausea after their chemotherapy treatment, whereas those 
with lower levels of expectancy share a similar decreased risk. This result was also 
found after controlling for age, gender, susceptibility to motion sickness, and quality 
of life, and again points to a causal influence of expectancy on post-chemotherapy 
nausea. 
   
 Another interesting finding was that susceptibility to motion sickness and 
nausea during pregnancy predicted expectancies for nausea. Although this is perhaps 
intuitive, it contradicts Montgomery and Bovbjerg’s (2003) finding that history of 
nausea was unrelated to expectancies for post-chemotherapy nausea. However, their 
analysis only involved a small sample for such an analysis, i.e. 31 patients, which may 
explain why they failed to find this effect. The current findings, therefore, suggest that 
patients’ experiences with nausea in other areas are likely to contribute to the nausea 
they expect to experience in response to chemotherapy. In addition to this, lower 
quality of life before treatment was associated with stronger expectancies for nausea. 
Here, the direction of causality is uncertain. It is possible that having strong 
expectancies for nausea following chemotherapy could detract from quality of life 
before treatment by creating apprehension and stress regarding the treatment. 
Conversely, it could be that those with lower quality of life before treatment are in a 
poorer state of health and therefore expect to be affected more by the chemotherapy 
treatment. 
 
Increases in average nausea resulted in poorer quality of life posttreatment, a 
result consistent with previous research (Ballatori & Roila, 2003; Ballatori et al., 
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2007; Cohen et al., 2007; Lindley et al., 1992; Osoba et al., 1997). Here, a 1-point 
increase in average nausea corresponded to a 5-point decrease in quality of life. Peak 
nausea also had a significant impact on quality of life after controlling for average 
nausea, although this effect was much smaller. This suggests that the continued 
presence of nausea has a more debilitating impact on chemotherapy patients’ quality 
of life compared with a bout of severe nausea. Average nausea and peak nausea 
independently of other variables accounted for 19.4% of the variability in post-
chemotherapy QoL, a very large effect. Clearly, not only does nausea remain 
prevalent, it also continues to be a significant burden to cancer patients’ quality of 
life.  
 
Given the current findings, patient expectancies reflect a possible point of 
intervention to reduce chemotherapy-induced nausea, as well as to improve cancer 
patients’ quality of life. A variety of studies in areas other than oncology have already 
shown that expectancy manipulations can have a beneficial impact on health 
outcomes. Perhaps most relevant is evidence that enhancing positive expectancies can 
decrease postoperative nausea in patients undergoing major gynaecological surgery 
(Williams et al., 1994) and protect against seasickness in naval cadets (Eden & Zuk, 
1995). However, these types of manipulations may be more difficult to implement for 
cancer patients. First, it would be unethical to provide patients with unrealistically low 
expectancies regarding the likelihood of experiencing nausea as a result of their 
chemotherapy. Second, in addition to what cancer patients are told to expect from 
their treating health professionals, they will also draw on information from their 
family, friends, and the media. As such, any successful expectancy manipulation 
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would have to consider the source of the patient’s expectancies and the significance 
attributed to that source before attempting to adjust any maladaptive expectancies. 
 
The finding that highly expectant patients experience more nausea than not 
expectant, slightly expectant, and somewhat expectant patients, and that these latter 
three did not differ significantly from each other may provide one answer. It suggests 
that completely eradicating expectancies for nausea is not necessary to gain a 
significant clinical improvement. For example, if a patient was initially highly 
expectant, but through discussion or some other manipulation became somewhat 
expectant, a significant decrease in both average nausea and peak nausea would be 
expected with a corresponding improvement in quality of life. Further reducing these 
expectancies to the level of slightly expectant, however, would produce only minimal 
additional benefit. Thus, a successful intervention might focus on patients who are 
highly expectant of experiencing nausea with the aim of reducing these maladaptive 
expectancies rather than removing all expectancy. In doing so, the patient would 
remain aware that there is a possibility of experiencing nausea, thereby avoiding any 
ethical concerns regarding giving patient’s unrealistically low expectations of 
experiencing nausea. Further, a small reduction in expectancy is likely to be much 
easier to achieve than convincing a highly expectant patient that he/she is very 
unlikely to experience nausea following chemotherapy.    
 
One possibility along these lines is to include a discussion of the patient’s 
expectancies regarding side effects as part of the chemotherapy education. This would 
allow for the identification of highly expectant patients and provide an excellent 
opportunity to discuss and challenge these potentially maladaptive expectancies. 
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Given the relationship between expectancy and pretreatment quality of life, reducing 
strong expectancies for nausea during chemotherapy education may also improve 
patients’ pretreatment quality of life. To the best of my knowledge, patient 
expectancies are rarely, if ever, addressed in chemotherapy education. 
 
These findings also have more general implications to do with placebo-
induced side effects. Firstly, the present findings suggesting that higher expectancies 
for nausea actually contribute to post-chemotherapy nausea supports the possibility of 
placebo-induced side effects. To date, evidence of such effects has been limited, as 
reviewed in Chapter 5. Secondly, the fact that this effect was relatively small, with 
expectancy only uniquely accounting for about 2% of the variance in post-
chemotherapy nausea, suggests that placebo-induced side effects could be relatively 
weak effects. This being the case, detecting placebo-induced side effects in this and 
other areas will likely require large sample size and this may partially explain the 
failure to find significant placebo-induced side effects in the previous study (see 
Chapter 6). Together with evidence of positive placebo effects, this supports the 
possibility raised in the previous chapter that providing informed consent or patient 
education is likely to lead to more benefit via the placebo effect than harm. However, 
some caution is required here as it did seem clear in the current study that strong 
expectancies for side effects can increase their likelihood in at least some patients. 
Thus, clinicians should remain mindful of how they present information about side 
effects to patients, as well as considering the extent to which patients already expect 
these side effects.  
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It is worth noting that, although susceptibility to motion sickness and nausea 
during pregnancy were included in the analysis, it is possible that the patients had 
other previous experiences of nausea, such as, medication-induced nausea. These 
other experiences of nausea may have affected patients’ expectancies for and/or actual 
experience of post-chemotherapy nausea, whether as a result of a general increased 
susceptibility to nausea or classical conditioning. If this were the case, then 
expectancy may simply have acted as a marker for other experiences with nausea 
rather than having a direct causal impact on post-chemotherapy nausea. However, the 
fact that expectancy was significantly associated with post-chemotherapy nausea after 
controlling for nausea during pregnancy, even though this predicted expectancy and 
both average and peak nausea itself, might suggest that this possibility is unlikely.  A 
second potential limitation to the current findings is that nausea was assessed via self 
report. Although the diary used here has been used widely in this area (e.g. Burish et 
al., 1987; Carey & Burish, 1988; Roscoe et al., 2004; Shelke et al., 2008), it remains 
possible that this introduced some bias in patients’ reports of their nausea. As 
discussed in Chapter 5, this is a difficult problem to overcome when assessing 
placebo-induced side effects because many side effects are inherently subjective in 
nature. A third possible limitation is that the current study did not control for 
psychological factors, such as anxiety and emotional distress.  
 
Overall, the current findings provide strong evidence that expectancy 
contributes to the development of post-chemotherapy nausea, which, in addition to 
being inherently unpleasant, also detracts from patients’ quality of life. Given that 
highly expectant patients appear at particular risk of experiencing post-chemotherapy 
nausea, an effective preventive strategy might be to target these patients. Including a 
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discussion of expectancies for nausea during chemotherapy education reflects a 
possibility that would have the added benefit of allowing direct exploration of the 
sources of these expectancies.  
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Chapter 8 – General Discussion 
 
8.1 Summary 
 The current project assessed the placebo effect in double-blind RCTs and its 
contribution to treatment side effects, both of which have received relatively little 
research attention to date. The first study (Chapter 3) involved reanalysing a double-
blind RCT of naltrexone and acamprosate for alcohol dependence and demonstrated 
that perceived treatment is a strong predictor of treatment outcomes in these types of 
trials. The role of perceived treatment in double-blind RCTs was explored further in 
Study 2 (Chapter 4) by developing an experimental model to test these effects. This 
involved two dummy (placebo) double-blind RCTs for cognitive performance. In 
these experiments, the bogus feedback given to participants about their performance 
heavily affected their perceived treatment, which in turn influenced their actual 
performance.  
 
 The two remaining studies investigated whether the placebo effect contributes 
to treatment side effects, labelled placebo-induced side effects. In the first of these 
(Chapter 6) a series of dummy trials for sleep difficulty were conducted, which 
involved manipulating the information participants received about potential, but 
bogus, side effects. Despite robust evidence for a placebo effect for sleep difficulty, 
these experiments produced minimal evidence for placebo-induced side effects. This 
raised the possibility that the placebo-induced side effects may exist, but that they are 
only small effects. The final study (Chapter 7) appeared to confirm this by showing 
that pretreatment expectancies for nausea predicted average and peak post-
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chemotherapy nausea in a large sample of first time chemotherapy patients. The main 
implications of these findings are discussed below.  
 
8.1.1 Perceived treatment in double-blind RCTs 
 The studies on perceived treatment in double-blind RCTs indicate a possible 
interplay between perceived treatment and observable outcomes. The development 
and application of an experimental model, in particular, demonstrated that perceived 
treatment can influence actual treatment outcomes via the placebo effect. If blinding 
fails, in that participants can guess their treatment allocation at rates better than 
chance, then the trial cannot validly determine whether the active treatment or the 
placebo effect led to any observed differences between study arms. Despite increasing 
acknowledgement of this problem (e.g. Benedetti, 2005; Benedetti, 2007; Day & 
Altman, 2000; Price, Finniss, & Benedetti, 2008), many researchers conducting 
double-blind RCTs fail to either test or report whether blinding was maintained 
(Fergusson et al., 2004; Hróbjartsson et al., 2007; Karanicolas et al., 2008). This 
means that the validity of these trials cannot be determined.  
 
 It is perhaps worth re-emphasising here that the aim of blinding is to evenly 
distribute expectancies across treatment groups and that this process is identical to 
randomising participants to study arms in an attempt to evenly distribute potentially 
confounding characteristics, such as, age, gender, and baseline severity of the 
condition. Seen in this light, the low rates of assessing blinding are highly peculiar, 
given that researchers almost always describe, compare, and control for differences in 
baseline characteristics across study arms that may influence treatment outcomes. 
Clearly researchers conducting double-blind RCTs should measure, assess, and 
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control for perceived treatment with the same consistency that they do for other 
potentially confounding patient characteristics. This would improve their ability to 
assess the validity of the trial’s outcome.   
 
8.1.2 Information about treatment and its side effects 
 The experimental studies on placebo-induced side effects revealed that 
informing participants about side effects had little impact on their subsequent reports 
of adverse effects. This was despite a substantial proportion (around 30%) of 
participants who received placebo treatment freely reporting at least one side effect. 
The warning itself only had an effect on adverse effects in the third experiment, 
where, rather unexpectedly, both the treatment and no treatment groups reported 
changes in appetite that were consistent with the warning they had received. There 
was, however, a clear placebo effect for sleep difficulty, evidenced by the treatment 
group’s consistent reduced global sleep difficulty and increased total sleep time. This 
suggests that patients who are provided with information about the goal of a treatment 
and are warned about its possible side effects are likely to experience more benefit 
from this information than harm, via the placebo effect. If so, then the process of 
informed consent should add to the efficacy of a treatment while producing minimal 
placebo-induced side effects, as long as it contains information about the goal of the 
treatment. Nonetheless, the study involving first time chemotherapy patients provided 
evidence that expectancies for side effects can increase both their average and peak 
severity and that these adverse symptoms detracted from the patients’ quality of life. 
Thus, clinicians should be mindful of how information about side effects is presented 
and whether their patients enter treatment with strong or inaccurate preconceptions 
about its likely outcomes.   
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8.1.3 Importance of controlling for natural history 
 The studies assessing placebo-induced side effects in sleep difficulty also 
highlighted the importance of controlling for natural history when examining the 
placebo effect. In these studies, participants allocated to a no treatment control group 
reported reduced global sleep difficulty and shorter sleep latency. Many researchers 
have stressed the importance of controlling for natural history (e.g. Benedetti, 2009; 
Colloca & Benedetti, 2005; Kienle & Kiene, 1997; Kirsch & Sapirstein, 1998; Miller 
& Rosenstein, 2006; Price et al., 2008). While the vast majority of recent 
experimental studies do so, many non-experimental studies do not. This is particularly 
so for meta-analyses of changes in placebo groups in double-blind RCTs (e.g. 
Bittencourt et al., 2008; Fulda & Wetter, 2008; Macedo, Banos, & Farre, 2008; 
McCall et al., 2003). These studies typically involve calculating pooled effect sizes 
for improvement in patients receiving placebo from baseline to one or more follow-
ups and erroneously claim that this reflects the placebo effect. However, it is clear 
from the three experiments on sleep difficulty that some participants receiving no 
treatment will report improvement and that an appropriate no treatment control group 
is required to differentiate changes that result from the placebo effect from those that 
result from the natural history of the condition.  
 
8.1.4 Level of expectancy and the placebo effect  
 The finding that first time chemotherapy patients with a high level of 
expectancy (top quartile) for post-chemotherapy nausea experienced more nausea 
than those with all other levels of expectancy, but that there were no differences in 
nausea between the lower levels was very interesting. If this difference is attributable 
to expectancy, then it suggests that the magnitude of the placebo effect may not 
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necessarily increase linearly with the strength of the expectancy. Instead, it might be 
the case that a certain level of expectancy is required to produce a placebo effect. If 
so, this has important implications for developing interventions aimed at either 
enhancing beneficial placebo effects or reducing adverse placebo effects. In the 
former case, any expectancy manipulation may have to be powerful enough to create 
sufficiently strong expectancies to cause a placebo effect. This could present a 
significant challenge to these types of interventions. On the other hand, reducing 
adverse placebo effects might require only a small reduction in expectancies, from 
high to moderate, which is likely to be much more attainable than completely 
eradicating expectancies for adverse outcomes. As a result, interventions aimed at 
reducing adverse placebo effects might be more successful than those aimed at 
enhancing beneficial placebo effects.  
 
8.2 Limitations 
 Specific limitations do to with each study have been discussed in the relevant 
chapters. However, there are two broader limitations that apply to these studies and to 
research on the placebo effect more generally. The first concerns the extent to which 
conveying uncertainty might undermine the placebo effect and the problems with 
conveying certainty, namely ethicality and credibility. The second concerns the 
relative advantages and disadvantages of measuring versus manipulating expectancies 
when attempting to evaluate the placebo effect and how best to measure expectancy.  
 
8.2.1 Uncertainty and the placebo effect 
In order for an informational intervention to produce a placebo effect it must 
elicit sufficiently strong expectancies for that effect. Conveying uncertainty may 
undermine this. Thomas (1987) found that general practice patients who were given 
 174 
placebo treatment and told that it was a medication certain to improve their symptoms 
reported significantly better outcomes than patients given the same placebo treatment 
but told that it was a medication that may or may not help them. This suggests that the 
magnitude of the placebo effect is sensitive to likelihood which is expressed about the 
efficacy of the treatment.  
 
The side effect warning in the current experiments involving sleep difficulty 
suggested that participants may experience mild adverse symptoms. This uncertainty 
may have reduced the extent to which this information induced expectancies about 
these adverse effects and, thereby, might have undermined the placebo effect and 
could explain why they failed to produce any firm evidence for placebo-induced side 
effects. If so, then warnings about side effects that suggested a higher probability and 
of adverse effects may have led to stronger expectancies for these adverse effects and, 
therefore, increased likelihood of placebo-induced side effects.  
 
However, there are questions regarding the credibility and ethicality of 
providing patients with information stating that a treatment is certain to be effective. 
Patients are likely to appraise the information they are provided with and whether it is 
consistent with their prior experience and any other information they have received. 
As such, a large proportion of patients are unlikely to find information declaring a 
treatment to work with absolute certainty credible. More importantly, although it may 
be acceptable in studies on healthy participants, providing patients with false 
information about the efficacy of their treatment would be unethical, especially if it 
undermined their ability to provide informed consent. This means that informational 
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manipulations will almost always contain some level of uncertainty and this may 
inhibit their ability to produce strong placebo effects.  
 
8.2.2 Measuring versus manipulating expectancy 
The current project used two approaches to examine the placebo effect. In the 
two studies on clinical populations, expectancies were measured and then their 
relationship with treatment outcomes was assessed. In the two studies on healthy 
volunteers, expectancy was experimentally manipulated via the information provided 
to these participants. This difference in approaches is also reflected in the placebo 
literature with some measuring expectancies (e.g. Andrykowski & Gregg, 1992; 
Linde et al., 2007; Olver et al., 2005; Roscoe et al., 2004; So, 2002) and others 
attempting to manipulate them (e.g. Amanzio & Benedetti, 1999; Benedetti, Amanzio 
et al., 1999; Levine, Stern, & Koch, 2006; Wolf, 1950).  
 
Studies that involve manipulating expectancies are better able to determine 
whether the information has a causal impact on the placebo effect because of their 
experimental nature and might be considered superior for this reason. However, these 
studies rarely directly assess expectancies and, as such, are entirely reliant on the 
ability of the informational manipulation to influence expectancies. This leads to 
problems determining whether an unsuccessful informational manipulation failed 
because it did not induce expectancies or because there was no placebo effect, as 
occurred in the experimental studies on placebo-induced side effects. In the latter 
case, this would mean that the informational manipulation induced expectancies but 
that these expectancies did not affect outcomes. Studies that simply measure 
expectancies can directly assess the relationship between expectancy and outcomes, 
thereby overcoming problems to do with relying on informational manipulation 
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affecting expectancies. However, these types of studies might be considered a weaker 
source of evidence for the placebo effect because they are correlational in nature.  
 
A simple way to overcome this might be to include measures of expectancy in 
experiments with informational manipulations, which some studies have done (e.g. 
Fillmore & Vogel-Sprott, 1992; Kirsch & Weixel, 1988; Shelke et al., 2008). 
However, this is probably more complicated than it may seem. As mentioned in 
Chapter 6, questioning participants about expectancies during an experiment could 
influence their expectancies and/or make them question the true purpose of the study. 
Determining the best time to assess expectancies is also difficult. Measuring them 
immediately following the intervention and before the outcome is assessed will 
provide a prospective measure, but expectancies may change between these two time 
points especially if these are separated by a week or more. On the other hand 
assessing them immediately before or immediately after the outcomes are assessed 
could lead to priming that artificially inflates the strength of the relationship between 
expectancy and the outcome. In addition to this, no attempts have been made to 
determine the best method of measuring expectancies, with researchers often using 
Likert-type scales, but with different numbers of response options and different 
response categories (e.g. Fillmore & Vogel-Sprott, 1992; Jacobsen et al., 1988; Kirsch 
& Weixel, 1988; Roscoe et al., 2004), and at least one used 100mm visual analogue 
scales (Olver et al., 2005). This was no different in the current project with each study 
employing differing methods of assessing expectancies.  
 
8.3 Future Directions 
 The implications and limitations to the current project suggest a number of 
interesting and important directions for future research. In terms of expectancies in 
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double-blind RCTs the experimental model developed here could serve as a useful 
method of further exploring the relationship between perceived treatment and 
outcomes. Of interest would be whether the same results would be obtained if the 
observable change manipulated involved a side effect. Such a study could determine 
whether side effects do influence perceived treatment, beyond the established 
correlational evidence (see Shapiro & Shapiro, 1997b for a review). If so, then this 
would provide a strong argument for incorporating active placebos into double-blind 
RCTs and may influence ethical considerations regarding the benefits and costs of 
doing so.  
 
  The experimental study on placebo-induced side effects highlighted potential 
difficulties associated with employing informational manipulations. Future studies 
could investigate how the content of the information affects expectancies and the 
placebo effect. In fact it was my intention to use dummy trials for sleep difficulty to 
compare the magnitude of placebo-induced side effects when participants are 
provided with high (60%) versus low (30%) probabilities about side effects. 
Unfortunately the failure to detect clear placebo-induced side effects did not permit 
this. However, such a study could be conducted in an area where there is robust 
evidence for the placebo effect, such as pain. This would provide confirmation of 
Thomas’ (1987) finding regarding conveying uncertainty and might indicate how best 
to develop a successful informational manipulation. Of course, in doing so researchers 
should be mindful of the trade-off between conveying certainty and the associated 
problems to do with credibility and ethicality. 
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 The study on first time chemotherapy patients’ expectancies and actual 
experience of nausea suggested that interventions targeted at patients with particularly 
high expectancies for nausea might be most successful. As mentioned earlier, one 
such intervention might be to incorporate a discussion of expectancies into the 
chemotherapy education session that most patients undergo. During this education 
session any overly strong expectancies for nausea could be challenged.  
 
  The issues to do with measuring versus manipulating expectancies could also 
be addressed empirically. In order to determine the possible influence of questioning 
participants about their expectancies, an experimental study involving an 
informational manipulation could have one group that is asked to rate their 
expectancies and another that is not. A similar design could also be used to determine 
whether the timing of the expectancy assessment affects outcomes. One such study 
could involve four groups. The first group would be asked to report their expectancies 
immediately following the informational manipulation. The second group would be 
asked immediately before reporting their treatment outcomes. The third group could 
be asked after reporting their treatment outcomes. The fourth group could be asked at 
all of these time points, which would enable examination of the effects of repeatedly 
questioning participants about their expectancies. Finally, it would be highly useful to 
attempt to compare actual measures of assessing expectancies, for example Likert-
type scales versus visual analogue scales, and whether a single item is sufficient or 
whether multiple items should be incorporated.  
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8.4 Conclusions 
 The current findings provided firm evidence that the placebo effect influences 
treatment outcomes in double-blind RCTs and some evidence that expectancy can 
increase the occurrence and severity of treatment side effects. These findings 
highlight the importance of considering the possible influence of patient expectancies 
when delivering medical treatment. Specifically, researchers conducting double-blind 
RCTs should measure and, where necessary, control for participants’ perceived 
treatment in order to ensure that any differences between the active treatment and the 
placebo can be attributed to the active treatment alone. In terms of side effects, 
reducing any unrealistically high expectancies for adverse effects through discussion, 
or some other intervention, could reduce the burden that these effects have on 
patients, which could in turn improve compliance and treatment outcomes. 
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Appendix 2 – List of conference presentations based on work undertaken for the         
degree of Doctor of Philosophy 
 
 
Experimental Psychology Conference, Wollongong, April 2008 – “Perceived treatment 
allocation in double-blind randomised placebo-controlled trials” 
 
 
Sydney Postgraduate Psychology Conference, Sydney, October 2008 – “Perceived 
allocation and its effects in double-blind randomised placebo-controlled trials” 
 
 
Sydney Cancer Conference, Sydney, July 2008 – “Expectancy, post-chemotherapy 
nausea, and QoL”  
 
 
Sydney University Postgraduate Psychology Conference, Sydney, October 2006 – 
“Expectancy as a mediating factor in double-blind RCTs”  
[Awarded Best Presentation] 
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Appendix 3a – Information Sheet for Study 2, Experiment 1.     
 
Prof. R A Boakes 
School of Psychology 
The University of Sydney 
 
 
Caffeine Effects  
 
Information for Participants 
 
Introduction 
You are invited to take part in a research study investigating the temporary effects of caffeine on 
cognitive performance. Caffeine is the world’s most consumed drug and may serve as a relatively 
cheap and safe short term cognitive enhancer. In this study, we are interested in whether caffeine 
will improve your performance on a cognitive task that requires sustained attention. The study is a 
double-blind placebo controlled trial of caffeine, so you will be allocated to receive either caffeine 
(150mg) or a placebo pill, but you will not be told which one you have been given and the researcher 
will also not know your allocation. To assess the effects of caffeine versus placebo you will be asked 
to complete a series of cognitive tasks over the course of the session.   
 
This study is being conducted by: 
Prof. Robert Boakes (Chief Investigator), 
 University of Sydney 
Mr Ben Colagiuri, 
 University of Sydney 
 
Study Procedures 
If you agree to participate in this study, you will be asked to sign the Participant Consent Form. You 
will then be asked to undergo the following procedures: 
1) Give some personal details (e.g. age, sex) and fill out a questionnaire about your usual 
caffeine intake habits. 
2) Complete a computer based sustained attention task (3 x 5min). 
3) Complete a questionnaire involving questions about your experiences while you were 
performing the cognitive task. 
 
Precautions 
You should not take part in this study if  
1) you have diabetes 
2) have high blood pressure 
3) have a serious heart condition 
4) are currently taking medication (excluding the contraceptive pill) 
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Benefits 
You will be awarded one hour of credit for participating in this experiment which will contribute 
1.25% to the total 5% credit allocated to experiment participation for Psychology 1002.  
 
Remember 
Your participation in this study is entirely voluntary. You may withdraw at anytime without 
having to give a reason. Whatever your decision, please be assured that it will not have any 
repercussions.   
 
When you have read this information, Ben Colagiuri will discuss it with you further and answer any 
questions you may have.  If you would like to know more at any stage, please feel free to contact 
him on 0402 236 400, or by email at benc@psych.usyd.edu.au. This information sheet is for you to 
keep.  
 
 
Any person with concerns or complaints about the conduct of this or any other study can 
contact the secretary of the Human Ethics Committee, University of Sydney, on (02) 9351 
4811. 
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Appendix 3b - Beliefs Questionnaire for Study 2, Experiment 1.     
 
Professor R A Boakes 
School of Psychology 
The University of Sydney 
 
 
Caffeine Study 
 
Caffeine Effects Questionnaire 
 
 
1) Do you think that you were given the caffeine pill or the placebo pill?  
 
   CAFFEINE   PLACEBO 
 
 
2) On a scale from 0 – 10, how certain are you that this is the medication you are receiving? 
 
 
3) Are there any particular reasons why you believe this? 
 
 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
 
 
 
 
 
 
 
GO TO NEXT PAGE
NOT AT ALL 0 1 2 3 4 5 6 7 8 9 10  EXTREMELY CERTAIN 
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4) Do you remember your accuracy scores for the three tests? 
 
 
Baseline  _______________ 
 
 
Posttest 1 _______________ 
 
 
Posttest 2 _______________ 
 
 
 
 
5) Please list any caffeinated products that you have consumed so far today? 
 
 
 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
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Appendix 3c – Information Sheet for Study 2, Experiment 2. (Double-blind Group)  
 
Prof. R A Boakes 
School of Psychology 
The University of Sydney 
 
 
Piracetam Trial   
 
Information for Participants 
 
Introduction 
You are invited to take part in a research study investigating the temporary effects of piracetam on 
cognitive performance and heart rate. Piracetam is an over-the-counter nootropic or “smart drug”. It 
has been shown to increase learning and memory when used consistently over a period of time. 
However, there is also some evidence to suggest that a single dose of piracetam can produce 
immediate short term improvements in cognitive performance. The most likely mechanism for this 
improved cognitive performance is an increase in blood flow via increased heart rate which provides 
more oxygen to the brain. In this study, we are interested in whether a single dose of piracetam will 
improve your cognitive performance on a task involving working memory and sustained attention 
and increase your heart rate. The study is a double-blind placebo controlled trial of piracetam, so you 
will be allocated to receive either piracetam (150mg) or a placebo pill, but you will not be told which 
one you have been given and the researcher will also not know your allocation. To assess the 
immediate effects of piracetam versus placebo you will be asked to complete a cognitive task and 
have you heart rate measured three times over the course of this session.   
 
This study is being conducted by: 
Prof. Robert Boakes (Chief Investigator), 
 University of Sydney 
Mr Ben Colagiuri, 
 University of Sydney 
 
Study Procedures 
If you agree to participate in this study, you will be asked to sign the Participant Consent Form. You 
will then be asked to undergo the following procedures: 
1) Provide some personal details (e.g. age, sex). 
2) Take one piracetam or placebo tablet, although you will not know which one you have 
been given. 
3) Have your heart rate measured using a blood volume pulse sensor (3 times). 
4) Complete a computer based sustained attention task (3x5min). 
5) Complete a questionnaire involving questions about the effect of the treatment you 
received.  
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Benefits 
You will be awarded one hour of credit for participating in this experiment which will contribute 
1.25% to the total 5% credit allocated to experiment participation for Psychology 1002.  
 
Remember 
Your participation in this study is entirely voluntary. You may withdraw at anytime without 
having to give a reason. Whatever your decision, please be assured that it will not have any 
repercussions.   
 
When you have read this information, Ben Colagiuri will discuss it with you further and answer any 
questions you may have.  If you would like to know more at any stage, please feel free to contact 
him on 0402 236 400, or by email at benc@psych.usyd.edu.au. This information sheet is for you to 
keep.  
 
 
Any person with concerns or complaints about the conduct of this or any other study can 
contact the secretary of the Human Ethics Committee, University of Sydney, on (02) 9351 
4811. 
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Appendix 3d – Information Sheet for Study 2, Experiment 2. (Control Group)  
 
 
Prof. R A Boakes 
School of Psychology 
The University of Sydney 
 
 
Piracetam Trial   
 
Information for Participants 
 
Introduction 
You are invited to take part in a research study investigating the temporary effects of piracetam on 
cognitive performance and heart rate. Piracetam is an over-the-counter nootropic or “smart drug”. It 
has been shown to increase learning and memory when used consistently over a period of time. 
However, there is also some evidence to suggest that a single dose of piracetam can produce 
immediate short term improvements in cognitive performance. The most likely mechanism for this 
improved cognitive performance is an increase in blood flow via increased heart rate which provides 
more oxygen to the brain. In this study, we are interested in whether a single dose of piracetam will 
improve your cognitive performance on a task involving working memory and sustained attention 
and increase your heart rate. You will be allocated either to receive piracetam (150mg) or to a no 
treatment control group that does not receive the piracetam. To assess the immediate effects of 
piracetam versus no treatment you will be asked to complete a cognitive task and have you heart rate 
measured three times over the course of this session.   
 
This study is being conducted by: 
Prof. Robert Boakes (Chief Investigator), 
 University of Sydney 
Mr Ben Colagiuri, 
 University of Sydney 
 
Study Procedures 
If you agree to participate in this study, you will be asked to sign the Participant Consent Form. You 
will then be asked to undergo the following procedures: 
1) Provide some personal details (e.g. age, sex). 
2) Be allocated to either receive a piracetam pill or no treatment. 
3) Have your heart rate measured using a blood volume pulse sensor (3 times). 
4) Complete a computer based sustained attention task (3x5min). 
5) Complete a questionnaire involving questions about the effect of the treatment    you 
received.  
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Benefits 
You will be awarded one hour of credit for participating in this experiment which will contribute 
1.25% to the total 5% credit allocated to experiment participation for Psychology 1002.  
 
Remember 
Your participation in this study is entirely voluntary. You may withdraw at anytime without 
having to give a reason. Whatever your decision, please be assured that it will not have any 
repercussions.   
 
When you have read this information, Ben Colagiuri will discuss it with you further and answer any 
questions you may have.  If you would like to know more at any stage, please feel free to contact 
him on 0402 236 400, or by email at benc@psych.usyd.edu.au. This information sheet is for you to 
keep.  
 
 
Any person with concerns or complaints about the conduct of this or any other study can 
contact the secretary of the Human Ethics Committee, University of Sydney, on (02) 9351 
4811. 
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Appendix 3e - Beliefs Questionnaire for Study 2, Experiment 2. (Double-blind Group) 
  
 
 
Professor R A Boakes 
School of Psychology 
The University of Sydney 
 
 
Piracetam Trial 
 
Piracetam Effects Questionnaire 
 
 
1) Do you think that you were given the piracetam pill or the placebo pill?  
 
   PIRACETAM   PLACEBO 
 
 
2) On a scale from 0 – 10, how certain are you that this was the medication that you 
received? 
 
 
3) Are there any particular reasons why you believe this? 
 
 
 
 
 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
 
 
 
 
 
 
GO TO NEXT PAGE
NOT AT ALL 0 1 2 3 4 5 6 7 8 9 10  EXTREMELY CERTAIN 
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4) Do you remember your accuracy scores for the three tests? 
 
 
Baseline  _______________ 
 
 
Posttest 1 _______________ 
 
 
Posttest 2 _______________ 
 
 
 
 
 
5) Do you have any additional comments about the study? 
 
 
 
 
 
 
 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
END OF QUESTIONNAIRE 
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Appendix 3f - Beliefs Questionnaire for Study 2, Experiment 2.  (Control Group) 
 
Professor R A Boakes 
School of Psychology 
The University of Sydney 
 
 
Piracetam Trial 
 
Piracetam Effects Questionnaire 
 
 
1) Did you receive piracetam or no treatment? 
  
   PIRACETAM   NO TREATMENT 
 
 
 
2) Do you remember your accuracy scores for the three tests? 
 
 
Baseline  _______________ 
 
 
Posttest 1 _______________ 
 
 
Posttest 2 _______________ 
 
 
 
 
3) Do you have any additional comments about the study? 
 
 
 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
_____________________________________________________________________ 
 
 
 
 
END OF QUESTIONNAIRE 
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Appendix 4a – Information Sheet for Study 3, Experiment 1 (Suggestion) 
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Risks 
Some people who take SX3752 report some minor side-effects. These may include 
feeling more sleepy than usual when you awaken, having a dry mouth, and mild 
headaches. If you do experience these side effects, they will go away completely when 
you stop taking SX3752.  
 
Benefits 
While we intend that this research study furthers medical knowledge and may help 
people experiencing difficulty sleeping, it may not be of direct benefit to you. 
 
Costs 
Participation in this study will not cost you anything, nor will you be paid. 
 
Voluntary Participation 
Participation in this study is entirely voluntary.  You do not have to take part in it.  If you 
do take part, you can withdraw at any time without having to give a reason.  
Whatever your decision, please be assured that it will not have any repercussions.   
 
Confidentiality 
All the information collected from you for the study will be treated confidentially, and only 
the researchers named above will have access to it. The study results may be presented 
at a conference or in a scientific publication, but individual participants will not be 
identifiable in such a presentation. 
 
Further Information 
When you have read this information, Ben Colagiuri will discuss it with you further and 
answer any questions you may have.  If you would like to know more at any stage, 
please feel free to contact him on 0402 236 400, or by email at 
benc@psych.usyd.edu.au.  
 
This information sheet is for you to keep.  
 
 
Any person with concerns or complaints about the conduct of a research 
study can contact the Senior Ethics Officer, Ethics Administration, 
University of Sydney, on (02) 9351 4811 (Telephone); (02) 9351 6706 
(Facsimile) or gbrody@mail.usyd.edu.au (Email).  
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Appendix 4b – Posttreatment Questionnaire for Study 3, Experiment 1  
 
 
 
 
Post Treatment Questionnaire 
 
Instructions: 
Please answer the following questions about your treatment with SX3752 over the last week as 
honestly as possible.  
 
1. How effective were the SX3752 tablets for reducing your sleep difficulty? 
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    VERY EFFECTIVE 
 
2. At the beginning of the study, how effective did you expect the SX3752 tablets would be for 
reducing your sleep difficulty?  
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    VERY EFFECTIVE 
 
3. Did you take one SX3752 tablet every night?   YES     NO 
 
         If no, how many nights did you miss taking the SX3752 tablet_________ 
 
         What led to you not taking the SX3752 tablets? 
  
 
 
 
 
4. Did you experience any side effects while you were taking the SX3752 tablets?     YES     NO 
 
         If yes, what were these side effects and how severe were they? 
 
Side effect 1 (please specify) ____________________________________ 
 
VERY MILD    0      1      2      3      4     5     6     7     8     9     10    VERY SEVERE 
 
Side effect 2 (please specify) ____________________________________ 
 
VERY MILD    0      1      2      3      4     5     6     7     8     9     10    VERY SEVERE 
 
Side effect 3 (please specify) ____________________________________ 
 
VERY MILD    0      1      2      3      4     5     6     7     8     9     10    VERY SEVERE 
Participant No.                   f 
 
Session                              . 
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Appendix 4c – Adverse Symptom Checklist for Study 3, Experiment 1  
 
 
 
 
General Health Questionnaire 
 
Instructions: 
Please answer the following questions about your general health over the past week as 
accurately as possible. Try to consider the entire week and not just the last couple of days.  
 
1. During the last week, have you felt more sleepy than usual when you wake up?  YES     NO 
 
            If yes, on how many days did this happen _________ 
 
                          On average, how much more sleepy did you feel than usual?  
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    VERY MUCH MORE 
 
2. During the last week, have you felt more tired than usual in the evenings?     YES       NO 
 
            If yes, on how many days did this happen _________ 
 
                          On average, how much more tired did you feel than usual?  
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    VERY MUCH MORE 
 
3. During the last week, have you experienced any drowsiness?    YES       NO 
 
            If yes, on how many days did you feel drowsy _________ 
 
                          On average, how severe would you rate this drowsiness? 
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    EXTREMELY SEVERE 
 
4. During the last week, have you experienced any headaches?     YES       NO 
 
            If yes, on how many days did you experience headaches _________ 
 
                          On average, how severe would you rate these headaches? 
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    EXTREMELY SEVERE 
 
5. During the last week, have you experienced any dizziness?    YES       NO 
 
            If yes, on how many days did you feel dizzy _________ 
 
                          On average, how severe would you rate this dizziness? 
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    EXTREMELY SEVERE 
Participant No.                   f 
 
Session                              . 
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6. During the last week, have you experienced any nausea?                 YES                NO 
 
            If yes, on how many days did you experience nausea _________ 
 
                          On average, how severe would you rate the nausea? 
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    EXTREMELY SEVERE 
 
7. During the last week, have you experienced a dry mouth?    YES       NO 
 
            If yes, on how many days did have a dry mouth_________ 
 
                          On average, how severe would you rate this dry mouth?  
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    EXTREMELY SEVERE 
 
8. During the last week, have you felt more restless than usual?    YES                NO 
 
            If yes, on how many days did you feel more restless than usual _________ 
 
                          On average, how much more restless did you feel than usual?  
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    MUCH MORE 
 
9. During the last week, have you felt more irritable than usual?    YES                NO 
 
            If yes, on how many days did you feel more irritable than usual _________ 
 
                          On average, how much more irritable did you feel than usual?  
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    MUCH MORE 
 
10. Did you experience any other general health symptoms during the past week?    YES     NO 
 
            If yes, what were these symptoms ____________________________ 
             
            On how many days did you experience these symptoms _________ 
 
                          On average, how severe would you rate these symptoms?  
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    VERY SEVERE 
 
11. Do you have any other comments about your general health over the last week?  
 
 
 
 
 
 
 
  
END OF QUESTIONNAIRE 
Please check that you have answered ALL questions.  
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Appendix 4d – Information Sheet for Study 3, Experiment 2 (Suggestion A) 
 
 
 
 
Sleep Trial 
 
Information for Participants 
 
Introduction 
You are invited to take part in a research study investigating the effectiveness of a new 
herbal medication, SX3752, designed to reduce difficulty sleeping. Difficulty sleeping is 
one of the most common general health problems reported today. It includes taking a 
long time to get to sleep, waking up frequently, and waking up earlier than expected and 
not being able to return to sleep. The main purpose of this study is to assess the 
effectiveness of SX3752 for reducing difficulty sleeping over a one week period. SX3752 
is a pill that you take by mouth with a glass of water each night before you go to bed. It is 
believed to be fast acting and to have the potential to reduce common sleep problems, 
such as, difficulty getting to sleep, waking continually throughout the night, and waking 
early in the morning. If you choose to participate in this study, you may be asked to take 
one SX3752 tablet each night for one week, or you may be assigned to a no-treatment 
control group, in which case you would not actually receive any SX3752 tablets.  
 
This study is being conducted by: 
Prof. Phyllis Butow (Chief Investigator),  
 University of Sydney 
Prof. Robert Boakes, 
 University of Sydney 
Mr. Ben Colagiuri, 
 University of Sydney 
 
Study Procedures 
If you agree to participate in this study, you will be asked to sign the Participant Consent 
Form . You will then be asked to: 
 
Initial Session (Approximately 30min) 
1) Provide some personal details, e.g. age, gender. 
2) Complete a questionnaire about your sleeping habits over the past month.  
3) Complete a questionnaire about some of your views on medical treatment.  
 
Over the next week 
1) Take one SX3752 tablet each night before you go to bed for the next week. You 
take these tablets by mouth with a glass of water.  
 
At the end of the week (Take-home Questionnaires, Approximately 30min)  
1) Complete a questionnaire about the quality of your sleep over the week. 
2) Complete a questionnaire about how effective you think the SX3752 tablets are. 
3) Complete a questionnaire about your general health symptoms over the week. 
4) Return these questionnaires within one week of the final day of your treatment.   
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Risks 
Some people who take SX3752 report some minor side-effects. These may include 
feeling drowsy, having a dry mouth, and nausea. If you do experience these side effects, 
they will go away completely when you stop taking SX3752.  
 
Benefits 
While we intend that this research study furthers medical knowledge and may help 
people experiencing difficulty sleeping, it may not be of direct benefit to you. 
 
Costs 
Participation in this study will not cost you anything, nor will you be paid. 
 
Voluntary Participation 
Participation in this study is entirely voluntary.  You do not have to take part in it.  If you 
do take part, you can withdraw at any time without having to give a reason.  
Whatever your decision, please be assured that it will not have any repercussions.   
 
Confidentiality 
All the information collected from you for the study will be treated confidentially, and only 
the researchers named above will have access to it. The study results may be presented 
at a conference or in a scientific publication, but individual participants will not be 
identifiable in such a presentation. 
 
Further Information 
When you have read this information, Ben Colagiuri will discuss it with you further and 
answer any questions you may have.  If you would like to know more at any stage, 
please feel free to contact him on 0402 236 400, or by email at 
benc@psych.usyd.edu.au.  
 
This information sheet is for you to keep.  
 
 
Any person with concerns or complaints about the conduct of a research 
study can contact the Senior Ethics Officer, Ethics Administration, 
University of Sydney, on (02) 9351 4811 (Telephone); (02) 9351 6706 
(Facsimile) or gbrody@mail.usyd.edu.au (Email).  
 
 213 
Appendix 4e – Information Sheet for Study 3, Experiment 2 (Suggestion B) 
 
 
 
 
Sleep Trial 
 
Information for Participants 
 
Introduction 
You are invited to take part in a research study investigating the effectiveness of a new 
herbal medication, SX3752, designed to reduce difficulty sleeping. Difficulty sleeping is 
one of the most common general health problems reported today. It includes taking a 
long time to get to sleep, waking up frequently, and waking up earlier than expected and 
not being able to return to sleep. The main purpose of this study is to assess the 
effectiveness of SX3752 for reducing difficulty sleeping over a one week period. SX3752 
is a pill that you take by mouth with a glass of water each night before you go to bed. It is 
believed to be fast acting and to have the potential to reduce common sleep problems, 
such as, difficulty getting to sleep, waking continually throughout the night, and waking 
early in the morning. If you choose to participate in this study, you may be asked to take 
one SX3752 tablet each night for one week, or you may be assigned to a no-treatment 
control group, in which case you would not actually receive any SX3752 tablets.  
 
This study is being conducted by: 
Prof. Phyllis Butow (Chief Investigator),  
 University of Sydney 
Prof. Robert Boakes, 
 University of Sydney 
Mr. Ben Colagiuri, 
 University of Sydney 
 
Study Procedures 
If you agree to participate in this study, you will be asked to sign the Participant Consent 
Form . You will then be asked to: 
 
Initial Session (Approximately 30min) 
1) Provide some personal details, e.g. age, gender. 
2) Complete a questionnaire about your sleeping habits over the past month.  
3) Complete a questionnaire about some of your views on medical treatment.  
 
Over the next week 
1) Take one SX3752 tablet each night before you go to bed for the next week. You 
take these tablets by mouth with a glass of water.  
 
At the end of the week (Take-home Questionnaires, Approximately 30min)  
1) Complete a questionnaire about the quality of your sleep over the week. 
2) Complete a questionnaire about how effective you think the SX3752 tablets are. 
3) Complete a questionnaire about your general health symptoms over the week. 
4) Return these questionnaires within one week of the final day of your treatment.   
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Risks 
Some people who take SX3752 report some minor side-effects. These may include 
feeling dizzy, having blurred vision, and getting sore eyes. If you do experience these 
side effects, they will go away completely when you stop taking SX3752.  
 
Benefits 
While we intend that this research study furthers medical knowledge and may help 
people experiencing difficulty sleeping, it may not be of direct benefit to you. 
 
Costs 
Participation in this study will not cost you anything, nor will you be paid. 
 
Voluntary Participation 
Participation in this study is entirely voluntary.  You do not have to take part in it.  If you 
do take part, you can withdraw at any time without having to give a reason.  
Whatever your decision, please be assured that it will not have any repercussions.   
 
Confidentiality 
All the information collected from you for the study will be treated confidentially, and only 
the researchers named above will have access to it. The study results may be presented 
at a conference or in a scientific publication, but individual participants will not be 
identifiable in such a presentation. 
 
Further Information 
When you have read this information, Ben Colagiuri will discuss it with you further and 
answer any questions you may have.  If you would like to know more at any stage, 
please feel free to contact him on 0402 236 400, or by email at 
benc@psych.usyd.edu.au.  
 
This information sheet is for you to keep.  
 
 
Any person with concerns or complaints about the conduct of a research 
study can contact the Senior Ethics Officer, Ethics Administration, 
University of Sydney, on (02) 9351 4811 (Telephone); (02) 9351 6706 
(Facsimile) or gbriody@mail.usyd.edu.au (Email). 
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Appendix 4f – Posttreatment Questionnaire for Study 3, Experiment 2 
 
 
 
 
Post Treatment Questionnaire 
 
Instructions: 
Please answer the following questions about your treatment with SX3752 over 
the last week as honestly as possible.  
 
1. How effective were the SX3752 tablets for reducing your sleep difficulty? 
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    VERY EFFECTIVE 
 
2. At the beginning of the study, how effective did you expect the SX3752 
tablets would be for reducing your sleep difficulty?  
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    VERY EFFECTIVE 
 
3. Did you take one SX3752 tablet every night?   YES     NO 
 
         If no, how many nights did you miss taking the SX3752 tablet_________ 
 
         What led to you not taking the SX3752 tablets? 
  
 
 
 
 
4. Did you experience any side effects while you were taking the SX3752 
tablets?     YES     NO 
 
         If yes, what were these side effects and how severe were they? 
 
Side effect 1 (please specify) ____________________________________ 
 
VERY MILD    0      1      2      3      4     5     6     7     8     9     10    VERY SEVERE 
 
Side effect 2 (please specify) ____________________________________ 
 
VERY MILD    0      1      2      3      4     5     6     7     8     9     10    VERY SEVERE 
 
Side effect 3 (please specify) ____________________________________ 
 
VERY MILD    0      1      2      3      4     5     6     7     8     9     10    VERY SEVERE 
Participant No.                   f 
 
Session                              . 
 216 
Appendix 4g – Adverse Symptom Checklist for Study 3, Experiment 2  
 
 
 
 
General Health Questionnaire 
 
Instructions: 
Please answer the following questions about your general health over the past week as 
accurately as possible. Try to consider the entire week and not just the last couple of days.  
 
1. During the last week, have you felt more sleepy than usual when you wake up?  YES     NO 
 
            If yes, on how many days did this happen _________ 
 
                          On average, how much more sleepy did you feel than usual?  
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    VERY MUCH MORE 
 
2. During the last week, have you felt more tired than usual in the evenings?     YES       NO 
 
            If yes, on how many days did this happen _________ 
 
                          On average, how much more tired did you feel than usual?  
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    VERY MUCH MORE 
 
3. During the last week, have you experienced any drowsiness?    YES       NO 
 
            If yes, on how many days did you feel drowsy _________ 
 
                          On average, how severe would you rate this drowsiness? 
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    EXTREMELY SEVERE 
 
4. During the last week, have you experienced any dizziness?    YES       NO 
 
            If yes, on how many days did you feel dizzy _________ 
 
                          On average, how severe would you rate this dizziness? 
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    EXTREMELY SEVERE 
 
 
5. During the last week, have you experienced any headaches?     YES       NO5 
 
            If yes, on how many days did you experience headaches _________ 
 
                          On average, how severe would you rate these headaches? 
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    EXTREMELY SEVERE 
Participant No.                   f 
 
Session                              . 
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6. During the last week, have you experienced any blurred vision?    YES       NO 
 
            If yes, on how many days did you have blurred vision _________ 
 
                          On average, how severe would you rate this blurred vision? 
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    EXTREMELY SEVERE 
 
 
7 During the last week, have you experienced sore eyes?    YES       NO 
 
            If yes, on how many days did you have sore eyes _________ 
 
                          On average, how severe would you rate these sore eyes? 
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    EXTREMELY SEVERE 
 
 
8. During the last week, have you experienced a dry mouth?    YES       NO 
 
            If yes, on how many days did have a dry mouth_________ 
 
                          On average, how severe would you rate this dry mouth?  
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    EXTREMELY SEVERE 
 
 
9. During the last week, have you experienced a sore throat?                 YES                NO 
 
            If yes, on how many days did you experience sore throat _________ 
 
                          On average, how severe would you rate this sore throat? 
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    EXTREMELY SEVERE 
 
 
10. During the last week, have you experienced any nausea?                 YES                NO 
 
            If yes, on how many days did you experience nausea _________ 
 
                          On average, how severe would you rate the nausea? 
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    EXTREMELY SEVERE 
 
 
11. During the last week, have you experienced any stomach cramps?             YES                NO 
 
            If yes, on how many days did you experience stomach cramps _________ 
 
                          On average, how severe would you rate these stomach cramps? 
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    EXTREMELY SEVERE  
 218 
 
12. Did you experience any other general health symptoms during the past week?    YES     NO 
 
            If yes, what were these symptoms ____________________________ 
             
            On how many days did you experience these symptoms _________ 
 
                          On average, how severe would you rate these symptoms?  
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    VERY SEVERE 
 
13. Do you have any other comments about your general health over the last week?  
 
 
 
 
 
 
 
  
END OF QUESTIONNAIRE 
Please check that you have answered ALL questions.  
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Appendix 4h – Information Sheet for Study 3, Experiment 3 (Increase) 
 
 
 
 
Sleep Trial 
 
Information for Participants 
 
Introduction 
You are invited to take part in a research study investigating the effectiveness of a new 
herbal medication, SX3752, designed to reduce difficulty sleeping. Difficulty sleeping is 
one of the most common general health problems reported today. It includes taking a 
long time to get to sleep, waking up frequently, and waking up earlier than expected and 
not being able to return to sleep. The main purpose of this study is to assess the 
effectiveness of SX3752 for reducing difficulty sleeping over a one week period. SX3752 
is a pill that you take by mouth with a glass of water each night before you go to bed. It is 
believed to be fast acting and to have the potential to reduce common sleep problems, 
such as, difficulty getting to sleep, waking continually throughout the night, and waking 
early in the morning. If you choose to participate in this study, you may be asked to take 
one SX3752 tablet each night for one week, or you may be assigned to a no-treatment 
control group, in which case you would not actually receive any SX3752 tablets.  
 
This study is being conducted by: 
Prof. Phyllis Butow (Chief Investigator),  
 University of Sydney 
Prof. Robert Boakes, 
 University of Sydney 
Mr. Ben Colagiuri, 
 University of Sydney 
 
Study Procedures 
If you agree to participate in this study, you will be asked to sign the Participant Consent 
Form . You will then be asked to: 
 
Initial Session (Approximately 30min) 
1) Provide some personal details, e.g. age, gender. 
2) Complete a questionnaire about your sleeping habits over the past month.  
3) Complete a questionnaire about some of your views on medical treatment.  
 
Over the next week 
1) Take one SX3752 tablet each night before you go to bed for the next week. You 
take these tablets by mouth with a glass of water.  
 
At the end of the week (Take-home Questionnaires, Approximately 30min)  
1) Complete a questionnaire about the quality of your sleep over the week. 
2) Complete a questionnaire about how effective you think the SX3752 tablets are. 
3) Complete a questionnaire about your general health symptoms over the week. 
Return these questionnaires within one week of the final day of your treatment.  
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Appendix 4i – Information Sheet for Study 3, Experiment 3 (Decrease) 
 
 
 
 
Sleep Trial 
 
Information for Participants 
 
Introduction 
You are invited to take part in a research study investigating the effectiveness of a new 
herbal medication, SX3752, designed to reduce difficulty sleeping. Difficulty sleeping is 
one of the most common general health problems reported today. It includes taking a 
long time to get to sleep, waking up frequently, and waking up earlier than expected and 
not being able to return to sleep. The main purpose of this study is to assess the 
effectiveness of SX3752 for reducing difficulty sleeping over a one week period. SX3752 
is a pill that you take by mouth with a glass of water each night before you go to bed. It is 
believed to be fast acting and to have the potential to reduce common sleep problems, 
such as, difficulty getting to sleep, waking continually throughout the night, and waking 
early in the morning. If you choose to participate in this study, you may be asked to take 
one SX3752 tablet each night for one week, or you may be assigned to a no-treatment 
control group, in which case you would not actually receive any SX3752 tablets.  
 
This study is being conducted by: 
Prof. Phyllis Butow (Chief Investigator),  
 University of Sydney 
Prof. Robert Boakes, 
 University of Sydney 
Mr. Ben Colagiuri, 
 University of Sydney 
 
Study Procedures 
If you agree to participate in this study, you will be asked to sign the Participant Consent 
Form . You will then be asked to: 
 
Initial Session (Approximately 30min) 
1) Provide some personal details, e.g. age, gender. 
2) Complete a questionnaire about your sleeping habits over the past month.  
3) Complete a questionnaire about some of your views on medical treatment.  
 
Over the next week 
1) Take one SX3752 tablet each night before you go to bed for the next week. You 
take these tablets by mouth with a glass of water.  
 
At the end of the week (Take-home Questionnaires, Approximately 30min)  
1) Complete a questionnaire about the quality of your sleep over the week. 
2) Complete a questionnaire about how effective you think the SX3752 tablets are. 
3) Complete a questionnaire about your general health symptoms over the week. 
4) Return these questionnaires within one week of the final day of your treatment.  
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Risks 
Some people who take SX3752 report experiencing a decreased appetite in response to 
the medication.  If you do experience a decreased appetite while taking SX3752 this will 
go away completely when you stop taking the tablets.  
 
Benefits 
While we intend that this research study furthers medical knowledge and may help 
people experiencing difficulty sleeping, it may not be of direct benefit to you. 
 
Costs 
Participation in this study will not cost you anything, nor will you be paid. 
 
Voluntary Participation 
Participation in this study is entirely voluntary.  You do not have to take part in it.  If you 
do take part, you can withdraw at any time without having to give a reason.  
Whatever your decision, please be assured that it will not have any repercussions.   
 
Confidentiality 
All the information collected from you for the study will be treated confidentially, and only 
the researchers named above will have access to it. The study results may be presented 
at a conference or in a scientific publication, but individual participants will not be 
identifiable in such a presentation. 
 
Further Information 
When you have read this information, Ben Colagiuri will discuss it with you further and 
answer any questions you may have.  If you would like to know more at any stage, 
please feel free to contact him on 0402 236 400, or by email at 
benc@psych.usyd.edu.au.  
 
 
Any person with concerns or complaints about the conduct of a research 
study can contact the Senior Ethics Officer, Ethics Administration, 
University of Sydney, on (02) 9351 4811 (Telephone); (02) 9351 6706 
(Facsimile) or gbrody@mail.usyd.edu.au (Email).  
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Appendix 4j – Posttreatment Questionnaire for Study 3, Experiment 3 
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Appendix 4k – Adverse Symptom Checklist for Study 3, Experiment 3  
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6. During the last week, have you experienced a dry mouth?    YES       NO 
 
            If yes, on how many days did have a dry mouth_________ 
 
                          On average, how severe would you rate this dry mouth?  
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    EXTREMELY SEVERE 
 
 
7. During the last week, have you noticed any changes in your mood?      YES          NO 
 
            If yes, please describe these changes in your mood: 
 
 
 
 
 
 
 
 
 
 
            On average, how severe would you rate this change in mood? 
 
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    EXTREMELY SEVERE 
 
 
8. During the last week, have you noticed any changes in your appetite?      YES          NO 
 
            If yes, please describe these changes in your appetite: 
 
 
 
 
 
 
 
 
 
 
            On average, how severe would you rate this change in appetite? 
 
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    EXTREMELY SEVERE 
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9. During the last week, have you noticed any changes in your energy levels?      YES        NO 
 
            If yes, please describe these changes to your energy levels: 
 
 
 
 
 
 
 
 
 
 
            On average, how severe would you rate this change in energy level? 
 
 
NOT AT ALL    0      1      2      3      4     5     6     7     8     9     10    EXTREMELY SEVERE 
 
 
10.  Do you have any other comments about your general health over the past week? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
END OF QUESTIONNAIRE 
 
